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ABSTRACT
INJECTABLE HYDROGELS FOR LOCAL PROTEIN DELIVERY TO ENGINEER
MYOCARDIAL REMODELING
Brendan P. Purcell
Jason A. Burdick, PhD
The endogenous tissue remodeling events that occur following a
myocardial infarction (MI) are inadequate to maintain left ventricular (LV)
function, and the progression towards heart failure is often inevitable. Our
increased understanding of protein regulators of post MI remodeling provides the
opportunity to intervene and engineer tissue remodeling through exogenous
protein delivery. The global hypothesis of this dissertation was that the local
delivery of therapeutic proteins (SDF-1! and TIMP-3) from injectable hyaluronic
acid (HA) hydrogels attenuates adverse post MI remodeling processes by
providing sustained concentrations of bioactive signals within the remodeling
myocardium.
To test this hypothesis, HA based hydrogels were designed with
crosslinking chemistries to allow hydrogel formation and protein encapsulation in
situ upon injection through a syringe, negatively charged polymer backbones to
bind encapsulated proteins through electrostatic interactions and sustain protein
release, and degradable crosslinks to release proteins in a controlled fashion.
Using these injectable hydrogel systems, adverse post MI remodeling events
were attenuated following experimental MI in animals by enhancing endogenous
cell homing to the myocardium through SDF-1! delivery and inhibiting matrix
metalloproteinase activity through TIMP-3 delivery.
Our results demonstrate the utility of implantable biomaterials to localize
and sustain biological signals to engineer tissue remodeling processes, and
provide insight into novel biological therapeutics to treat LV remodeling following
MI.
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CHAPTER 1
Introduction
1.1. Significance
The loss of functional tissue following a myocardial infarction (MI) is
detrimental to heart function. Over 3 million people in the United States currently
suffer from heart failure caused by MI1 and more than 1 million MIs occur each
year2.

These troubling statistics amount to an economic burden of over $30

billion in the United States2. Current clinical treatments for MI include coronary
stents and bypass surgeries to overcome the blocked artery and reperfuse the
ischemic tissue.

In addition, current pharmacological treatments lessen the

workload of the injured heart. While these treatments delay the onset of heart
failure following MI, they do little to alter the tissue remodeling process initiated
after coronary artery occlusion.

The changes in myocardial tissue structure

during post MI remodeling cause global changes to left ventricle (LV) geometry,
compromise LV function, and lead to the progression of heart failure.
Unfortunately, whole organ-transplants remain the only current treatment for
patients with end-stage heart failure, and these are severely limited by the low
number of donor hearts.
1.2. Post MI remodeling
An MI occurs when arterial blood flow to the myocardium is interrupted,
typically by a ruptured atherosclerotic plaque in the coronary arteries. The lack of
oxygen supply (hypoxia) to the highly aerobic myocardium following coronary
artery occlusion induces the expression of proteins active in tissue remodeling.
These include surface adhesion molecules and soluble factors that activate the
coronary endothelium and signal the infiltration of endogenous cells3-6. Within
the first few hours post MI, neutrophils accumulate in the ischemic myocardium
and release ROS and proteolytic enzymes that damage both vasculature and
1!

parenchymal cells in the myocardium6-9. In addition, marrow derived monocytes
infiltrate the myocardium and differentiate into macrophages upon adherence to
the damaged ECM10,

11

.

These matured macrophages phagocytize necrotic

cells, provide a major source of proteases, and secrete growth factors to activate
fibroblast proliferation10.

Proliferating fibroblasts within the MI region also

express a number of proteins and proteolytic enzymes that contribute to tissue
remodeling12-15. Together, proteins expressed from both recruited cells and cells
native to the myocardium orchestrate the post MI remodeling process that occurs
locally in the MI region of the myocardium. While there are potentially hundreds
of proteins that contribute to tissue remodeling post MI, the following two sections
will highlight two families of proteins that are particularly important post MI and
the focus of the research that follows.
1.3. Matrix metalloproteinases (MMPs)
The abundance of protease activity in the setting of MI contributes to ECM
degradation, instability in the MI region, and myocardial expansion. A family of
proteolytic enzymes that contribute to MI expansion are the MMPs16, 17. MMPs
hydrolyze peptide bonds with a high level of amino acid specificity and regulation.
Under normal physiological conditions, MMP activity is precisely controlled to
maintain a low level of structural protein, cell receptor, and growth factor
turnover. However, following a stimulus such as an injury, there is a loss of
control over MMP activity which causes maladaptive changes to tissue
architectures and functions, often resulting in the progression of disease18. For
example, MMP dysregulation has been observed in patients during post MI
remodeling and heart failure19, 20. Specifically, MMP expression was upregulated
following MI, while the expression of endogenous tissue inhibitors of MMPs
(TIMPs) was not. Subsequent clinical studies quantified MMP/TIMP levels in the
circulation and found that plasma levels of MMPs increased following MI without
a concomitant increase in plasma TIMPs. In particular, plasma TIMP-3 levels
significantly decreased in the early post MI period, at a time when maximal MMP
2!

induction and release was occurring

21-26

.

This prolonged MMP/TIMP

dysregulation was correlated with myocardial expansion in patients following MI.
Further, regional MMP/TIMP expression has been quantified in the myocardium
following experimental MI in pigs27,

28,17,29-31

.

LV samples were harvested 8

weeks following induced MI, and immunoblotting revealed a significant induction
of the representative classes of MMPs whereas the relative levels of the 4 TIMPs
(TIMP-1,2,3,4) were decreased or remained the same following MI. Further, to
quantify MMP activity within the remote, border and MI regions, a fluorogenicmicrodialysis assay was developed and revealed that induction of MMP activity is
highly localized to the MI region29-31.
1.4. Stromal cell-derived factor-1 alpha (SDF-1!)
SDF-1! chemokine mediates steady state homing of progenitor cells to
the bone marrow by binding to the CXCR4 receptor, but is also expressed by
endothelial cells in ischemic tissue through activation of hypoxia inducible
transcription factors32, 33. SDF-1! expression is upregulated in the myocardium
during the first few days following MI, but is quickly downregulated34-36. Separate
studies have shown a concomitant increase in CXCR4+ circulating cells during
the first few days following MI suggesting that these cells are mobilized and
respond to the myocardial SDF-1! homing signal37-39. In addition, the mobilized
CXCR4+ cells express cardiac specific markers suggesting that the SDF1!/CXCR4 homing axis contributes to myocardial repair following MI37-40. The
importance of this homing axis in post MI remodeling was shown by systemic
administration of a pharmacological CXCR4 antagonist41. A single dose of the
antagonist following MI increased progenitor cell numbers in the circulation and
in the heart, promoted myocardial vascularity, reduced fibrosis, and improved
cardiac function and survival.

Continuous antagonist infusion increased

circulating progenitor cell numbers, but blocked their engraftment in the
myocardium, leading to worsened outcomes. Therefore, enhancing endogenous
cell homing involves both mobilizing cells from their native niche and sustaining
3!

local signals to promote their engraftment in the myocardium. Sustaining SDF1! levels in the myocardium through exogenous delivery of recombinant SDF-1!
has been shown to increase myocardial c-kit+ and CXCR4+ progenitor cells
densities, increased vascular structures and improved cardiac function36, 42, 43.
1.5. Engineered proteins
Collectively, endogenous protein expression following MI is inadequate to
prevent maladaptive changes to myocardial tissue structure, which ultimately
cause a gradual loss of LV function. However, our increased understanding of
these protein regulators provides an opportunity to intervene and engineer tissue
remodeling through exogenous delivery of protein based therapeutics. Delivery
of proteins over small pharmaceutical drugs has several advantages including
the highly specific functions of proteins that cannot be mimicked by chemical
compounds, and the well-tolerated immunological response to proteins because
of their natural amino acid composition44.

In addition, advances in genetic

engineering and chemical ligation technologies have allowed for large-scale
production of proteins for therapeutic use.
Recombinant proteins are produced by isolating a human gene for the
protein of interest, then expressing the gene in a cell culture platform using
recombinant DNA technology45.

A variety of cell types have been used for

recombinant protein production including bacteria, yeast, insect cells, and
mammalian cells46-48. In addition, transgenic animals and plants have been used
for recombinant protein production. This technique has proven to be a powerful
way to produce many of the thousands of sequenced human proteins in large
quantities, as primary sources of human tissues are limited. In addition, while
protein sequences are often conserved between species, isolation of proteins for
therapeutic use from animal sources can be problematic. Tissue extraction and
purification processes are difficult and costly, and the purified product still carries
the risk of disease and immunological rejection in humans44. While more efficient
and less expensive than extraction of proteins from tissues, recombinant proteins
4!

for therapeutic use are still very expensive, with estimates up to $100,000 per
patient per year for some disease treatments49.
As an alternative to cell-based protein production, where the cell is used
as a factory to synthesize proteins with its innate machinery, chemical synthesis
technologies have been developed to produce proteins through purely synthetic
routes50.

For example, solid-phase peptide synthesis (SPPS) grows a

polypeptide chain from a functionalized polymer resin by utilizing protecting
groups to couple amino acids from C to N terminus, one at a time. The Nterminal amine of the growing polypeptide chain is deprotected and then reacted
with the activated carboxylic acid of an N-protected amino acid. The coupling
reactions are forced to completion by using an excess of activated soluble amino
acid to improve yield of the final polypeptide chain. The solid-phase is then
washed of excess amino aicds and the coupling reaction repeated for
subsequent amino acids.

Following completion of polypeptide synthesis, the

polypeptide is cleaved from the polymer solid-phase and isolated for use. SPPS
is typically limited to proteins that are shorter than approximately 30kDa. SPPS
synthesis can proceed rapidly in an automated fashion, and produces large
yields of purified product50. Longer proteins can be achieved using chemical
ligation techniques to couple two SPPS synthesized proteins together51. One
major advantage to SPPS over recombinant technologies is the ease with which
proteins of almost any desired sequence can be generated. SPPS is commonly
used to generate minimal peptide sequences designed from protein active sites
in order to study protein interactions or to provide simpler mimics of the fulllength protein for therapeutic use.
1.6. Limitations of protein therapeutics
These advances in protein engineering have led to more than 130 peptide
or protein drugs approved for clinical use by the US Food and Drug
Administration (FDA), and many more are in development44.

While proteins

continue to be a major focus of drug development efforts, significant challenges
5!

remain in maximizing their efficacy towards treating disease. Specifically, short
half-lives and rapid clearance of systemically delivered proteins require frequent
dosage to maintain protein concentrations within the therapeutic window to
effectively treat the patient. In addition, diseases local to a specific organ (e.g.,
MI) present a challenge to provide physiologic concentrations of the protein in the
organ, while limiting systemic actions of the protein.

One attractive way to

overcome these challenges is the use of a device that encapsulates proteins and
protects them from degradation and rapid clearance, while releasing physiologic
protein concentrations locally, and in a sustained fashion.
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CHAPTER 2
Research Overview
2.1. Objectives
As discussed in the Introduction to this dissertation (Chapter 1), there is a
pressing need for treatment strategies that attenuate adverse left ventricular (LV)
remodeling following myocardial infarction (MI).

Injectable hydrogels are

developing as a unique therapeutic platform to treat patients with MI, through a
range of both biochemical and biomechanical signaling.

Additionally,

recombinant and chemically synthesized proteins offer an attractive source of
biological therapeutics to modulate post MI tissue remodeling processes;
however, their short half-lives in blood plasma and ubiquitous involvement in
normal biological processes throughout the body make continuous, systemic
delivery of the drugs problematic.
With this in mind, the goal of my dissertation work has been to develop
hydrogels that can be injected onto or into the myocardium to encapsulate and
sustain the release of protein therapeutics locally following MI.

Generally,

injectable hydrogel systems were designed using a hyaluronic acid (HA)
backbone to mimic a hydrated tissue-like environment.

These HA-based

hydrogels were engineered for (1) injectability through formation of covalent
bonds on or within myocardial tissue, (2) controlled degradation through either
hydrolytic or enzymatic means, and (3) interactions with proteins through charge
association, all features to alter the local release and presentation of
therapeutics. More specifically, HA hydrogels were designed that form in vivo
through either free-radical polymerization of methacrylate groups initiated with
photo or re-dox mechanisms or via formation of a hydrozone bond through the
combination of polymers with aldehyze or hydrazide functionality.

Next,

degradation was mediated through crosslinks that contained either hydrolytically
degradable ester bonds for passive degradation or the incorporation of matrix
10!
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metalloproteinase (MMP) cleavable peptides for cell-mediated degradation.
Finally, many proteins interact natively with HA due to charge interactions and
these responses were enhanced by the incorporation of sulfated polysaccharides
or by directly adding sulfate groups to HA.
Two proteins were chosen for delivery based on their roles in post MI
remodeling and their natural association with polysaccharides in the ECM; (1)
stromal-derived factor-1 alpha (SDF-1!) is a chemokine that regulates trafficking
of cells between the bone marrow and ischemic tissues, as well as promotes
angiogenic responses and enhances cell viability and (2) tissue inhibitor of matrix
metalloproteinase-3 (TIMP-3) is a protease inhibitor that regulates MMP activity
by forming a non-covalent complex with MMPs. Delivery of each molecule was
investigated separately to determine efficacy of each therapeutic strategy (i.e.,
cell recruitment and MMP inhibition). In all studies, experiments were pursued
both in vitro, to illustrate the release behavior and activity of either SDF-1! or
TIMP-3, and in vivo, to illustrate the influence of local release on LV remodeling
and cardiac function in animal models.
2.2. Specific Aims and Hypotheses
The global hypothesis of this dissertation was that the local delivery of
therapeutic proteins (SDF-1! and TIMP-3) from injectable HA hydrogels
modulates post MI remodeling processes by providing sustained concentrations
of bioactive signals within the remodeling myocardium. To test this hypothesis,
five specific aims were identified and completed.
Specific Aim 1: Demonstrate that local SDF-1! delivery from HA hydrogels
homes mobilized bone marrow derived cells (BMCs) to the heart post MI.
Specific Hypothesis 1:

Epicardial delivery of SDF-1! from adherent HA

hydrogels will enhance engraftment of mobilized BMCs in the heart.
HA was modified with hydroxyethylmethacrylate (HEMA) groups to allow freeradical initiated crosslinking of hydrolytically degradable macromers for
11!
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encapsulation and delivery of SDF-1!. A visible light photo-initiator system was
utilized to form hydrogels in the presence of light, which allowed in situ formation
of HA gels on the epicardial surface of the myocardium through light exposure.
SDF-1! binding affinity to HA macromers, along with photo-encapsulated SDF1! release kinetics and hydrogel degradation was quantified in vitro. In addition,
the activity of released molecules was assessed using BMCs in an in vitro
chemotaxis assay. After demonstrating sustained release of active molecules in
vitro, a mouse MI model (collaboration with Dr. Kenneth Margulies, UPenn) was
developed to quantify and track systemically infused BMCs with epicardial
delivery of SDF-1! from adherent HA hydrogel patches. The experiments were
designed to demonstrate the utility of HA hydrogels to localize and sustain SDF1! release and provide proof-of-concept that this system promotes endogenous
BMC homing to the heart following MI.
Specific Aim 2: Assess the therapeutic benefit of an engineered SDF-1!
analogue (ESA) delivery from injectable HA hydrogels post MI.
Specific Hypothesis 2: ESA delivery from injectable HA hydrogels will attenuate
post MI remodeling by providing a sustained homing signal within the
myocardium.
To expand on the work of Aim 1 that investigated the ability of local delivery of
SDF-1! from degradable HA hydrogels to effectively home BMCs to the heart,
these hydrogels were utilized for encapsulation and delivery of ESA, a truncated
version of SDF-1! produced via chemical peptide synthesis (collaboration with
Dr. Joseph Woo, UPenn). For therapeutic assessment, a redox-initiator system
was used to form hydrogels within the myocardium via injection through a
syringe. Kinetics of hydrogel formation was quantified using rheometry to ensure
rapid gelation in situ for maximal ESA encapsulation.

Release kinetics of

encapsulated ESA and hydrogel degradation were quantified in vitro, along with
released molecule activity using BMCs in a chemotaxis assay.

After

demonstrating sustained release of active molecules in vitro, encapsulated ESA
12!
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release was quantified in vivo using ESA labeled with a near-infrared tag and
delivery from injectable HA hydrogels in a rat model of MI.

Functional

assessment of ESA delivery from HA hydrogels post MI was compared to MI only
and hydrogel alone controls using echocardiography and hemodynamic analysis.
In addition, myocardial tissue structure was analyzed with immunohistochemistry
to provide a mechanistic understanding of any observed improvements in LV
function.
Specific Aim 3: Investigate the effect of local TIMP-3 release from injectable
HA hydrogels on MMP activity and LV remodeling following MI.
Specific Hypothesis 3: Local delivery of TIMP-3 from injectable HA hydrogels will
reduce myocardial expansion and attenuate global LV remodeling through MMP
inhibition within the MI region.
HEMA modified HA macromers, along with the redox-initiator system used in Aim
2 were used for encapsulation and delivery of TIMP-3 in this Aim.

TIMP-3

binding to HA macromers was quantified as in Aim 1, and TIMP-3 release from
redox-initiated hydrogels along with hydrogel degradation was quantified in vitro.
In order to investigate the effects of TIMP-3 delivery post MI, a pig MI model
(collaboration with Dr. Frank Spinale, University of South Carolina, and Dr.
Robert Gorman, UPenn) was used to quantify regional MMP activity, infarct
expansion, and LV function after injection.

These metrics were compared

between hydrogel/TIMP-3 group and control groups of MI only and hydrogel
alone, and biochemical analysis of tissues from all groups was analyzed with
immunohistochemistry and for the expression of a range of genes involved in the
remodeling process to investigate the biological effects of TIMP-3 delivery.
Specific Aim 4: Develop sulfated HA macromers to incorporate high TIMP-3
binding affinity into injectable HA hydrogels.
Specific Hypothesis 4: Incorporation of sulfate groups into HA macromers will
enhance binding of TIMP-3 and therefore allow control of TIMP-3 delivery from
13!
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injectable HA hydrogels.
HEMA modified HA macromers used in Aims 1-3 were synthetically sulfated
using a method that maintains reactive group chemistry to allow incorporation of
sulfated HA into injectable HA hydrogels. Sulfate content, charge, and TIMP-3
binding of HA macromers were analyzed before and after sulfation reaction and
compared to the naturally sulfated heparin. Sulfated HA macromers were mixed
with unsulfated HA macromers and hydrogel crosslinking was quantified with
rheometry and compared to hydrogels consisting of only unsulfated HA
macromers to confirm covalent incorporation of sulfated HA macromers. Further,
TIMP-3 or bovine serum albumin (BSA) was encapsulated into the hydrogels and
protein release along with hydrogel degradation were analyzed with incorporation
of sulfated HA to investigate the influence of sulfation on protein release from HA
hydrogels.
Specific Aim 5: Engineer injectable HA hydrogels with MMP sensitive
degradation for localized TIMP-3 delivery as a function of MMP expression
within the MI region.
Specific Hypothesis 5: Incorporation of MMP-sensitive crosslinks will permit
TIMP-3 release based on local MMP concentrations and alter LV remodeling
when injected into infarct tissue.
Based on our results in Aim 3 using HEMA modified HA hydrogels with hydrolytic
degradation and therefore passive rTIMP-3 release to inhibit MMP activity post
MI, we designed injectable HA hydrogels that degrade and release rTIMP-3 in
direct proportion to local MMP activity.

To accomplish this, hydrogels were

developed with MMP degradable crosslinks that form stable networks in the
absence of MMP activity, but degrade in the presence of MMP-2 and MMP-9.
Based on our results in Aim 4 on sulfated polymers that bind and immobilize
TIMP-3 within hydrogels, dextran sulfate was also incorporated into HA
hydrogels for this Aim in order to limit passive TIMP-3 release. Further, polymers
were modified with complimentary reactive groups to form hydrogels rapidly upon
14!
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injection through a dual-barrel syringe without the need for free-radical initiators,
using hydrazone chemistry (formation through reaction of hydrazide and
aldehyde containing polymers).

TIMP-3 binding to sulfated polymers was

quantified in vitro and compared to unsulfated HA and sulfated heparin controls.
Hydrogel crosslinking was quantified using rheometry and MMP mediated
hydrogel degradation was quantified in vitro. TIMP-3 release from the hydrogels
was quantified and the effect of TIMP-3 encapsulation on MMP mediated
hydrogel degradation was investigated in vitro.

After demonstrating MMP-

triggered release of encapsulated TIMP-3 in vitro, the injectable hydrogel system
was applied in the pig MI model used in Aim 3 and the same outcomes were
pursued to assess therapeutic efficacy of this unique delivery approach.
2.3. Chapter Outline
An extensive review of the use of injectable hydrogels for treating MI will
be presented first in Chapter 3. Next, each Specific Aim of this dissertation will
constitute its own chapter consisting of introduction, methods, results, and
discussion sections in the following order: Specific Aim 1 - Chapter 4, Specific
Aim 2 - Chapter 5, Specific Aim 3 - Chapter 6, Specific Aim 4 - Chapter 7,
Specific Aim 5 - Chapter 8. Finally, the conclusions related to each Specific Aim
along with any limitations of the studies will follow in Chapter 9.
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CHAPTER 3
Injectable acellular hydrogels for cardiac repair: a review
(Adapted from : E. Tous*, B.P. Purcell*, J.L. Ifkovits, J.A. Burdick, J Cardiovasc
Transl Res, 2011, 4:528-542 *Authors contributed equally)
3.1. Introduction
Left ventricular (LV) remodeling caused by a myocardial infarction (MI) is
responsible for almost 70% of the 5 million cases of heart failure that have
occurred in the United States in recent years1.

Early infarct expansion or

stretching has been associated with poor long-term prognosis2-4 and has been
identified as the mechanical phenomenon that initiates and sustains the process
of adverse post-MI LV remodeling that leads to heart failure5-10.

Infarct

expansion causes abnormal stress distributions in myocardial regions outside the
infarction, especially in the adjacent borderzone (BZ) region, putting this region at
a mechanical disadvantage. With time, increased regional stress is the impetus
for several maladaptive biologic processes, such as myocyte apoptosis and
matrix metalloproteinase activation that inherently alter the contractile properties
of normally perfused myocardium11-13.

Once initiated, these maladaptive

processes lead to a heart failure phenotype that is difficult to reverse by medical
or surgical means.
Previous work has demonstrated that the use of ventricular restraints,
such as polymeric meshes wrapped around the heart or sutured to the surface of
the infarcted myocardium, reduces infarct expansion by mechanically stabilizing
the heart and forcing it to maintain its original shape, thus limiting long-term
global LV remodeling in large animal models10,14-17 However, these approaches
are limited by the invasive procedure in which they are applied and clinical
adoption has not occurred.

In order to circumvent the invasive surgical

placement of restraining devices early post-MI, our group and others have begun
to explore the use of injectable materials, and specifically hydrogels, to limit
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infarct expansion and normalize the regional stress distribution18-35.
Hydrogels are water-swollen polymer networks that exhibit many tissuelike properties and have been explored for numerous tissue engineering and
drug delivery applications36-38.

Hydrogels can form through numerous

techniques, including via self-assembly, through non-covalent interactions with
ionic species, through covalent crosslinking via chemical reaction, and through
thermal transitions that lead to gelation36-38. These techniques are advantageous
as they could potentially translate to catheter delivery for minimally-invasive,
percutaneous therapies.

Hydrogels are finding application in cardiac therapy

alone as a means for thickening and stabilizing the myocardium via tissue
bulking, as well as for the delivery of a wide variety of therapies, such as cells
and growth factors39, 40. This review will specifically focus on the application of
hydrogels for (1) tissue bulking and (2) molecule delivery approaches that may
translate quickly to the clinic since difficulties related to finding an adequate cell
source for transplantation are eliminated.
3.2. Injectable Hydrogels as Bulking Agents
Over the past decade it has become clear that the mechanical changes
that occur after MI must be considered when developing post-MI therapies35,41,42.
MI leads to extracellular matrix (ECM) breakdown and results in geometric
changes in both the infarcted and healthy myocardium. LV dilation results in
stretched cardiomyocytes in the border zone (BZ) and healthy myocardium,
which subsequently lose the ability to efficiently contract43.

Globally, this is

manifested as a shift to a more spherical shape and a reduction in the transmural
wall thickness. The Law of Laplace (Eq. 3.1) illustrates how the resulting dilation
(increased radius) and thinning of the myocardium post-MI leads to increased
stress; where stress (T) is directly proportional to pressure (P) and the radius of
curvature (R), and inversely to the thickness of the myocardial wall (h).

17

(Eq. 3.1)

As mentioned above, past strategies to attenuate LV expansion have included
surgeries to reconstruct the dilated ventricle and restraints placed around the
myocardium or infarct to physically prevent dilation16,44-47. Injectable hydrogels
may present a material system that is applied in a non-invasive manner (liquid to
solid transition) and leads to limited LV expansion. In this section we will review
common natural and synthetic hydrogels that have been investigated to this end,
as well as comment on the underlying mechanisms of therapy.

The reader

should refer to Table 3.1 throughout this section, which summarizes the various
materials that have been investigated in animal models of MI.
Table 3.1. Summary of injectable hydrogels and their assessment in animal models of MI.
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Natural Hydrogels
Christman and colleagues pioneered the field of acellular injectable
biomaterials by exploring the effects of fibrin glue as a bulking agent18,23,34,49.
Fibrin has natural binding domains for soluble growth factors and cellular integrin
receptors, motivating its use for wound healing applications. Although fibrin is
commonly utilized for these biological properties, it can also be used as a
mechanical support for the myocardium18,29,34,49.

Specifically, fibrin forms a

crosslinked 3-D hydrogel in the myocardium upon injection with a dual-barreled
syringe. One barrel contains fibrinogen and aprotinin, a fibrinolysis inhibitor, and
the second barrel contains thrombin, factor XIIIa, and CaCl218,23,29,49. Following a
similar mechanism to that involved in the normal clotting cascade in vivo, when
fibrinogen and thrombin are mixed, fibrinogen is converted to fibrin which self
assembles and is crosslinked via the factor XIIIa.
Christman et al. injected these fibrin hydrogels into the ischemic LV one
week following induced MI in rats (reperfusion- MI model) and animals were
sacrificed 5 weeks later. Echocardiograph and explant data showed that fibrin is
capable of maintaining fractional shortening (FS) and preserving infarct scar
thickness after the material was resorbed18. In later studies, using the same
model, Christman et al. demonstrated the ability of fibrin to substantially
decrease infarct size and increase arteriole density in the infarct area compared
to control BSA injections49. These results imply that in addition to its bulking
effects, fibrin may also elicit a bioactive response that influences LV remodeling.
Significant increases in neovasculature formation (capillary density) following
fibrin injection in rat models of MI were later confirmed by Huang et al.23.
Natural materials that are relatively bioinert such as alginate have also
been explored as injectable hydrogels to treat MI. Alginate is a linear seaweedderived copolymer consisting of linked !-D-mannuronate (M) and "-L-guluronate
(G) residues and can be crosslinked into hydrogels with the addition of divalent
cations

57

. Unlike fibrin, alginate must be modified with adhesive peptides to
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facilitate cell binding.

Both non-modified alginate and alginate modified with

adhesive peptides such as Arg-Gly-Asp (RGD) or Tyr-Ile-Gly-Ser-Arg (YIGSR)
have been explored as bulking agents26,31,34,50,51 and comparisons have been
performed between the two31,50. Yu et al. compared modified alginate to nonmodified alginate using a rat reperfusion-MI model with injections 5 weeks postMI, more indicative of a chronic response50. Five weeks after hydrogel injections,
both alginate groups improved FS, reduced LV dimensions and significantly
increased myocardial wall thickness compared to control BSA injections.
Although both non-modified and modified groups also increased the number of
arterioles in the infarct area, modified alginate resulted in higher densities,
indicating the ability of adhesive peptide modifications to promote angiogenesis
following MI. Tsur-Gang et al. also observed improved geometry and function
following injection of non-modified alginate hydrogels; however, they observed
conflicting data with modified alginate hydrogels31. Specifically, modified alginate
showed a reduced benefit compared to non-modified alginate in terms of LV
diastolic and systolic dimension (LVDD and LVSD), LV diastolic and systolic
areas (LVDA and LVSA), FS, and fractional area change, although no significant
differences in relative scar thickness or blood vessel densities were observed.
Utilizing a large animal swine model, Mukherjee et al. injected composite
hydrogels containing both fibrin and alginate to prevent geometric LV
remodeling29. One week post-MI, 200µL injections (25 total) were applied to the
infarct area via a double barreled injection device; one component was
comprised of fibrinogen, fibronectin, factor XIII, plasminogen and gelatin-grafted
alginate dissolved in an aprotinin solution, while the second consisted of
thrombin and 40mM CaCl2. Therapeutic outcomes included increased posterior
wall thickness 1 week post injection and a reduction in infarct expansion 21 and
28 days post-MI; however, no functional improvements were observed. Other
interesting findings included a significant reduction of soluble collagen in the
treatment groups, suggesting that collagen was less vulnerable to protease
degradation.

This observation was supported by a significant decrease in
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protease levels (e.g., MMP-2) in the composite hydrogel injection group, which
could favor infarct stiffening and, thus, attenuate maladaptive remodeling in the
future.
Chitosan

is

a

linear

polysaccharide

that

is

biocompatible

and

biodegradable and therefore has been used in a wide variety of tissue
engineering applications58.

Chitosan hydrogels can be formed upon mixing

commercially produced chitosan with a glycerol phosphate and glyoxal solution.
These gels exhibit a thermoresponsive gelation that is tuned to occur at 37°C by
changing the glyoxal concentration, while hydrogel degradation is controlled by
the degree of deacetylation59,60. In a rat infarct model, a thermally responsive
chitosan was injected 1 week post-MI28. Four weeks after hydrogel injection, the
myocardium thickness was significantly increased compared to PBS controls,
even though the amount of chitosan present in the myocardium after 4 weeks
had substantially decreased due to hydrogel degradation.

There were also

significant improvements in infarct size, FS, ejection fraction (EF), end systolic
diameter (ESD), end diastolic diameter (EDD), and microvessel density.
Although the material was not completely degraded at the end of this study, like
fibrin, this is an example of a degradable material that was effective in not only
preserving thickness but also function.
Hyaluronic acid (HA) is a polysaccharide that is abundant in the body and
can play several biological roles that include angiogenesis, cell migration, and
scar reduction depending on its molecular weight and the addition of function
groups allows for tunability in material properties61-66. In one example, acrylatedHA was mixed with a thiol-terminated PEG crosslinker (PEG-SH4) and
crosslinked via Michael-type addition; the mixture was injected into a rat MI
model 2 weeks post-MI33.

Four weeks after treatment, heart function was

evaluated; HA treatment led to significantly decreased infarct size, increased EF
and increased arteriole and capillary density.

Interestingly, results showed

significant increases in infarct thickness while histology showed complete
degradation of the HA gels. Improvements in this work were attributed to the
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biological role of HA, which like fibrin has proven to play a large role in wound
healing applications.

Additional work with engineered HA hydrogels will be

discussed in a section below on modulating hydrogel properties.
Collagen is a natural ECM protein that has been applied for LV remodeling
therapies due to the ability to inject as a liquid, which subsequently gels at
37°C19,23. Collagen injections in 1 week old rat infarcts substantially increased
infarct thickness, stroke volume (SV) and EF compared to saline inject controls;
there was also a trend for improved end systolic volume (ESV)19. While this
study did not show any evidence of angiogenesis or cell infiltration, Huang et al,
using a reperfused model, were able to demonstrate both increased
angiogenesis and myofibroblast infiltration in the infarct zone compared to
controls23. Contradicting results may be attributed to variables in methodology
(Table 1) or differences in collagen types and concentrations used. Dai et al.
used a mixture of collagen I (95%) and collagen III (5%) at 65 mg/mL, while
Huang et al. used a collagen I at 1 mg/mL.

As an alternative to hydrogels

composed solely of isolated collagen, Matrigel is commercially available hydrogel
derived from the ECM that is primarily composed of collagen, but also contains
numerous other molecules derived from the basement membrane. Studies with
Matrigel alone in a mouse model showed trends towards increased scar
thickening and improved function compared to infarct controls25; thickening and
improved EDD were also observed in a rat model54. In addition, studies by Huang
et al. showed significantly increased capillary density with Matrigel injection23.
Extracellular matrix (ECM) components isolated from healthy myocardium
have been recently explored to treat MI.

Singelyn et al., decellularized and

solubilized the ECM from pig hearts for use as an injectable scaffold30. The
isolated ECM material maintained a complex composition including collagen and
glyocosaminoglycan content and exhibited a natural thermoresponsive behavior
as it self-assembled into a nanofibrous gel at 37°C from a liquid precursor at
25°C.

Interestingly, the cocktail of isolated ECM components stimulated the

migration of human coronary artery endothelial cells (HCAEC) and rat aortic
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smooth muscle cells (RASMC) in vitro. For in vivo application, 90 µL hydrogels
were successfully pushed through a catheter into the non-infarcted myocardium
of rats where they induced a significant increase in arteriole formation 11 days
post-injection. In later work, Seif-Naraghi et al. isolated both porcine and human
pericardial ECM (PPM and HPM respectively) to evaluate their potential as
autologous scaffolds for treating MI55. Similarly, these gels polymerized under
thermal stimulation and maintained native components of the pericardial ECM.
While in vitro results demonstrated that PPM was more effective in promoting
migration of HCAEC, RASMC, and rat epicardial cells (RECs) compared to HPM,
in vivo data 2 weeks post injection (90 µL) indicated that both PPM and HPM
similarly promoted neovascularization (76 ±13 arterioles per mm2 and 51±42
arterioles per mm2, respectively). Interestingly, stem cell evaluation revealed that
although very slight, c-kit+ cells were present within the injection regions, eluding
to a role in endogenous homing of these materials. These studies demonstrate
that providing cardiac-specific cues to the injured myocardium via decellularized
ECM injectable hydrogels provides a useful strategy to promote cardiac-specific
tissue formation.
Synthetic Hydrogels
Natural materials may provide numerous important cellular-interactive
cues (e.g., adhesion and cell-mediated degradation), but are generally limited in
the extent that their properties can be adjusted (ie: mechanics, degradation, and
viscosity).

In contrast, synthetic materials provide additional potential in

engineering a variety of gelation mechanisms and physical properties. One
synthetic thermosensitive polymer, comprised of dextran (Dex) grafted
poly(caprolactone)-2-hydroxyethyl methacrylate (PCL-HEMA) and copolymerized
with poly(N-isopropylacrylamide) (PNIPAAm) termed Dex-PCL-HEMA/PNIPAAm,
was developed to gel in situ. Material injections were performed 4 days post-MI
in a rabbit model and resulted in significant reductions in infarct scar and
improvement in EF and LV end diastolic and systolic diameter (LVEDD and
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LVSD) compared to PBS control injections when assessed 30 days after
injection32. Significant thickening was observed despite no histological evidence
of material remaining.
Similarly, Fujimoto et al. synthesized a biodegradable, temperature
responsive hydrogel composed of N-PNIPAAm, acrylic acid, and hydroxyethyl
methacrylate-poly(trimethylene

carbonate)

(poly(NIPAAm-co-AAc-co-

HEMAPTMC)) with slower degradation than the previously discussed polymer
(Figure

3.1)22.

Like

Dex-PCL-HEMA/PNIPAAm,

poly(NIPAAm-co-AAc-co-

HEMAPTMC) was engineered to undergo gelation at body temperature. In this
particular study, a hydrogel with a maximum tensile strength of 6.1 kPa and
complete hydrogel degradation after 5 months was evaluated for its efficacy in
preventing LV remodeling in a rat MI model. The polymer was injected two
weeks post-MI; after 8 weeks the myocardium thickness, EDA and fractional area
change were significantly improved compared to PBS injection controls.

Figure 3.1. In vivo application of injectable synthetic polymers. Chemical structure of
poly(NIPAAm-co-AAc-co-HEMAPTMC) (a), representative images of PBS (b) and gel (c) injected
hearts at 8 weeks, and hematoxylin and eosin stained section of PBS control (d) and gel
treatment (e) hearts at 8 weeks. Scale bar: 5 mm in (b,c), 500 µm in (d,e). Figure adapted from
22
.
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Another synthetic material consisting of !cyclodextrin (!-CD) and poly(ethylene
glycol) (MPEG-PCL-PEG) triblock polymer that has the ability to gel in situ has
also

demonstrated

therapeutic

benefits

when

injected

to

target

LV

remodeling24,32. Degradation can be controlled by the PCL block and hydrogels
were formed upon mixing the linear MPEG-PCL-MPEG polymer with !-CD.
When injected 5 minutes post-MI in a rat model, the hydrogel-treated groups
showed a significant reduction in infarct size, LVEDD, LVESD, and an increase in
FS compared to PBS inject controls. No increase in neovascularization was
observed32. In 1 week old infarcts in a rabbit model, significant improvements in
thickness, infarct size, LVEDD, LVESD, and EF were observed with no increase
in microvessel density24.
The aforementioned synthetic materials have all been degradable.

In

contrast, a non-degradable vinyl sulfone derivatized PEG (PEG-VS) has also
been investigated to treat MI21. PEG-based hydrogels are bioinert and can be
tailored to have high mechanical properties. PEG-VS was polymerized upon
combination with dithiothreitol (DTT) and injected into a rat MI model 2 minutes
post-MI.

PEG-VS significantly increased the wall thickness at 4 weeks, and

although no longer significant, was still thicker than saline controls at 13 weeks.
Despite PEG-VS thickening the myocardial wall, echocardiograph analysis
showed significant improvements in EDD only 4 weeks after MI; this was not
maintained at 13 weeks. FS was also not improved in treatment groups. Here,
in this small animal model, it is observed that prolonged material presence (or
stabilization) is not sufficient to attenuate LV remodeling.
Limitations of Experimental Assessment of Bulking Agents
From the above reviewed results, it is clear that bulking agents may
attenuate remodeling post-MI; however, the mechanism involved in their success
still remains to be elucidated. If anything, these results reveal the complexity in
the material interaction with the myocardial tissue, including both the biological
(e.g., material remodeling, inflammatory response) and mechanical (e.g., stress
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reduction) responses. Variable results from these studies indicate that material
thickness21,26,29,34, infarct size34, and/or increased angiogenesis19,24,56 do not
necessarily correlate directly with improved heart function.

However,

discrepancies in results could be due to inconsistencies in methodology (Table
3.1) (e.g., animal models, infarct, amount of material injected, timing of injection)
and material properties and their importance should be considered when
investigating LV remodeling.

Specifically, several animal models have been

used to study the efficacy of bulking agents. The most popular model is by far
the rat model, possibly due to costs and ease of implementation; however, this
model has several limitations. The most obvious is the lack of clinical relevance
associated with a small animal model, as well as infarct consistency. In the
clinical setting, factors such as the LV volume and structure, material injection
volume, and method for injection will be very different than in the rat.
Material injection of bulking studies has been performed as early as
immediately post-MI21,25 as late at 8 weeks post-MI26. In separate studies with
fibrin, injection at 1 week was more effective in improving myocardium function18
versus injection 5 weeks post-MI34. Utilizing a permanent ligation rat model,
Landa et al. directly compared injections into new (1 week post-MI) and old (2
months post-MI) infarcts and demonstrated the efficacy of alginate in both
(although to different extents)26. Recent infarcts resulted in improvements in wall
thickening and LV dilation; while older infarcts also showed improvements,
results were more pronounced, implying that post-MI therapies are more effective
when applied early in the LV remodeling process, potentially before irreversible
processes have occurred. Similar to injection time, data collection time points
are also important to consider. The longest study evaluated in this review was 3
months post treatment21 and 4 months post-MI26.
Material Optimization: Theoretical Evaluation
Theoretical models have implied that material properties, specifically
mechanics and volume, are important to consider when selecting the type of
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bulking agent to ameliorate dilation and increased stress in the myocardial
wall35,67-69. Using a finite element (FE) model to simulate the effects of injecting a
non-contractile material into the myocardium, Wall et al. showed that bulking the
myocardium was sufficient to attenuate post-MI geometric changes and, thus,
decrease stress in the myocardial wall35. More specifically, they demonstrated
that injections of 4.5% of the LV wall volume and 20% of the stiffness of the
natural myocardium into the BZ were able to decrease the fiber stress by 20%
compared to control simulations with no injections.

Other approaches have

validated the importance of infarct compliance using FE, as well as lumpparameter models; results reveal similar overall beneficial outcomes35,67,68.

FE

models have also been employed to evaluate the effects of material volume and
distribution in the myocardium and showed that they influence the extent of
remodeling (Figure 3.2)35,69.

After testing several injection patterns it was

determined that the maximum number of injections leads to the highest reduction
in fiber stress69. These simulations provide insight to the relevance of bulking
material properties, specifically mechanics and volume distribution, and present
more evidence to pursue injectable material therapies to control LV remodeling.

Figure 3.2. Finite element (FE) model of injected polymeric materials. Reference FE model
for infarcted canine heart (a) and modified FE model with polymeric inclusion injection pattern into
dilated LV (b) can be used to assess the effects of material volume and distribution on myofiber
stress. Figure adapted from69.
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Material Optimization: Comparing Different Materials
Only two studies have directly compared different materials and their
efficacy in preventing LV remodeling23,34.

Utilizing an infarct-reperfusion rat

model, Yu et al. compared non-modified alginate to fibrin with injections applied 5
weeks post-MI34. Two days after injection, both materials were similarly effective
in improving FS, LV dimensions and wall thickness. However, 5 weeks post
injection, alginate demonstrated greater improvements than fibrin in FS, LV
dimensions, and wall thickness.

This could be attributed to the extended

presence of alginate in the myocardium while fibrin was no longer detectable;
however, fibrin treatment did result in thicker myocardial walls when compared to
BSA control injections.

Interestingly, while unable to promote cell adhesion,

alginate, like fibrin, resulted in significantly higher arteriole density.

Despite

alginate’s superiority in long-term functional outcomes, fibrin treatment groups
had significantly smaller infarcts compared to controls. This comparison
highlights potential differences in the efficacy of material stabilization in
preventing LV remodeling, due to differences in material degradation and
biological activity.

In another study, Huang et al. compared the extent of

angiogenesis between fibrin, collagen and Matrigel post-MI and determined that
while all three polymers significantly increased capillary density, only collagen
significantly increased the degree of myofibroblast infiltration23.
Material Optimization: Comparing Properties
Few studies have experimentally evaluated the role of material properties
(e.g., volume and mechanics) on LV remodeling. A review of injectable materials
illustrates that a wide range of volumes have been injected as bulking agents
(Table 3.1). As a single example of differences in injected volumes, Leor et al.
injected an alginate-calcium solution into the LAD 4 days post-MI via a coronary
catheter in swine51. During this time post MI, the vasculature of the infarcted
myocardium is leaky, allowing the alginate mixture to be delivered to the infarct
site. Due to inadequate levels of calcium in the vasculature, the alginate solution
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does not crosslink until released into the myocardium where levels of calcium
suffice to stimulate gelation. Various volumes of 1, 2 and 4 mL were injected; 2
and 4 mL injections led to superior LVDA and LVSA with 2 mL injections resulting
in significant thickening (despite material degradation) and more pronounced
trends for functional improvements. These findings illustrate the importance of
injection volume in stabilizing the myocardial wall69. Other parameters, such as
number and pattern of injections, although relevant through theoretical analysis69,
have yet to be investigated in a clinically relevant model.
The influence of material properties may also be an important parameter
to control, yet few studies have investigated this, particularly in a controlled
manner.

This may be due to limitations in material systems where various

important properties can be decoupled. For example, fibrin properties can be
varied by adjusting the concentration of fibrinogen and thrombin70 and Martens et
al. adjusted these parameters to optimize fibrin viscosity and gelation for catheter
delivery71.

Similarly, alginate properties can be adjusted by varying weight

percent and the ratio of M and G units
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. However, in both of these systems

viscosity may be changed during injection and lead to differences in not only final
mechanics, but also material dispersion and biomaterial concentration.
A recent study by Ifkovits et al. was the first to explore how the mechanical
properties of injectable materials influence LV remodeling (Figure 3.3)53. A highly
modified HA polymer (methacrylated HA, MeHA) with a high compressive
modulus (43 kPa) was directly compared to lower modified MeHA with a low
compressive modulus (7.7 kPa). This study demonstrated that although both
materials similarly thickened, or bulked, the infarcted myocardial wall, high MeHA
was able to also decrease infarct size and dilation as well as improve function
under stress compared to the infarct control. This provides evidence that the
mechanical properties of the injectable material are important to consider for
attenuating LV remodeling. Studies with tunable injectable materials will broaden
the understanding of factors, such as mechanics and degradation that should be
regarded to target LV remodeling via bulking agents.
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Figure 3.3. Injectable hyaluronic acid hydrogel. Chemical structure of methacrylated
hyaluronic acid (a), schematic of gel formation process where functional macromers react via a
radical polymerization to form a gel (b), and a representative Masson’s Trichrome stain of the gel
in myocardium 8 week post-MI (c). G=Gel, Scale Bar, 50 µm. Figure adapted from53.

Likewise, the biological activity of materials cannot be overlooked.

A study by

Ryan et al. injected a biocompatible dermal and soft tissue filler (Radiesse)
composed of calcium hydroxyapatite microspheres suspended in an aqueous gel
carrier of water, glycerin, and carboxymethylcellulose. The uncrosslinked gel
carrier allows endogenous cells to access the encapsulated microspheres to
promote collagen synthesis73. Radiesse was injected into the myocardium 45
minutes after ligation in an ovine MI model and analyzed at 4 weeks; injection
resulted in a thickened myocardial wall, increased global EF and reduced LV end
systolic volumes compared to controls.

Unlike the previously mentioned

hydrogel systems that directly bulk the myocardium through hydrogel
crosslinking, this approach provides an effective means to induce tissue bulking
by promoting the biological response to materials for attenuated LV remodeling
and preserved cardiac function52, 74-78.
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3.3. Injectable Hydrogels for Molecule Delivery
In addition to mechanically supporting the injured myocardium as
described above, injectable hydrogels provide a water-swollen matrix to
encapsulate therapeutic molecules for targeted molecule delivery to the
myocardium following MI. Exogenous delivery of therapeutic molecules including
growth factors, cytokines and DNA plasmids can be used to manipulate
endogenous post-MI remodeling processes; however, the high rates of diffusion
and short half-life during which these molecules retain their biological activity in
vivo make successful application of these molecules to treat MI difficult79. To this
end, injectable hydrogels provide a useful platform to sustain the release of
therapeutic molecules in the setting of MI. Molecules are encapsulated in the
hydrogel matrix and released locally over time to sustain target levels of the
molecule in the myocardium while preventing detrimental systemic effects. The
pioneering work of Dr. Robert Langer and Dr. Judah Folkman showed that
polymer matrices can be used to sustain the release of encapsulated molecules
for up to 100 days80. Molecule release from these hydrogels exhibited an initial
‘burst release’ in which molecule release rates are rapid, followed by sustained
released profiles with slower release rates (Figure 3.4). This initial burst release
was significantly decreased with higher polymer concentrations (i.e., higher
polymer-to-water ratios) and the overall release kinetics were unique for each
polymer-molecule

combination.

Polymer-molecule

interactions,

polymer

hydrophobicity, and hydrogel degradation all influence the diffusion of
encapsulated molecules in the hydrogel matrix and therefore determine
encapsulated molecule release kinetics81. The following sections will review the
range of combinations of therapeutic molecules and injectable hydrogel
formulations that have been applied to treat MI.
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Figure 3.4. Representative release behavior from injectable hydrogels. Molecules are
mixed into a hydrogel precursor solution (a), encapsulated after hydrogel formation upon injection
(b), and are released from the network through both diffusion (c) and degradation (d)
mechanisms. Molecule release from these systems can be controlled through polymer
concentration, crosslink density and by incorporating affinity between the encapsulated molecule
and hydrogel (e). Release profiles are unique for each polymer-molecule combination and are
therefore often determined experimentally.

Anti-apoptotic Molecules
In order to attenuate the loss of viable myocardium following MI, protective
growth factors have been delivered locally from injectable hydrogels to the at-risk
myocardium.

Ruvinov et al. developed alginate hydrogel microparticles with

sulfate group modifications to affinity-bind encapsulated insulin-like growth factor1 (IGF-1) and hepatocyte growth factor (HGF) for sustained molecule release in
the setting of MI82. IGF-1 has been shown to be cytoprotective and HGF has
been shown to be pro-angiogenic and anti-fibrotic; therefore, this group
hypothesized that delivery of both of these molecules following MI would have an
additive effect on preserving the viability and structure of the myocardium.
Modifying hydrogels with negatively charged groups is a common way to mimic
the natural affinity of glycosaminoglycans (GAGs) for proteins in order to localize
and sustain the release of exogenously delivered proteins. In this particular
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system, the modified alginate microparticles exhibited a dual release behavior
with distinct release kinetics for IGF-1 and HGF (IGF-1 release was faster than
HGF release), indicating a difference in the affinity of each molecule for the
sulfate group modifications (Figure 3.5).

Importantly, the molecules released

from the microparticles remained active (confirmed in vitro with cell culture
assays) and were protected by protease degradation when bound to the sulfate
modified alginate (as evidenced by mass spectroscopy). When injected 1 week
after induced MI in rats, the alginate microparticles facilitated significant
improvements in IGF-1/HGF mediated repair compared to IGF-1/HGF injected in
saline and alginate microparticles injected without growth factors.

These

improvements include reductions in fibrotic area (collagen staining), apoptotic
cells (caspase-3 expression), and increases in vessel densities and areas (!SMA expression), proliferating cardiomyocytes (Ki67 expression), and evidence
of cardiogenesis (GATA4 expression) 4 weeks following injection.

Figure 3.5. Molecule release from affinity-binding alginate hydrogels. Release kinetics of
IGF-1 and HGF from the same hydrogel (a) and from separate hydrogels (b). Cumulative protein
released (%) = (cumulative released protein up to each time point/total protein recovered from the
hydrogel) ! 100. Residual protein entrapped in the hydrogels at the end of the study was
recovered with sodium citrate treatment. Figure adapted from82.

In addition to GAG affinities, the natural affinity of streptavidin for biotin
has been exploited to sustain the release of IGF-1 from injectable hydrogels20.
Davis et al., biotinylated self-assembling (SA) oligopeptides and IGF-1 to form a
streptavidin-biotin complex upon mixing the biotinylated oligopeptides and IGF-1
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with tetravalent streptavidin. The oligopeptides were designed with alternating
hydrophilic and hydrophobic amino acids in order to “self-assemble” into
nanofibrous hydrogels upon exposure to physiologic pH and osmolarity. IGF-1
release from the hydrogels was sustained for up to 84 days in vivo after injection
into the myocardium or rats. Tethering IGF-1 to the peptide scaffold using the
streptavidin-biotin strategy had significant effects on improving cardiomyocyte
survival in vitro (cardiomyocyte [3H]phenylalanine incorporation) and in vivo
(caspase-3 cleavage of implanted neonatal cardiac myocytes) confirming the
activity of released IGF-1.

Combining the IGF-1/SA peptide hydrogels with

neonatal cardiac myocytes significantly improved functional outcomes post MI,
however the contribution of the IGF-1/SA peptide hydrogels alone was not
investigated.
These self-assembling peptide hydrogels have also been explored to
deliver platelet derived growth factor (PDGF) to prevent cardiomyocyte apoptosis
post MI83.

The amphiphilic nature of the oligopeptides provided sustained

release of PDGF through weak molecular interactions between the oligopeptides
and PDGF. PDGF release was sustained from hydrogels for 14 days following
injection into the myocardium of rats. The released PDGF activated its receptor
(PDGFR-!) in cardiomyocytes adjacent to the injection areas and attenuated
cardiomyocyte death (caspase-3 cleavage) 14 days after induced MI and
PDGF/SA peptide hydrogel injection. In addition, global LV geometry and LV
function (fractional shortening) was preserved 14 days following MI with the
PDGF/SA peptide hydrogels.

A subsequent study confirmed the therapeutic

benefit of these PDGF releasing hydrogels84.

LV geometry and function

(hemodynamic parameters) and myocardial tissue structure (vascular density,
regional blood flow, and infarct size) were significantly improved 4 months
following induced MI in rats with injection of the PDGF/SA peptide hydrogels.
Importantly, the locally delivered PDGF did not have adverse systemic effects
(pulmonary hypertension) as confirmed by no observed change in pulmonary
artery thickness.
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Another group of proteins that can recover cell viability during periods of
environmental stress, the heat shock family of proteins, have also been delivered
in the setting of MI using injectable hydrogels.

Lee et al. used calcium

crosslinked alginate hydrogels as a delivery matrix for poly(lactic-co-glycolic acid)
(PLGA) microspheres loaded with heat shock protein 27 (HSP27) fused to a
transcriptional activator (TAT) (to facilitate cell uptake of HSP27)85. HSP27-TAT
was encapsulated in the PLGA microspheres using water/oil/water emulsions, a
frequently used method for preparing microspheres containing proteins, and
these loaded microspheres were embedded in the alginate hydrogel during
calcium crosslinking upon injection.

Loading HSP27-TAT in the densely

crosslinked microspheres prevented the burst release that is typical of proteins
encapsulated in hydrogels. Released HSP27-TAT remained active as evidenced
by reduced cardiomyocyte apoptosis and restored cardiomyocyte proliferation
under ischemic conditions in vitro, although this system was not tested in the
setting of MI.
Angiogenic Factors
Another common strategy to preserve viable myocardium following MI is
to restore blood flow to the ischemic myocardium by stimulating neovasculature
formation in the infarct area with localized release of pro-angiogenic growth
factors.

Sustained release of fibroblast growth factor (FGF) from injectable

hydrogels has been extensively explored to stimulate angiogenesis following
MI60,86-91. FGF is a powerful angiogenic molecule, but has a very short half-life in
vivo.

Sakakibara et al., showed that radiolabeled FGF delivered to the

myocardium

via

bolus

venous

injections,

intracoronary

injections

or

intramyocardial injections is nearly undetectable 24 hrs after administration89.
However, by using gelatin hydrogel microspheres as a carrier matrix, effective
concentrations of radiolabeled FGF were sustained in the peri-infarct area of the
myocardium 24 and 72 hrs after injection (all groups injected 4 weeks after
induced MI in rats). To assess the therapeutic effects of sustaining FGF levels in
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the myocardium with this hydrogel system, FGF loaded microspheres were
injected 4 weeks after induced MI in swine. Upon evaluation at 4 weeks after
injection, LV remodeling was significantly attenuated (echocardiography) and
neovasculature was significantly increased (capillary density) compared to a
control MI group. Other groups have also reported the efficacy of using gelatin
microspheres to deliver FGF in the setting of MI89,90.

In addition to gelatin

microspheres, injectable chitosan hydrogels have been used to deliver FGF86.
Wang et al. encapsulated FGF in thermoresponsive chitosan hydrogels upon
injection into the myocardium by mixing FGF with the chitosan solution. This
system significantly improved heart function compared to injecting FGF alone in
a rat model of chronic MI (hydrogels injected 1 week post-MI).
While the sustained delivery of pro-angiogenic factors to ischemic tissue
has stimulated neovasculature formation, as evidenced by increases in capillary
densities, the stability and connectivity of these newly formed vessels has been a
concern92. In order to form more stable vessels with supporting smooth muscles
cells, dual delivery of angiogenic growth factors using injectable hydrogels has
been explored to treat MI. Hao et al., encapsulated vascular endothelial growth
factor (VEGF) and platelet derived growth factor (PDGF) in alginate hydrogels by
mixing a solution of purified alginate and growth factors with a calcium sulfate
solution upon injection into the myocardium93. The rationale for choosing these
two molecules was to first stimulate endothelial vessel formation with VEGF
delivery, followed by smooth muscle cell recruitment with PDGF delivery to
support the immature vessels.

To this end, VEGF release preceded PDGF

release from the alginate hydrogels and release of both molecules was sustained
for over 30 days in vitro as the hydrogel degraded.

When applied 1 week

following induced MI in rats, the dual growth factor releasing hydrogels
significantly increased the number of !-SMA containing blood vessels around the
injection site 4 weeks after injection compared to hydrogels loaded with each
growth factor alone.
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To further control VEGF delivery in the setting of MI, Wu et al. conjugated
VEGF to N-hydroxysuccinimide (NHS) terminated PVL-b-PEG-b-PVL block
copolymers (NHS reacts with primary amines on the protein)94.

The block

copolymers were designed to form a hydrogel at 37°C for injectability and
completely degraded after 42 days when implanted subcutaneously in rats.
When injected into the myocardium 1 week following induced MI in rats, the
VEGF conjugated hydrogels showed significant improvements in heart function
(FS, EF, LV EDV and ESV, dP/dt max, dP/dt min) and structure (scar area,
capillary density) 4 weeks after injection compared to VEGF alone and VEGF
injected with the hydrogel but not conjugated (Figure 3.6).

Figure 3.6. Tissue response to delivered growth factors. Representative heart slices
obtained at 35 days after post-MI injection of PBS, hydrogel (HG), hydrogel with soluble VEGF
(HG+VEGF), or hydrogel with VEGF tethered through covalent linkage (HG-VEGF). Arrows
indicate the location of the infarct in individual slices. Figure adapted from94.

Finally, plasmid DNA encoding angiogenic molecules has been delivered
with injectable hydrogels. Kwon et al. synthesized multiblock copolymers with
acid-labile acetal linkages (for controlled degradation) that form hydrogels at
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37°C for VEGF plasmid delivery following MI95.

The injectable hydrogels

significantly enhanced the efficacy of the VEGF plasmid over injecting the naked
plasmid, as confirmed by VEGF expression in the infarct area 2 weeks after
injection. This enhanced expression was correlated with increases in capillary
density and a more preserved myocardium in the infarct area.

To further

enhance angiogenesis, injectable hydrogels with adhesive sites can be used as a
carrier of angiogenic plasmids to provide a matrix that facilitates cell migration.
The combination of plasmid and adhesive matrix (termed gene-activated matrix)
enhances gene transfection by localizing the plasmid until endogenous cells
migrate into the implanted scaffold and become transfected to express the
encoded protein48,96,97. For example, Christman et al. used an injectable fibrin
glue that forms upon mixing fibrinogen and thrombin to localize a plasmid
encoding the angiogenic molecule pleiotrophin (PTN) in the infarct myocardium48.
Injecting the PTN plasmid in fibrin glue 1 week following induced MI in rats
increased the formation of arterioles (!-SMA staining) that were functionally
connected to existent coronary vasculature (confirmed with fluorescent
microbead perfusion) 5 weeks after injection.
Chemoattractants
For control of endogenous cell recruitment, chemokines that selectively
recruit stem/progenitor cells have been delivered from injectable hydrogels. For
example, stromal derived factor-1 alpha (SDF-1!) has been locally delivered in
the setting of MI using the injectable peptide hydrogels described in the previous
section98.

Release of SDF-1! was controlled by tethering the protein to the

oligopeptide scaffold through a peptide sequence that is cleaved by endogenous
proteases.

The amino acid sequence of SDF-1! was engineered to resist

protease degradation to ensure that active SDF-1! was released from the
scaffold in the presence of proteases. Released SDF-1! was detectable for up
to 7 days around the injection site in vivo and led to significant increases in cells
expressing the receptor for SDF-1! in the MI region, which co-expressed
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markers of stem/progenitor cells and endothelial cells.

In addition, capillary

(isolectin) and arteriole (!-SMA) densities increased significantly 4 weeks after
injecting the SDF-1! containing hydrogels compared to MI controls in rats.
These tissue-level observations were correlated with significant improvements in
LV function.
3.4. Summary
Although only in its infancy, it is clear that the field of injectable hydrogels
to treat cardiac tissue post-MI has high potential as a translatable therapy. The
lack of a cell source needed for transplantation will only accelerate development
of percutaneous delivered hydrogels, whether they act as tissue bulking agents
or for the controlled delivery of therapeutic molecules. A wide range of both
natural and synthetic materials have been investigated and each has unique
properties, including mechanics, degradation, and cellular interactions. Future
work should further investigate the various mechanisms in which these materials
act, both biologically and mechanically, and focus on clinically relevant
parameters, such as the animal model and mode of delivery. This information
will lead to a clear understanding and illustration of the efficacy of injectable
hydrogels to treat patients that have experienced an MI and to prevent the LV
remodeling events that can lead to heart failure.

39

3.5. References
1.
2.
3.

4.
5.

6.

7.

8.
9.
10.

11.
12.
13.
14.

15.

Gheorghiade M, Bonow RO. Chronic heart failure in the united states - a
manifestation of coronary artery disease. Circulation. 1998;97:282-289
Eaton LW, Weiss JL, Bulkley BH, Garrison JB, Weisfeldt ML. Regional cardiac
dilatation after acute myocardial-infarction - recognition by 2-dimensional
echocardiography. New England Journal of Medicine. 1979;300:57-62
Erlebacher JA, Weiss JL, Weisfeldt ML, Bulkley BH. Early dilation of the infarcted
segment in acute transmural myocardial-infarction - role of infarct expansion in
acute left-ventricular enlargement. Journal of the American College of
Cardiology. 1984;4:201-208
Weisman HF, Healy B. Myocardial infarct expansion, infarct extension, and
reinfarction - pathophysiologic concepts. Progress in Cardiovascular Diseases.
1987;30:73-110
Epstein FH, Yang ZQ, Gilson WD, Berr SS, Kramer CM, French BA. Mr tagging
early after myocardial infarction in mice demonstrates contractile dysfunction in
adjacent and remote regions. Magnetic Resonance in Medicine. 2002;48:399403
Jackson BM, Gorman JH, Moainie SL, Guy TS, Narula N, Narula J, John-Sutton
MG, Edmunds LH, Gorman RC. Extension of borderzone myocardium in
postinfarction dilated cardiomyopathy. Journal of the American College of
Cardiology. 2002;40:1160-1167
Jackson BM, Gorman JH, Salgo IS, Moainie SL, Plappert T, St John-Sutton M,
Edmunds LH, Gorman RC. Border zone geometry increases wall stress after
myocardial infarction: Contrast echocardiographic assessment. American Journal
of Physiology-Heart and Circulatory Physiology. 2003;284:H475-H479
Kramer CM, Lima JAC, Reichek N, Ferrari VA, Llaneras MR, Palmon LC, Yeh IT,
Tallant B, Axel L. Regional differences in function within noninfarcted
myocardium during left-ventricular remodeling. Circulation. 1993;88:1279-1288
Lima JAC, Becker LC, Melin JA, Lima S, Kallman CA, Weisfeldt ML, Weiss JL.
Impaired thickening of nonischemic myocardium during acute regional ischemia
in the dog. Circulation. 1985;71:1048-1059
Pilla JJ, Blom AS, Gorman JH, 3rd, Brockman DJ, Affuso J, Parish LM,
Sakamoto H, Jackson BM, Acker MA, Gorman RC. Early postinfarction
ventricular restraint improves borderzone wall thickening dynamics during
remodeling. Ann Thorac Surg. 2005;80:2257-2262
Gorman RC, Jackson BM, Gorman JH. The potential role of ventricular
compressive therapy. Surgical Clinics of North America. 2004;84:45-+
Mann DL. Mechanisms and models in heart failure - a combinatorial approach.
Circulation. 1999;100:999-1008
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction:
Pathophysiology and therapy. Circulation. 2000;101:2981-2988
Blom AS, Pilla JJ, Gorman RC, 3rd, Gorman JH, Mukherjee R, Spinale FG,
Acker MA. Infarct size reduction and attenuation of global left ventricular
remodeling with the corcap cardiac support device following acute myocardial
infarction in sheep. Heart Fail Rev. 2005;10:125-139
Enomoto Y, Gorman JH, Moainie SL, Jackson BM, Parish LM, Plappert T,
Zeeshan A, St John-Sutton MGS, Gorman RC. Early ventricular restraint after
myocardial infarction: Extent of the wrap determines the outcome of remodeling.
Annals of Thoracic Surgery. 2005;79:881-887

40

16.

17.

18.
19.
20.

21.
22.

23.
24.

25.

26.
27.

28.

29.

Kelley ST, Malekan R, Gorman JH, 3rd, Jackson BM, Gorman RC, Suzuki Y,
Plappert T, Bogen DK, Sutton MG, Edmunds LH, Jr. Restraining infarct
expansion preserves left ventricular geometry and function after acute
anteroapical infarction. Circulation. 1999;99:135-142
Moainie SL, Guy S, Gorman JH, Plappert T, Jackson BM, St John-Sutton MG,
Edmunds LH, Gorman RC. Infarct restraint attenuates remodeling and reduces
chronic ischemic mitral regurgitation after postero-lateral infarction. Annals of
Thoracic Surgery. 2002;74:444-449
Christman KL, Fok HH, Sievers RE, Fang QH, Lee RJ. Fibrin glue alone and
skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial
infarction. Tissue Engineering. 2004;10:403-409
Dai WD, Wold LE, Dow JS, Kloner RA. Thickening of the infarcted wall by
collagen injection improves left ventricular function in rats. Journal of the
American College of Cardiology. 2005;46:714-719
Davis ME, Hsieh PCH, Takahashi T, Song Q, Zhang SG, Kamm RD, Grodzinsky
AJ, Anversa P, Lee RT. Local myocardial insulin-like growth factor 1 (igf-1)
delivery with biotinylated peptide nanofibers improves cell therapy for myocardial
infarction. Proceedings of the National Academy of Sciences of the United States
of America. 2006;103:8155-8160
Dobner S, Bezuidenhout D, Govender P, Zilla P, Davies N. A synthetic nondegradable polyethylene glycol hydrogel retards adverse post-infarct left
ventricular remodeling. J Card Fail. 2009;15:629-636
Fujimoto KL, Ma ZW, Nelson DM, Hashizume R, Guan JJ, Tobita K, Wagner
WR. Synthesis, characterization and therapeutic efficacy of a biodegradable,
thermoresponsive hydrogel designed for application in chronic infarcted
myocardium. Biomaterials. 2009;30:4357-4368
Huang NF, Yu J, Sievers R, Li S, Lee RJ. Injectable biopolymers enhance
angiogenesis after myocardial infarction. Tissue Eng. 2005;11:1860-1866
Jiang XJ, Wang T, Li XY, Wu DQ, Zheng ZB, Zhang JF, Chen JL, Peng B, Jiang
H, Huang C, Zhang XZ. Injection of a novel synthetic hydrogel preserves left
ventricle function after myocardial infarction. J Biomed Mater Res A.
2009;90:472-477
Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC. Novel
injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue
restoration on the beating heart after myocardial injury. Circulation.
2005;112:I173-177
Landa N, Miller L, Feinberg MS, Holbova R, Shachar M, Freeman I, Cohen S,
Leor J. Effect of injectable alginate implant on cardiac remodeling and function
after recent and old infarcts in rat. Circulation. 2008;117:1388-1396
Leor J, Miller L, Feinberg MS, Shachar M, Landa N, Holbova R, Cohen S. A
novel injectable alginate scaffold promotes angiogenesis and preserves left
ventricular geometry and function after extensive myocardial infarction in rat.
Circulation. 2004;110:279-279
Lu WN, Lu SH, Wang HB, Li DX, Duan CM, Liu ZQ, Hao T, He WJ, Xu B, Fu Q,
Song YC, Xie XH, Wang CY. Functional improvement of infarcted heart by coinjection of embryonic stem cells with temperature-responsive chitosan hydrogel.
Tissue Eng Part A. 2009;15:1437-1447
Mukherjee R, Zavadzkas JA, Saunders SM, McLean JE, Jeffords LB, Beck C,
Stroud RE, Leone AM, Koval CN, Rivers WT, Basu S, Sheehy A, Michal G,
Spinale FG. Targeted myocardial microinjections of a biocomposite material

41

30.
31.

32.
33.
34.

35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.

46.
47.

reduces infarct expansion in pigs. Ann Thorac Surg. 2008;86:1268-1276
Singelyn JM, DeQuach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ,
Christman KL. Naturally derived myocardial matrix as an injectable scaffold for
cardiac tissue engineering. Biomaterials. 2009;30:5409-5416
Tsur-Gang O, Ruvinov E, Landa N, Holbova R, Feinberg MS, Leor J, Cohen S.
The effects of peptide-based modification of alginate on left ventricular
remodeling and function after myocardial infarction. Biomaterials. 2009;30:189195
Wang T, Wu DQ, Jiang XJ, Zhang XZ, Li XY, Zhang JF, Zheng ZB, Zhuo R,
Jiang H, Huang C. Novel thermosensitive hydrogel injection inhibits post-infarct
ventricle remodelling. Eur J Heart Fail. 2009;11:14-19
Yoon SJ, Fang, Y.H., Lim, C.H., Kim, B.S., Son, H.S., Park, Y., Sun K.
Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel.
Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2008:9
Yu J, Christman KL, Chin E, Sievers RE, Saeed M, Lee RJ. Restoration of left
ventricular geometry and improvement of left ventricular function in a rodent
model of chronic ischemic cardiomyopathy. J Thorac Cardiovasc Surg.
2009;137:180-187
Wall ST, Walker JC, Healy KE, Ratcliffe MB, Guccione JM. Theoretical impact of
the injection of material into the myocardium: A finite element model simulation.
Circulation. 2006;114:2627-2635
Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chemical Reviews.
2001;101:1869-1879
Minh KN, Lee DS. Injectable biodegradable hydrogels. Macromolecular
Bioscience. 2010;10:563-579
Yu L, Ding JD. Injectable hydrogels as unique biomedical materials. Chemical
Society Reviews. 2008;37:1473-1481
Nelson DM, Ma Z, Fujimoto KL, Hashizume R, Wagner WR. Intra-myocardial
biomaterial injection therapy in the treatment of heart failure: Materials, outcomes
and challenges. Acta Biomater. 2011;7:1-15
Shapira K, Dikovsky D, Habib M, Gepstein L, Seliktar D. Hydrogels for cardiac
tissue regeneration. Biomed Mater Eng. 2008;18:309-314
Gupta KB, Ratcliffe MB, Fallert MA, Edmunds LH, Jr., Bogen DK. Changes in
passive mechanical stiffness of myocardial tissue with aneurysm formation.
Circulation. 1994;89:2315-2326
Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial
infarcts. Annu Rev Biomed Eng. 2005;7:223-253
Pfeffer MA, Pfeffer JM. Ventricular enlargement and reduced survival after
myocardial infarction. Circulation. 1987;75:IV93-97
Batista R. Partial left ventriculectomy--the batista procedure. Eur J Cardiothorac
Surg. 1999;15 Suppl 1:S12-19; discussion S39-43
Starling RC, Jessup M, Oh JK, Sabbah HN, Acker MA, Mann DL, Kubo SH.
Sustained benefits of the corcap cardiac support device on left ventricular
remodeling: Three year follow-up results from the acorn clinical trial. Ann Thorac
Surg. 2007;84:1236-1242
Sartipy U, Albage A, Lindblom D. The dor procedure for left ventricular
reconstruction. Ten-year clinical experience. Eur J Cardiothorac Surg.
2005;27:1005-1010
Klodell CT, Jr., Aranda JM, Jr., McGiffin DC, Rayburn BK, Sun B, Abraham WT,
Pae WE, Jr., Boehmer JP, Klein H, Huth C. Worldwide surgical experience with

42

48.
49.

50.
51.

52.

53.

54.

55.

56.

57.
58.
59.
60.
61.

the paracor heartnet cardiac restraint device. J Thorac Cardiovasc Surg.
2008;135:188-195
Christman KL, Fang QZ, Yee MS, Johnson KR, Sievers RE, Lee RJ. Enhanced
neovasculature formation in ischemic myocardium following delivery of
pleiotrophin plasmid in a biopolymer. Biomaterials. 2005;26:1139-1144
Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ. Injectable
fibrin scaffold improves cell transplant survival, reduces infarct expansion, and
induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol.
2004;44:654-660
Yu J, Gu Y, Du KT, Mihardja S, Sievers RE, Lee RJ. The effect of injected rgd
modified alginate on angiogenesis and left ventricular function in a chronic rat
infarct model. Biomaterials. 2009;30:751-756
Leor J, Tuvia S, Guetta V, Manczur F, Castel D, Willenz U, Petnehazy O, Landa
N, Feinberg MS, Konen E, Goitein O, Tsur-Gang O, Shaul M, Klapper L, Cohen
S. Intracoronary injection of in situ forming alginate hydrogel reverses left
ventricular remodeling after myocardial infarction in swine. J Am Coll Cardiol.
2009;54:1014-1023
Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF.
Macrophage phenotype and remodeling outcomes in response to biologic
scaffolds with and without a cellular component. Biomaterials. 2009;30:14821491
Ifkovits JL, Tous E, Minakawa M, Morita M, Robb JD, Koomalsingh KJ, Gorman
JH, 3rd, Gorman RC, Burdick JA. Injectable hydrogel properties influence infarct
expansion and extent of postinfarction left ventricular remodeling in an ovine
model. Proc Natl Acad Sci U S A. 2010;107:11507-11512
Kofidis T, de Bruin JL, Hoyt G, Lebl DR, Tanaka M, Yamane T, Chang CP,
Robbins RC. Injectable bioartificial myocardial tissue for large-scale intramural
cell transfer and functional recovery of injured heart muscle. J Thorac Cardiovasc
Surg. 2004;128:571-578
Seif-Naraghi SB, Salvatore MA, Schup-Magoffin PJ, Hu DP, Christman KL.
Design and characterization of an injectable pericardial matrix gel: A potentially
autologous scaffold for cardiac tissue engineering. Tissue Eng Part A.16:20172027
Wang T, Jiang XJ, Lin T, Ren S, Li XY, Zhang XZ, Tang QZ. The inhibition of
postinfarct ventricle remodeling without polycythaemia following local sustained
intramyocardial delivery of erythropoietin within a supramolecular hydrogel.
Biomaterials. 2009;30:4161-4167
Rowley JA, Madlambayan G, Mooney DJ. Alginate hydrogels as synthetic
extracellular matrix materials. Biomaterials. 1999;20:45-53
Kim IY, Seo SJ, Moon HS, Yoo MK, Park IY, Kim BC, Cho CS. Chitosan and its
derivatives for tissue engineering applications. Biotechnol Adv. 2008;26:1-21
Ruel-Gariepy E, Shive M, Bichara A, Berrada M, Le Garrec D, Chenite A, Leroux
JC. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel.
Eur J Pharm Biopharm. 2004;57:53-63
Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD,
Leroux JC, Atkinson BL, Binette F, Selmani A. Novel injectable neutral solutions
of chitosan form biodegradable gels in situ. Biomaterials. 2000;21:2155-2161
Chung C, Beecham M, Mauck RL, Burdick JA. The influence of degradation
characteristics of hyaluronic acid hydrogels on in vitro neocartilage formation by
mesenchymal stem cells. Biomaterials. 2009;30:4287-4296

43

62.
63.
64.
65.
66.
67.

68.
69.

70.
71.
72.
73.
74.
75.
76.
77.
78.
79.

80.
81.
82.

Khetan S, Burdick J. Cellular encapsulation in 3d hydrogels for tissue
engineering. J Vis Exp. 2009
Khetan S, Chung C, Burdick JA. Tuning hydrogel properties for applications in
tissue engineering. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:2094-2096
Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992;6:2397-2404
Sahoo S, Chung C, Khetan S, Burdick JA. Hydrolytically degradable hyaluronic
acid hydrogels with controlled temporal structures. Biomacromolecules.
2008;9:1088-1092
Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev
Cancer. 2004;4:528-539
Dang AB, Guccione JM, Mishell JM, Zhang P, Wallace AW, Gorman RC,
Gorman JH, 3rd, Ratcliffe MB. Akinetic myocardial infarcts must contain
contracting myocytes: Finite-element model study. Am J Physiol Heart Circ
Physiol. 2005;288:H1844-1850
Pilla JJ, Gorman JH, 3rd, Gorman RC. Theoretic impact of infarct compliance on
left ventricular function. Ann Thorac Surg. 2009;87:803-810
Wenk JF, Wall ST, Peterson RC, Helgerson SL, Sabbah HN, Burger M, Stander
N, Ratcliffe MB, Guccione JM. A method for automatically optimizing medical
devices for treating heart failure: Designing polymeric injection patterns. J
Biomech Eng. 2009;131:121011
Sierra DH, Eberhardt AW, Lemons JE. Failure characteristics of multiplecomponent fibrin-based adhesives. J Biomed Mater Res. 2002;59:1-11
Martens TP, Godier AF, Parks JJ, Wan LQ, Koeckert MS, Eng GM, Hudson BI,
Sherman W, Vunjak-Novakovic G. Percutaneous cell delivery into the heart using
hydrogels polymerizing in situ. Cell Transplant. 2009;18:297-304
Augst AD, Kong HJ, Mooney DJ. Alginate hydrogels as biomaterials. Macromol
Biosci. 2006;6:623-633
Ryan LP, Matsuzaki K, Noma M, Jackson BM, Eperjesi TJ, Plappert TJ, JohnSutton MGS, Gorman JH, Gorman RC. Dermal filler injection: A novel approach
for limiting infarct expansion. Annals of Thoracic Surgery. 2009;87:148-155
Anderson JM. Biological responses to materials. Annu. Rev. Mater. Res.
2001;31:20
Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials.
Semin Immunol. 2008;20:86-100
Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM.
Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue
Eng Part A. 2008;14:1835-1842
Rodriguez A, Meyerson H, Anderson JM. Quantitative in vivo cytokine analysis at
synthetic biomaterial implant sites. J Biomed Mater Res A. 2009;89:152-159
Ziats NP, Miller KM, Anderson JM. In vitro and in vivo interactions of cells with
biomaterials. Biomaterials. 1988;9:5-13
Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. Therapeutic
interventions for enhancing collateral development by administration of growth
factors: Basic principles, early results and potential hazards. Cardiovasc Res.
2001;49:532-542
Langer R, Folkman J. Polymers for sustained-release of proteins and other
macromolecules. Nature. 1976;263:797-800
Gombotz WR, Pettit DK. Biodegradable polymers for protein and peptide drugdelivery. Bioconjugate Chemistry. 1995;6:332-351
Ruvinov E, Leor J, Cohen S. The promotion of myocardial repair by the

44

83.
84.
85.

86.

87.

88.

89.

90.

91.

92.
93.

94.
95.

sequential delivery of igf-1 and hgf from an injectable alginate biomaterial in a
model of acute myocardial infarction. Biomaterials. 2011;32:565-578
Hsieh PCH, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of
pdgf-bb for myocardial protection using injectable self-assembling peptide
nanofibers. Journal of Clinical Investigation. 2006;116:237-248
Hsieh PCH, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local controlled
intramyocardial delivery of platelet-derived growth factor improves postinfarction
ventricular function without pulmonary toxicity. Circulation. 2006;114:637-644
Lee J, Tan CY, Lee SK, Kim YH, Lee KY. Controlled delivery of heat shock
protein using an injectable microsphere/hydrogel combination system for the
treatment of myocardial infarction. Journal of Controlled Release. 2009;137:196202
Wang HB, Zhang XL, Li YM, Ma YT, Zhang Y, Liu ZG, Zhou J, Lin QX, Wang
YM, Duan CM, Wang CY. Improved myocardial performance in infarcted rat
heart by co-injection of basic fibroblast growth factor with temperature-responsive
chitosan hydrogel. Journal of Heart and Lung Transplantation. 2010;29:881-887
Sakakibara Y, Yamamoto M, Nishimura K, Nishina T, Miwa S, Handa N, Nomoto
T, Tanbara K, Tabata Y, Komeda M. Prevasculrization using gelatin microsphere
containing basic-fibroblast growth factor enhances the benefits of
cardiomyocytes transplantation in rats with ischemic cardiomyopathy. Circulation.
2000;102:650-650
Yamamoto T, Suto N, Okubo T, Mikuniya A, Hanada H, Yagihashi S, Fujita M,
Okumura K. Intramyocardial delivery of basic fibroblast growth factorimpregnated gelatin hydrogel microspheres enhances collateral circulation to
infarcted canine myocardium. Japanese Circulation Journal-English Edition.
2001;65:439-444
Iwakura A, Fujita M, Kataoka K, Tambara K, Sakakibara Y, Komeda M, Tabata
Y. Intramyocardial sustained delivery of basic fibroblast growth factor improves
angiogenesis and ventricular function in a rat infarct model. Heart and Vessels.
2003;18:93-99
Liu Y, Sun LJ, Huan Y, Zhao HT, Deng JL. Effects of basic fibroblast growth
factor microspheres on angiogenesis in ischemic myocardium and cardiac
function: Analysis with dobutamine cardiovascular magnetic resonance tagging.
European Journal of Cardio-Thoracic Surgery. 2006;30:103-107
Fujita M, Ishihara M, Morimoto Y, Simizu M, Saito Y, Yura H, Matsui T, Takase
B, Hattori H, Kanatani Y, Kikuchi M, Maehara T. Efficacy of photocrosslinkable
chitosan hydrogel containing fibroblast growth factor-2 in a rabbit model of
chronic myocardial infarction. Journal of Surgical Research. 2005;126:27-33
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J.
Vascular-specific growth factors and blood vessel formation. Nature.
2000;407:242-248
Hao XJ, Silva EA, Mansson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G,
Wardell E, Brodin LA, Mooney DJ, Sylven C. Angiogenic effects of sequential
release of vegf-a(165) and pdgf-bb with alginate hydrogels after myocardial
infarction. Cardiovascular Research. 2007;75:178-185
Wu J, Zeng FQ, Huang XP, Chung JCY, Konecny F, Weisel RD, Li RK. Infarct
stabilization and cardiac repair with a vegf-conjugated, injectable hydrogel.
Biomaterials. 2011;32:579-586
Kwon JS, Park IK, Cho AS, Shin SM, Hong MH, Jeong SY, Kim YS, Min JJ,
Jeong MH, Kim WJ, Jo S, Pun SH, Cho JG, Park JC, Kang JC, Ahn Y. Enhanced

45

96.
97.
98.

angiogenesis mediated by vascular endothelial growth factor plasmid-loaded
thermo-responsive amphiphilic polymer in a rat myocardial infarction model.
Journal of Controlled Release. 2009;138:168-176
Bonadio J, Smiley E, Patil P, Goldstein S. Localized, direct plasmid gene delivery
in vivo: Prolonged therapy results in reproducible tissue regeneration. Nature
Medicine. 1999;5:753-759
Shea LD, Smiley E, Bonadio J, Mooney DJ. DNA delivery from polymer matrices
for tissue engineering. Nature Biotechnology. 1999;17:551-554
Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local
delivery of protease-resistant stromal cell derived factor-1 for stem cell
recruitment after myocardial infarction. Circulation. 2007;116:1683-1692

46

CHAPTER 4
Synergy of SDF-1! and degradable hyaluronic acid hydrogels in directing
bone marrow derived cell homing to the remodeling heart
(Adapted from: B.P. Purcell, J.A. Elser, A. Mu, K.B. Margulies, J.A. Burdick,
Biomaterials, 2012, 33:7849-7857)
4.1. Introduction
Nearly 1 million Americans suffer a myocardial infarction (MI) each year
and many patients progress to heart failure due to limited treatment options to
attenuate the remodeling response post-MI1. Following MI, a dynamic tissue
remodeling process, characterized by cell death and the formation of avascular
scar tissue, induces global changes to ventricle geometry (i.e., wall thinning and
chamber dilation), which ultimately compromise heart function2.

In order to

attenuate the progression to heart failure, therapeutics using bone marrowderived cells (BMCs) are being widely explored to promote repair in the
remodeling myocardium.

In particular, autologous BMC transplantation has

received the greatest attention in a clinical setting; yet, only modest
improvements in ventricular function have been demonstrated after intracoronary
BMC delivery, potentially due to limited cell engraftment in the myocardium3.
Inconsistencies in cell isolation and storage procedures4, the timing of BMC
administration following MI5, and the location of BMC administration6 complicate
outcomes by altering the delicate signaling mechanisms that are critical for cell
engraftment.
BMC engraftment in the bone marrow microenvironment (i.e., BMC
homing) is regulated by the expression of chemokines and extracellular matrix
(ECM) molecules under steady state conditions.

In response to injury or under

pathological conditions, elevated concentrations of these regulatory molecules in
the peripheral circulation mobilize BMCs and direct their engraftment in
remodeling tissues to mediate repair.

In particular, stromal-derived factor-1
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alpha (SDF-1!), along with its receptor (CXCR4), are critical regulators of BMC
homing to the bone marrow, but also orchestrate BMC mobilization into the
peripheral circulation and local engraftment in the heart following MI7.
Myocardial SDF-1! expression post MI is accompanied by a concomitant
increase in bone marrow derived CXCR4+ circulating cells, suggesting that these
cells are mobilized and respond to the myocardial SDF-1! signal8.
Despite evidence that the mobilized BMCs home to the myocardium via
SDF-1! and contribute to tissue repair, the extent of this endogenous response
is insufficient to prevent the eventual onset of heart failure following MI.
Enhancing endogenous BMC homing (and therefore repair) through myocardial
delivery of SDF-1! increases progenitor cell markers in the heart, stimulates
angiogenesis, and attenuates global ventricular remodeling9. However, due to its
very low molecular weight (8kDa) and proteolytic susceptibility, SDF-1! delivery
to the myocardium following MI is challenging. Researchers have addressed this
challenge by covalently linking recombinant SDF-1! (rSDF-1!)10 or SDF-1!
peptide analogs11 to scaffolds that incorporate sites for integrin mediated
adhesion. Beyond integrin mediated interactions, there are other components of
the bone marrow niche, such as interactions with glycosaminoglycans (GAGs)
that might aid in SDF-1! delivery and BMC engraftment with improved efficacy.
Naturally, local concentrations of small, cationic chemokines like SDF-1!
are regulated by GAGs in the ECM12.

SDF-1! binds to GAGs through ionic

interactions between basic amino acid residues and acidic groups along the
disaccharide backbone13.

The affinity between SDF-1! and GAGs plays an

important role in localizing SDF-1! on the endothelium to direct cell homing14
and sustaining SDF-1! activity in the presence of proteases15.

In addition to

their roles in chemokine presentation, some GAGs play a more direct role in
BMC homing through receptor interactions. For example, hyaluronic acid (HA) is
abundant in the bone marrow, where it serves as an anchoring molecule for BMC
homing through binding to the CD44 receptor16. Interestingly, HA is localized to
regions of SDF-1! expression in the bone marrow and HA and CD44 mediate
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cell responsiveness to SDF-1! during cell migration in vitro and cell homing in
vivo17.
In this work, we exploit the cooperative roles of SDF-1! and HA in order to
enhance endogenous BMC homing to the heart following MI.

Specifically,

recombinant SDF-1! was encapsulated in degradable HA hydrogels that form in
situ on the heart, in order to localize SDF-1! and HA homing cues to the
remodeling heart for enhanced engraftment of circulating BMCs in the
myocardium.
4.2. Materials and Methods
Animals
Adult BALB/CAnNHsd mice (Charles River, Production) were housed in a
dedicated vivarium under conventional conditions. Mice received a standard diet
(LabDiet 5010) and water ad libitum. All experimental procedure were performed
according to the NIH Guide for Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of Pennsylvania.
Macromer synthesis
A degradable HA macromer with methacrylate functionality was
synthesized through hydroxyethyl methacrylate (HEMA) modification of the HA
backbone in a three step process. (1) Sodium hyaluronate (74 kDa, Lifecore) was
converted to a tetrabutylammonium (TBA) salt by acidic ion exchange with
Dowex resin (50W×8–200, Sigma), followed by neutralization with TBA-OH, and
lyophilization.

(2) 2-hydroxyethyl methacrylate was reacted with succinic

anhydride in dichloroethane (DCE) via a ring opening reaction (65°C, 16hrs) in
the presence of N-methylimidazole to obtain HEMA-COOH. HEMA-COOH was
purified via hydrochloric acid wash, DI H2O wash, and DCE evaporation with a
rotary evaporator. (3) HEMA-COOH was coupled to HA-TBA in anhydrous
dimethyl sulfoxide through an esterification reaction in the presence of 449!
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dimethylaminopyridine (DMAP) and di-tert-butyl dicarbonate (BOC2O) activating
agents (45°C, 20hrs).

The following molar ratios of reactants were used: HA-

TBA (1), HEMA-COOH (1.4), BOC2O (1.2), DMAP (0.1). The modified HEMA-HA
macromer was purified via overnight dialysis in DI H2O at 4°C, acetone
precipitation, another 5 days of dialysis in DI H2O at 4°C, followed by
lyophilization.

1

H NMR was used to determine the degree of modification and

purity of the HEMA-HA.
SDF-1! electrostatics
Electrostatic surface potentials of SDF-1! were visualized with Adaptive
Poisson-Boltzmann Solver (APBS) software18.

The PDB file for SDF-1!

(2KEC19) was first converted to a PQR file with PDB2PQR software20 using a
PARSE forcefield and PROPKA software21 to assign protonation states at pH =
7.4. All calculations were performed on a web server hosted by the National
Biomedical Computation Resource and surface potentials were visualized with
Jmol22.
Macromer binding affinity
Binding affinity between rSDF-1! and HEMA-HA was quantified using an
intrinsic protein fluorescence quenching technique23. Fluorescence titration
experiments were performed on a Tecan infinite m200 plate reader (Grödig,
Austria) at 25°C. The fluorescence of a 2 µM rSDF-1! (460-SD, R&D Systems)
solution in 100 mM HEPES buffer (pH 7.4) was recorded at 280/350nm
excitation/emission. Fluorescence quenching was monitored by increasing the
concentration of HEMA-HA in rSDF-1! solution in 13.5 µM increments.

Dry

macromer was dissolved in the rSDF-1! solution, mixed, and incubated for a 2
min equilibration period before measuring fluorescence.

The normalized

changes in fluorescence with each HEMA-HA titration were plotted against
HEMA-HA concentration and resulting binding isotherms were fit by nonlinear
regression (Mathematica, Wolfram Research, Inc.) to the equation describing
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bimolecular association:

where F is the change in fluorescence over initial fluorescence (-!F/Fo), Fi is the
initial value for (-!F/Fo), Ff is the final value for (-!F/Fo), and Kd is the dissociation
constant 23.
Hydrogel formation
Hydrogels were formed upon visible light exposure using a previously
established initiator system consisting of eosin Y, triethanolamine (TEOA), 1vinyl-2-pyrrolidinone (VP), and a halogen curing light (Elipar 2500, 3M)24. 50 µL
hydrogel precursor solutions were prepared by mixing HEMA-HA and initiators in
PBS at final concentrations of: 6 wt% HEMA-HA, 0.02 wt% eosin Y, 225 mM
TEOA, and 37 mM VP. 200 ng rSDF-1α was mixed into the 50 µL hydrogel
precursor solution for HA Gel/rSDF-1α groups.

Hydrogels were formed in

cylindrical molds upon light exposure for 90 seconds. For release studies, gels
were incubated in 1 mL of chemically defined (CD) media comprised of α-MEM
media (Invitrogen) supplemented with 20 mM L-glutamine, 100 U/mL penicillin,
100 μg/mL streptomycin, and 0.1% bovine serum albumin (BSA). Gels were
moved to fresh media at the indicated time points and media containing eluted
molecules were stored at -20°C. rSDF-1α was quantified with ELISA (DY350,
R&D Systems) and HA was quantified with a previously established uronic acid
assay25.
Enzyme-linked Immunosorbent Competition Assay
An ELISA kit (DY350, R&D Systems) was used to quantify rSDF-1! (460SD, R&D Systems) as summarized in the General ELISA protocol from R&D
Systems. Prior to loading samples, 0.5 ng/mL rSDF-1! was preincubated in
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serial dilutions of a 5 mg/mL HEMA-HA solution in PBS for 90 min at 25°C.
Percent inhibition of monoclonal antibody binding to rSDF-1! due to the added
HEMA-HA was calculated after quantifying rSDF-1! in each sample.

BMC isolation
Adult

BALB/CAnNHsd

mice

(10–12

weeks

old,

22-26

g)

were

anesthetized with 100 mg/kg ketamine and 20 mg/kg xylazine. Unfractionated
BMCs were obtained by removing the femurs, and flushing the marrow cavity
with sterile PBS over a 40 µm filter. The cells were pelleted by centrifugation and
resuspended in lysis buffer (BD Biosciences) for 1 min to lyse red blood cells.
Cells were again pelleted and resuspended in 1 mL PBS to remove remaining
lysis buffer. To visualize the cells in vitro and in vivo, PKH fluorescent linker kits
were employed (Sigma).
In vitro BMC chemotaxis
The chemotactic activities of rSDF-1! and HEMA-HA were quantified
using freshly isolated BMCs in microchemotaxis chambers (NeuroProbe)
following a modified boyden chamber assay26. Briefly, BMCs (2x106 cells/mL) in
CD media were separated from active molecules in CD media by a porous
polycarbonate membrane (5 µm pores) coated with type 1 collagen (PureCol,
Advanced BioMatrix). After 4 hrs at 37°C, non-migrated cells on the top side of
the membrane were scraped away, while migrated cells on the bottom side were
fixed in 4% formalin and imaged. PKH67GL fluorescence was used to visualize
cells and Image J Particle Analysis software was used to quantify cells as
follows. For each well containing fluorescently tagged cells, a circle was drawn to
denote the well area using Image J. The same well area was used for all wells in
each experiment. After converting fluorescent images to 8-bit, the images were
threshold to eliminate background without excluding cells. Total cell counts in
each well were quantified using the “Analyze Particles” function in Image J. Cells
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were counted manually to validate threshold levels, and the same threshold was
used for all wells in each experiment. For each experiment, the average number
of migrated cells per well for each condition were normalized to the average
number of migrated cells per well for control wells containing only CD media (n=6
wells per condition). A monoclonal antibody to CD44 (ab25064, abcam) was
used for HA specific blocking at 3 µg/mL, while a CXCR4 antagonist (AMD3100,
Calbiochem) was used for SDF-1! specific blocking at 0.5 µg/mL.
hMSC culture and chemotaxis
Human mesenchymal stem cells (hMSCs) were obtained from Lonza
Corporation (Walkersville, MD) and expanded in growth media (!-MEM, 16.7%
(v/v) fetal bovine serum, 20 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL
streptomycin). hMSCs were used at passage 4 after thawing from liquid N2
storage and culturing overnight on tissue culture polystyrene (TCPS) in growth
media under anaerobic conditions (GasPak EZ, Becton Deckinson).

hMSCs

were removed from TCPS with TrypLE Express (Invitrogen), washed with CD
media, and resuspended in CD media for chemotaxis experiments. Cells were
seeded at 2x105 cells/mL in upper wells of chemotaxis chambers using collagencoated membranes with 8 µm pores, and DAPI stained after formalin fixing to
visualize cells. Recombinant human SDF-1! (350-NS, R&D systems), 3 µg/mL
mouse monocolonal antibody for CD44 (ab6124, abcam) and 0.5 µg/mL
AMD3100 (Calbiochem) were used for hMSC chemotaxis experiments.
Experimental MI
A cryoinjury model of MI was used to initiate MI remodeling27.

Adult

BALB/CAnNHsd mice (10–12 weeks old, 22-26 g) were anesthetized with 20
mg/kg ketamine and 4 mg/kg xylazine, shaved and disinfected with alcohol. The
mice were kept under anesthesia (1.5% isoflurane), incubated and ventilated with
95% O2 using a mechanical ventilator (MiniVent, Harvard Apparatus). The heart
was exposed through a left lateral thoracotomy and cryoinjury was introduced by
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applying a round 2 mm diameter stainless steel probe frozen with liquid nitrogen
to the epicardial surface of the ventricle for 10 sec. After removing the probe, the
cryoinjured area was confirmed by a white disk-shaped region.

For mice

receiving hydrogels, 25 µL of the liquid hydrogel precursor solutions were applied
to the surface of the injured ventricle through a 27G syringe in the presence of
curing lamp exposure. For mice receiving SDF-1! only, 10 µL of a 10 µg/mL
rSDF-1! solution was injected into the ventricle wall using a 30G syringe. The
order of therapeutic intervention was rotated from animal to animal. Following
manipulations to the heart, the intercostal space and skin were closed with
sutures. Mice received 100% oxygen until responding to interdigital pinch, after
which the endotracheal tube was withdrawn.
heating blanket during recovery.

Mice were kept warm with a

Meloxicam (5 mg/kg) was administered via

intraperitoneal injection 1 hr after surgery and once a day for 1 week following
surgery to minimize pain.
In vivo BMC homing
After a recovery period of 3 hrs following MI induction, mice were
anesthetized with 20 mg/kg ketamine and 5 mg/kg xylazine. Freshly isolated
BMCs from a donor mouse were fluorescently tagged with PKH linker kit,
counted on a Vi-CELL (Beckman Coulter, Inc.), and 9x106 cells in 300 µL sterile
PBS was injected into the femoral vein of the MI mouse. Blood samples were
collected 1 day after BMC injection via retro orbital bleed, treated for RBC lysis,
and analyzed for PKH+ cells using flow cytometry. Briefly, cells were gated for
viability using 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen), size and
granularity using characteristic BMC distributions of forward scatter (FSC) and
size scatter (SSC), respectively, and fluorescent intensity using appropriate
controls (Figure 4.1)28. PKH+ cells in the blood were reported as a percentage of
total cells in the blood within the characteristic BMC size distribution. Mice were
anesthetized 7 days after experimental MI with 100 mg/mL ketamine and
xylazine, blood samples were collected from the abdomen, and hearts were
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excised and either perfusion digested with collagenase (150 U/mL type 2
collagenase in Krebs buffer, Worthington) for PKH+ cell quantification using flow
cytometry28 or flash frozen in embedding medium for PKH+ cell visualization
using histology. Quantified PKH+ cells in the blood were again reported as a
percentage of total BMCs in the blood, while quantified PKH+ cells in the heart
were reported as a total number of cells/heart. Embedded hearts were sectioned
at a 12 µm thickness and imaged immediately upon thawing at room
temperature.

A

Size

B

PKH

Blood

C

D

Heart

Figure 4.1. PKH- BMC negative controls for flow cytometry gating. After gating for viability with
DAPI, BMCs in the blood (A) and the heart (C) were gated based on the typical size of freshly
isolated BMCs (A, inset). The cells within this size range were then analyzed for PKH
fluorescence (C and D). This gating strategy minimized PKH false-positive counts in the blood
and heart to less than 1 per 106 events (D). Abbreviations: SSC – side scatter, FSC – forward
scatter.

Statistical analysis
Values are reported as mean ± standard error of the mean. Statistical
differences between groups were determined using ANOVA in conjunction with a
student’s two-tailed t-test (Microsoft Excel), with P < *0.05, **0.01, and ***0.001
considered as significant.
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4.3. Results
HEMA-HA synthesis
HA macromers were synthesized to facilitate photoinitiated crosslinking
into hydrogels through a terminal methacrylate group and degradation through
hydrolysis of ester groups between the methacrylate and the HA backbone
(Figure 4.2 A). The extent of HEMA modification was determined to be ~25% of
disaccharide repeat units along the HA backbone via 1H NMR (Figure 4.3). This
percent can be easily tuned with the molar ratio of HEMA-COOH to BOC2O in the
coupling reaction29.

Figure 4.2. Electrostatic interactions between HEMA-HA and rSDF-1!. (A) Repeat unit of HEMAHA macromer synthesized with reactive methacrylate group and hydrolyzable ester groups (black
arrows) between the methacrylate functionality and HA backbone. The macromer carries a
negative charge due to carboxylic acid groups along the HA backbone. (B) SDF-1! surface
potentials visualized using APBS software package (left) that correspond to the beta sheet rich in
basic amino acids (right). Scale for surface potentials is in units of kT/e where k is Boltzman’s
constant, T is temperature, and e is the charge of an electron. (C) Fluorescence quenching of
rSDF-1! with HEMA-HA titration. Data fit to bimolecular association equation to calculate KD 23 (n
= 3 independent experiments).

Figure 4.3. 1H NMR of purified HEMA-HA macromer. Approximately 25% of the disaccharide
repeat units were modified with HEMA. The 1H peaks from the methacrylate group on HEMA (A)
1
were normalized to the H peaks from the methyl groups on N-acetylglucosamine (B) to
determine percent modification.
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HEMA-HA and SDF-1! binding
To investigate ionic interactions between the HEMA-HA macromer and
rSDF-1!, the electrostatic surface potentials of SDF-1! were visualized and
binding association constants were experimentally determined. Visualization of
SDF-1! using APBS revealed an overall positive surface charge with the most
positive charges of nearly +10 kT/e concentrated along the beta sheet of the
protein structure (Figure 4.2 B).

This charge distribution is attributed to an

abundance of basic amino acids (i.e., arginine and lysine residues) in the beta
sheet, which have important roles in SDF-1! binding to negatively charged
GAGs13.

Indeed, binding between rSDF-1! and the purified HEMA-HA

macromer was observed with a dissociation constant (KD) of 36 ± 5 µM (Figure
4.2 C). This interaction was significantly stronger than the measured interaction
between HEMA-HA and BSA (KD = 157 ± 4 µM, data not shown), illustrating the
specificity of small, positively charged chemokines for negatively charged GAGs
(i.e., HA) in the ECM.
BMC chemotaxis to rSDF-1! and HEMA-HA
In order to model endogenous BMC homing, unfractionated BMCs were
isolated from mouse femurs, fluorescently tagged with PKH linker dyes, and used
to assess the activity of rSDF-1! and HEMA-HA in vitro and in vivo. In vitro, both
rSDF-1! and HEMA-HA stimulated chemotaxis of BMCs in a dose dependent
manner, nearly 4-fold at the highest concentrations investigated (Figure 4.4, ***P
= 0.0001 and ***P = 0.0008, respectively).

The observed chemotaxis was

specific to cell surface receptors for SDF-1! (CXCR4) and HA (CD44) as
evidenced by antagonist and antibody blocking, respectively. Specifically, the
introduction of the antagonist or antibody completely diminished any increased
migration in response to the molecule and was indistinguishable from control
groups. The chemotactic activity of rSDF-1! and HEMA-HA was also observed
using a purified population of bone marrow derived stem cells, human
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mesenchymal stem cells (hMSCs) (Figure 4.5). The hMSC response to rSDF-1!
and HEMA-HA was also diminished in response to the introduction of a CXCR4
antagonist and CD44 antibody blocking, respectively.

A

hMSC Chemotaxis
(normalized)

Figure 4.4. Chemotactic activity of rSDF-1! and HEMA-HA. (A) rSDF-1! stimulated significant
dose-dependent chemotaxis of unfractionated BMCs and was blocked with a CXCR4 antagonist,
AMD3100. (B) HEMA-HA stimulated similar dose-dependent chemotaxis of BMCs and was
blocked with a monoclonal antibody to CD44. For each experiment, the average number of
migrated cells per well for each condition was normalized to the average number of migrated cells
per well for negative control wells containing only chemically defined media (mean ± SEM, n = 6
wells per condition). (C) Representative negative control well with migrated PKH+ BMCs. (D)
Representative 100 ng/mL rSDF-1! well containing migrated PKH+ BMCs. E) Fluorescent
visualization of migrated PKH+ BMCs. Scale bars: C-D = 500 µm; E = 50 µm.
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Figure 4.5. hMSC chemotaxis to rSDF-1! and HEMA-HA. (A) rSDF-1! stimulated chemotaxis of
hMSCs in a dose-dependent manner and was blocked with a CXCR4 antagonist, AMD3100. (B)
HEMA-HA stimulated chemotaxis of hMSCs in a dose dependent manner and was blocked with a
monoclonal antibody to CD44. The average number of migrated cells per well for each condition
was normalized to the average number of migrated cells per well for negative control wells
containing only chemically defined media (n = 6 wells per condition). (C) Representative wells
containing migrated cells for negative control (upper) and 100 ng/mL rSDF-1! (lower) conditions.
Scale bars: C = 500 µm.

Molecule release from HEMA-HA hydrogels
To sustain release of rSDF-1! and HEMA-HA in the setting of MI, a visible
light initiator system was used to crosslink the HEMA-HA macromer into
hydrogels from a liquid precursor solution (containing rSDF-1!, HEMA-HA, and
photoinitiator) upon blue light exposure.

Photocrosslinked HEMA-HA
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hydrogels sustained the release of rSDF-1! and HA, measured over 7 days in
vitro (Figure 4.6 A-B).

HEMA-HA hydrogels exhibit hydrolytic degradation of

ester groups in the HEMA side groups, releasing HA,
Figure 4.6. Molecule release from
photocrosslinked
HA
Gels.
(A)
Cumulative release of encapsulated
rSDF-1! was sustained for 7 days in
vitro as determined by ELISA. (B)
Cumulative release of uncrosslinked
HEMA-HA and degradation products of
the hydrogel was sustained for 7 days in
vitro as determined by uronic acid
analysis. Quantity of rSDF-1! and HA
was measured from buffer collected and
replaced at specified time points. Gels
remained intact after the 7-day
incubation. Insets indicate quantity of
molecules in each sample (n = 3 gels,
mean ± SEM).
(C) The HA Gel
significantly enhanced BMC chemotaxis
for up to 7 days, which was further
enhanced with release of encapsulated
rSDF-1!. For each experiment, the
average number of migrated cells per
well for each condition was normalized
to the average number of migrated cells
per well for negative control wells
containing only chemically defined
media (mean ± SEM, n = 6 wells per
condition).
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entrapped rSDF-1!, and poly(methacrylic acid) kinetic chains with time.
Generally, the release of rSDF-1! and HA was rapid in the first few days, due to
diffusion of peripheral rSDF-1! and uncrosslinked HEMA-HA, and then slowed
as release of encapsulated molecules was mediated by hydrogel degradation.
Gels were still intact after 7 days in buffer at 37°C, while little additional rSDF-1!
release was measured. While the ELISA kit provides a low limit of detection for
rSDF-1!, this antibody “sandwich” technique was unable to detect rSDF-1! in the
presence of soluble HEMA-HA, which acted as a binding competitor to the
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monoclonal antibodies with 44% inhibition at 0.08 mg/mL HEMA-HA (Figure 4.7).
Therefore, we suspect that reported concentrations of released rSDF-1! are for
the free, unbound protein in solution, and that rSDF-1!/HEMA-HA complexes are
also present in the release samples. Importantly, released molecules from HA
hydrogels and HA hydrogels containing rSDF-1! both stimulated chemotaxis of
BMCs over 7 days (Figure 4.6 C), indicating the influence of both HA and rSDF1! components on BMC chemotaxis.
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2.50 5.00
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Figure 4.7. ELISA inhibition by soluble HEMA-HA.
HEMA-HA inhibited ELISA detection of rSDF-1!.

Incubating rSDF-1! in serial dilutions of

BMC homing to the remodeling heart
In order to quantify BMC homing in vivo, fluorescently tagged BMCs were
infused into the circulation following experimental MI in mice and tracked in the
blood and the heart using flow cytometry (Figure 4.8 A). Myocardial delivery of
homing factors (HA and rSDF-1!) from hydrogels (formed on heart using blue
light, Figure 4.8 B) was assessed for the ability to enhance BMC homing to the
heart and compared to controls of MI only and MI with intramyocardial injection of
rSDF-1!.

Hydrogels were localized to the injury site and adhered to the

myocardium for sustained delivery of homing molecules (Figure 4.8 C-D).
The circulating PKH+ BMCs were readily quantified in the blood and heart
using flow cytometry (Figure 4.8 E). The fluorescence intensity of the cells varied
over a wide range, so a PKH+/PKH- threshold was chosen to quantify PKH+
BMCs while minimizing PKH- false-positive events in the blood and the heart
(Figure 4.1).

Using this threshold, we observed a decrease in fluorescence

intensity of the PKH+ BMCs in the blood from day 1 to day 7 (Figure 4.8 E).
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Figure 4.8. In vivo model to quantify BMC homing. (A) HA Gels were applied to the heart
immediately following experimental MI. Freshly isolated BMCs were fluorescently tagged with
PKH linker dyes and infused into the circulation via a femoral vein injection 3 hrs after MI. Blood
samples were collected 1 and 7 days following MI and hearts were digested 7 days following MI
to quantify PKH+ BMCs. (B) Hydrogels formed in situ by applying a liquid precursor solution to
the epicardial surface of the ventricle upon blue light exposure. (C) This technique allowed the
hydrogels to be localized on the injured myocardium for localized molecule delivery. (D) The
hydrogels adhered to the myocardium while processing the tissue for histology and H&E staining.
(E) Representative flow cytometry with constant threshold to quantify PKH+ BMCs in the blood
and heart. Scale bars: B-10 mm; C-5 mm; D-100 µm.

Considering that the PKH linker dyes are stable in vivo for weeks, the decrease
in fluorescent intensity could be due to cell proliferation, or simply due to
preferential retaining of cell types in the blood that do not uptake PKH dyes as
effectively as others30. Interestingly, BMCs quantified in the blood on day 1 were
primarily larger cells around the size and granularity of granulocytes, while the
BMCs quantified in the blood on day 7 were primarily smaller cells around the
size and granularity of lymphocytes (Figure 4.9); however, both size phenotypes
show similar ranges of PKH staining intensity immediately after exposure to the
PKH linker dye.

Figure 4.9. Size of PKH+ BMCs in the blood. Circulating PKH+ BMCs exhibited a larger
phenotype characteristic of granulocytes 1 day after infusion (A), while PKH+ BMCs exhibited a
smaller phenotype characteristic of lymphocytes/monocytes 7 days after infusion (B). Both cell
phenotypes were increased to the same extent in the blood after rSDF-1! delivery to the heart.
Abbreviations: SSC – side scatter, FSC – forward scatter.
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Delivery of the HA Gel with encapsulated rSDF-1! and delivery of rSDF1! as a bolus injection significantly increased the number of infused BMCs
circulating in the blood 1 day after infusion (Figure 4.10 A, ***P < 0.001 and *P =
0.01, respectively).

Both rSDF-1! delivery groups more than doubled the

number of circulating BMCs on day 1 from 1% to 2% of native BMCs; however,
this effect was only apparent in the HA Gel/ rSDF-1! group on day 7, although
not statistically significant (Figure 4.10 B). All intervention groups significantly
increased the number of BMCs engrafted in the heart compared to MI only, and
the HA Gel with encapsulated rSDF-1! significantly increased BMC engraftment
compared to rSDF-1! alone and the HA Gel alone (Figure 4.10 C, #P = 0.01 and
0.047, respectively), indicating synergy between the released molecules.

Figure 4.10. Quantification of BMC homing with molecule delivery to the heart. A) rSDF-1!
delivery to the heart significantly increased the number of circulating PKH+ BMCs 1 day after
infusion. B) This effect was sustained, although not statistically significant, 7 days after infusion
when rSDF-1! was delivered from the HA Gel. PKH+ BMCs in the blood are reported as a
percentage of total cells in the blood within the BMC size and granularity gating. C)
Intramyocardial injection of rSDF-1! and application of the HA Gel alone following MI significantly
enhanced the number of PKH+ BMCs in the heart compared to MI only 7 days after MI and cell
infusion. Application of the HA Gel with encapsulated rSDF-1! further enhanced PKH+ BMC
engraftment in the heart compared to delivering rSDF-1! or the HA gel individually. D) When
normalized to the percent of PKH+ BMCs in the blood 1 day after infusion, the HA Gel enhances
engraftment of circulating PKH+ BMC with a constant efficiency. (mean ± SEM, n = 7 animals for
all groups except for MI only, n = 6).
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When normalized to the percentage of BMCs circulating in the blood, the
HA Gel (with and without rSDF-1!) enhanced myocardial engraftment of
circulating BMCs at a significantly improved rate, over 3-fold greater than the
bolus rSDF-1! injection and MI control, which showed the same engraftment rate
(Figure 4.10 D). While both the HA Gel/rSDF-1! and bolus rSDF-1! injection
groups had the same effect on circulating BMCs 1 day after infusion (2.2 ± 0.2
and 2.2 ± 0.3% native BMCs, respectively), they had significantly different effects
on enhancing BMC engraftment in hearts 7 days after infusion, 570 ± 130 and
170 ± 40 BMCs per heart, respectively.
Engrafted BMCs localized to the infarct region (IR) and border region (BR)
in the heart following MI (Figure 4.11), while PKH+ BMCs in other regions of the
myocardium were very rare.

The infarct region was characterized by dense

collagen staining with Masson’s Trichrome (Figure 4.11 A-B). This collagen scar
tissue autofluoresced, allowing the infarct region to be easily identified for
characterizing engrafted BMC locations within the heart, and PKH+ BMC
fluorescence was bright enough to distinguish the BMCs against the tissue
background as indicated by white arrows (Figure 4.11 C). PKH+ BMCs were
identified in the infarct region in all groups, but were rare in the border region for
all groups except for the HA Gel/rSDF-1! group. Border region BMCs in this
group were commonly localized within and around vascular structures (Figure
4.11 D). Some cells also appeared to integrate into the tissue and align with the
native tissue morphology (Figure 4.11 E).
4.4. Discussion
The objective of this study was to develop a biomaterial system to
enhance BMC homing to the remodeling myocardium through exogenous
delivery of the chemokine rSDF-1!. To accomplish this, we synthesized an in
situ crosslinkable and degradable hydrogel system based on the molecule HA to
encapsulate and sustain the local release of rSDF-1! to the myocardium.
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Figure 4.11. Visualization of PKH+ BMCs in the myocardium 7 days after systemic infusion. A)
The cryoinjury resulted in the formation of a nontransmural collagen rich scar tissue (blue region)
7 days following MI as visualized with Masson’s Trichrome. An infarct region (IR) and border
region (BR) were defined to assess PKH+ BMC locations within the heart. B) Vasculature in the
IR and BR remained intact following the cryoinjury. C) PKH+ BMCs were identified in the IR of all
groups, while PKH+ BMCs in the BR were rare except in the HA Gel/rSDF-1! group. PKH+
BMCs were not found in remote regions of the myocardium for all groups. White arrowheads
indicate PKH+ BMCs. D) PKH+ BMCs in the BR were often localized in and around vascular
structures. E) In addition, cells in the BR appeared to align with the myocardial tissue structure.
Scale bars: A-500 µm; B-50 µm; C-100 µm; D and E-50 µm.

Our rationale for choosing HA as our biomaterial was two-fold: (1) HA is a
negatively charged GAG that naturally regulates chemokines in tissues, and (2)
HA is the major ligand for CD44, which mediates cell motility processes that
govern BMC homing.
GAGs are linear polysaccharides with an abundance of acidic groups that
are negatively charged under physiologic conditions. Chemokines, on the
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other hand, are characterized by an abundance of basic amino acid residues that
are positively charged under the same conditions. These complimentary charges
induce binding between GAGs and chemokines with an affinity that is dependent
on the specific GAG chemistry, the size of the GAG molecule, and the net charge
of the chemokine12. In particular, heparin sulfate (HS) has been shown to bind
SDF-1! with high affinity (KD~30 nM)13. Binding between SDF-1! and HS in the
glycocalyx of the cell surface is important to localize SDF-1! and facilitate
binding to CXCR413; however, soluble HS has been shown to inhibit the
chemotactic activity of SDF-1! in a dose dependent manner (0.1 to 100 µg/mL
HS)31. Since the CXCR4 binding domain remains exposed after HS binding13,
the soluble HS is likely acting as a binding competitor to glycocalyx HS,
preventing SDF-1! from achieving close contact with CXCR4 on the cell surface.
Therefore, GAG chemistries with less affinity for SDF-1! may be optimal as a
carrier matrix to allow glycocaylx sequestration of released SDF-1! in the
presence of the degraded matrix.

HA has 1 carboxylic acid per repeat unit

compared to 3 sulfate groups per repeat unit of HS; therefore, we expected HA to
bind SDF-1! with much less affinity (higher KD) than HS. Indeed, we measured a
KD of 36 µM between our HA macromer and SDF-1! (Figure 4.2 C), which was
selective to the positively charged SDF-1! (KD,BSA=157 µM). This micromolar
affinity was sufficient to slow SDF-1! diffusion within the HA Gels where the
concentration of HA is very high (~100 mg/mL), without inhibiting cell chemotaxis
to released SDF-1! in the presence of HA released from the gels (10 to 100
µg/mL HA) (Figure 4.6 B-C).
HA also interacts cooperatively with SDF-1! in directing cell motility
through CD44 and CXCR4 receptor signaling crosstalk17. SDF-1!-CXCR4
binding on hematopoetic progenitor cells stimulated cell spreading on HA coated
substrates through CD44 binding and CD44 polarized to the leading edge of cells
migrating towards gradients of SDF-1! in vitro17. HA-CD44 binding initiates Gprotein-dependent signal transduction that stimulates cell motility through RhoROCK signaling32, as well as cell adhesion through integrin expression33. These
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signaling pathways are important regulators of BMC homing processes in the
bone marrow17, as well as in peripheral tissues during inflammation34.

For

example, intravenously injected MSCs home to the injured kidney in a CD44
dependent process35. The role of HA in this process was corroborated in vitro as
the MSCs exhibited CD44 dependent chemotaxis to HA.
In line with these studies, we showed that our modified HA macromer
stimulates chemotaxis of BMCs through CD44 (Figures 4.4, 4.5).

When

delivered to the myocardium as an epicardial hydrogel immediately following
experimental MI, the HA Gel enhanced engraftment of circulating BMCs in the
myocardium (Figure 4.10 C).

BMC engraftment was further enhanced by

encapsulating rSDF-1! in the HA Gel (Figure 4.10 C). To form the hydrogels in
situ, a photo-initiated crosslinking mechanism was utilized in order to localize
molecule release to the myocardium while avoiding biomaterial injections that
could cause further damage due to the small thickness of a mouse ventricle wall.
In experimental models with larger ventricle wall thicknesses, a redox-initiated
crosslinking mechanism can be used to form these hydrogels upon injection
through a syringe29.
Interestingly, delivering rSDF-1! to the heart had systemic effects in
significantly increasing the number of PKH+ BMCs circulating in the blood, and
sustained release of rSDF-1! from the HA Gel prolonged this effect (Figure 4.10
A-B). Separate studies have shown that an increase in circulating CXCR4+ cells
coincides with the temporal expression of rSDF-1! in the heart following MI8,9. In
addition, elevating SDF-1! concentrations in the blood has been shown to
mobilize BMCs into the circulation36. Since we report the number of PKH+ BMCs
in the blood as a percentage of total BMCs in the blood, an increase in this
percentage may indicate that systemic concentrations of SDF-1! are high
enough to prevent circulating PKH+ BMCs from homing to other organs, such as
the bone marrow or spleen37,38, but not high enough to mobilize native BMCs
from SDF-1! gradients in the bone marrow. Indeed, mobilizing agents have
been administered systemically following MI in order to mobilize CXCR4+ BMCs
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into the circulation and therefore enhance the response to SDF-1! signals in the
heart39.
To model BMCs mobilized from the bone marrow, unfractionated BMCs
were injected directly into the systemic circulation. These cells were used with
minimal manipulations to include all CXCR4+ and CD44+ BMC populations that
are present in vivo, and avoid culture conditions that are known to affect cell
responsiveness to chemokines40. Using this model system, we were able to
definitively quantify BMC homing with molecule delivery to the heart; however,
investigation of how homed BMCs contribute to myocardial repair is beyond the
scope of the model. Nevertheless, a growing body of literature suggests that
delivery of SDF-1! and HA would promote a beneficial healing response
following MI. For example, CXCR4 is expressed on selective populations of
BMCs that have been implicated in myocardial tissue repair, including
hematopoetic progenitor cells41, mesenchymal stem cells42, dendritic cells43, T
lymphocytes44, and even committed tissue-specific stem cells45. Furthermore,
SDF-1! delivery has been shown to largely promote neovascularization in
ischemic tissues through BMC homing9-11.

While enhancing CXCR4 positive

cells in the heart has been shown to significantly attenuate post-MI remodeling,
this approach seems to require complimentary growth factor and cell adhesion
molecule expression that occurs in the early stages of post MI remodeling46.
Therefore, early therapeutic intervention may be a limiting factor in translating
SDF-1!-based therapies to the clinic.
Like SDF-1!/CXCR4, HA/CD44 interactions have important roles in
regenerative processes during tissue remodeling including cell migration,
proliferation, and differentiation47.

In the setting of MI, CD44 expression is

abundant on infiltrating leukocytes, myofibroblasts and endothelial cells that
contribute to tissue repair48.

CD44 knockout animals showed a prolonged

maldaptive inflammatory response and diminished collagen synthesis, causing
further ventricle dilation following MI48. Here, we report that dual delivery of SDF1! and HA from in situ forming hydrogels enhances BMC homing to the
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remodeling myocardium.

This finding highlights the importance of using

materials that mimic components of the bone marrow niche to provide BMC
specific cell adhesion ligands that act synergistically with SDF-1!/CXCR.
However, applying these systems beyond the early stages of post MI remodeling
remains to be investigated.
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CHAPTER 5
Sustained release of SDF-1! polypeptide analogue from injectable
hyaluronic acid hydrogels attenuates post MI remodeling
(Adapted from: J.W. MacArthur Jr., B.P. Purcell, P.F. Hsiao, A.S. Fairman, E.C.
Yang, A. Trubelja, W. Hiesinger, Y. Shudo, P. Atluri, J.A. Burdick, J.Y. Woo,
Circulation, in press)
5.1. Introduction
Heart disease is the cause of significant morbidity and mortality in the US
with estimates of nearly 800,000 new acute coronary events each year, a
disease accounting for a substantial proportion of the national health care
expenditure1, 2. On a cellular level, the events following a myocardial infarction
include a change in composition of the extracellular matrix with a shift towards
collagen deposition, hypocontractile scar formation, myocyte apoptosis, and
progressive ventricular dilatation3" The deleterious remodeling that occurs over
time leads to augmentation in the stress-strain relationship of ventricular
myocytes, inefficient contractility, and ultimately heart failure.

When current

treatments for coronary artery disease fail, they usually do so because
microvascular perfusion is not adequately restored – a critical, independent
predictor of ventricular remodeling, reinfarction, heart failure, and death4"
In an effort to restore microvascular perfusion, various cytokines have
been used to stimulate angiogenesis, with moderate success.

One such

cytokine, stromal cell-derived factor 1-alpha (SDF-1), is a key regulator in
hematopoietic stem cell trafficking between the bone marrow and peripheral
circulation and effectively localizes endothelial progenitor cells to areas of
ischemia5,

6

.

It has been shown by our group and others to increase

vasculogenesis, decrease cardiac myocyte apoptosis, increase cardiac myocyte
survival, and preserve ventricular geometry7-10" The functional and regenerative
benefits of SDF-1 treatment are directly related to its ability to bind its receptor,
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CXCR4. However, there is a temporal mismatch between peak expression of
SDF-1 and upregulation of CXCR4 on bone marrow and cardiac stem cells.
Within an hour of ischemia, cardiac SDF-1 expression is rapidly upregulated in
the heart, while CXCR4 peaks at 96 hours, by which time SDF-1 is nearly
absent5, 11, 12. Contributing to this mismatch is that SDF-1 is rapidly cleared from
the circulation and cleaved by matrix metalloproteinase-2 and CD-2613-16"
In order to address the temporal mismatch in the SDF-1:CXCR4 axis,
SDF-1 concentration within cardiac tissue must be maintained over the course of
several weeks to prolong its trophic effects on CXCR4+ cells, thereby optimizing
angiogenesis, cardiac myocyte preservation, and ventricular performance. In the
current study, we hypothesized that a hyaluronic acid based hydrogel could
sustain the release of our previously reported engineered SDF-1 analog (ESA)
over several weeks, resulting in the temporal realignment of the SDF:CXCR4
axis and consequently improved angiogenesis, limited ventricular remodeling,
and preserved cardiac function in a rat model of myocardial infarction.
5.2. Methods
Custom Peptide Synthesis
We have previously reported on the design and synthesis of an
engineered SDF-1! peptide analogue (ESA)17,

18

. Briefly, the CXCR4 receptor

binding N-terminus and the molecular stabilizing C-terminus were preserved
while the central beta pleated sheet was deleted and replaced with 2 proline
“linker” residues.

Using mathematical modeling, this modified sequence was

predicted to retain as similar a three-dimensional protein configuration to the
native SDF-1! as possible. The designed protein was synthesized using solid
phase peptide synthesis, where the N !-amino acids are incorporated into the
peptide in a step-wise fashion while one end is attached to a solid support matrix.
Additionally, we added HiLyte Fluor TR (AnaSpec, San Jose, California) during
the synthesis process as a fluorophore tag for use in the in vitro studies, and
HiLytefluor 750 (AnaSpec, San Jose, California) was added for the in vivo study.
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Macromer Synthesis
Sodium hyaluronate (74kDa, Lifecore) was chemically modified with h
ydroxyethyl methacrylate (HEMA) to incorporate a terminal methacrylate
group for free-radical initiated crosslinking and ester bonds to introduce hydrolytic
degradation19" Briefly, HEMA was reacted with succinic anhydride via a ring
opening polymerization in the presence of N-methylimidazole to obtain HEMACOOH, which was then coupled to a tetrabutylammonium salt of HA in the
presence of 4-dimethylaminopyridine. The resulting HA macromer with HEMA
group modification (HEMA-HA) was purified via dialysis, lyophilized, and the
percentage of HA disaccharides modified with a HEMA group was determined to
be ~15% using 1H NMR.
Hydrogel Crosslinking
To form hydrogels rapidly upon injection into the myocardium, a twocomponent redox initiator system consisting of ammonium persulfate (APS) and
N,N,N!,N!-tetramethylethylenediamine (TEMED) was utilized. APS and TEMED
were added to a final concentration of 10mM in a 4% (w/v) HEMA-HA solution
and kept on ice. The kinetics of gel formation were characterized with rheometry
at 37°C by monitoring the storage (G’) and loss (G”) modulus with time, while
applying oscillatory strain (20mm 1o cone geometry, 1% strain, 1Hz, Texas
Instruments AR 2000ex). For in vitro release kinetics, 25µg ESA was added per
50µL gel precursor solution, and 50uL gels were formed in cylindrical molds for
30 min at 37°C. Gels were incubated in 1mL PBS supplemented with 1% BSA at
37°C and buffers were refreshed every 2 days. Fluorescence of eluted ESA from
each 2 day sample, extending over a 4 week period, was quantified on a
microplate reader (TECAN, Austria), while HA content was quantified with a
uronic acid assay20" After 28 days, hydrogels were enzymatically degraded with
hyaluronidase (800 units/mL, Sigma) and evaluated for remaining ESA and HA.
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Endothelial Progenitor Cell Chemotaxis
Bone marrow mononuclear cells were isolated from the long bones of
syngeneic adult male Wistar rats (Charles River) by density centrifugation with
Histopaque 1083 (Sigma-Aldrich), plated on vitronectin coated dishes, and
cultured in endothelial basal medium-2 supplemented with EGM-2 SingleQuot
(Lonza) containing human epidermal growth factor, FBS, vascular endothelial
growth factor, basic human fibroblast growth factor, recombinant human long R3
insulin-like growth factor-1, ascorbic acid, heparin, gentamicin, and amphotericinB.

Media was changed on culture day 4 and non-adherent bone marrow

mononuclear cells were discarded, enriching for the EPC phenotype.
A modified transwell migration assay (Neuro Probe, Gaithersburg, MD)
was used to assess EPC migration. Briefly, 8-!m filters were loaded into control
and experimental chambers. Seven-day EPCs cultured in endothelial-specific
media on vitronectin-coated plates were trypsinized, counted, and brought to a
concentration of 90 cells/!l in Dulbecco’s phosphate buffered saline (DPBS).
The bottom chamber was loaded with either DPBS or the eluted ESA from the
hydrogel at each respective 2 day time point. DPBS from hydrogel without ESA
served as a control. A 560!l cell suspension was added to the top chamber of
each. All chambers were incubated at 37ºC, 5% CO2 for 3.5 hours. The cells
remaining in the top chamber were wiped clean with a cotton swab and the filter
was removed, placed on a glass slide, and mounted with Vectashield w/ DAPI
(Vector Laboratories). Slides were visualized on a DF5000B Leica fluorescent
microscope and analyzed via LASAF version 2.0.2 (Leica) software. Boyden
chamber analyses were performed in triplicate.
Animal Care and Biosafety
Male Wistar rats weighing 250-300g were obtained from Charles River
Labs (Wilmington, Massachusetts). Food and water were provided ad lib. All
experiments pertaining to this investigation conformed to the “Guide for the Care
and Use of Laboratory Animals,” published by the US National Institutes of
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Health (Eighth Edition, 2011). The protocol was approved by the Institutional
Animal Use and Care Committee of the University of Pennsylvania (protocol
number 803394).
Animal Model
Myocardial infarction was induced in 33 male Wistar rats using an
established and highly reproducible model. Briefly, the rats were anesthetized in
a 2L induction chamber (VetEquip, Pleasantville, CA) and 3% isofluorane was
continuously delivered. A 16-gauge angiocatheter was used for endotracheal
intubation and connected to mechanical ventilation (Hallowedl EMC, Pittsfield
Mass) where 1% isofluorane was maintained throughout the operation.

A

thoracotomy was performed through the left 4th intercostal space, the heart was
exposed, and a 7-0 polypropylene suture was placed around the left anterior
descending artery 2mm below the left atrium. The suture was briefly snared to
verify the size and location of myocardial ischemia based on color change, and
permanently tied down to produce a large anterolateral MI8-10, 17, 18. The animals
were then randomized into 3 groups and received 4 separate peri-infarct
intramyocardial injections of either saline (100!l, n=8) hydrogel alone (100!l,
n=10), or hydrogel/25!g ESA (100!l, n=9).

The thoracotomy was closed in

multiple layers and tissue adhesive (VetBond, 3M, Minneapolis, MN) was applied
over the incision.

All rats were implanted with subcutaneous microchips

(BioMedic Data Systems, Boise, ID), and recovered from anesthesia.
Buprenorphine (0.5mg/kg) was administered for post-operative pain control.
Echocardiographic and Hemodynamic Assessment
LV geometry and function were evaluated pre-operatively and at 4 weeks
in all animals21" A Phillips Sonos 5500 revD ultrasound system (Philips Medical
Systems, Amsterdam ND) was used, utilizing a 12-MHz transducer at an image
depth of 2cm. Left ventricular parasternal short axis 2D and M-mode images at
the level of the papillary muscle were used to obtain echocardiographic data. All
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analyses were performed by a single investigator who was blinded to the
treatment groups.
Four weeks after LAD ligation, all three groups of animals underwent
invasive

hemodynamic

measurements

with

a

pressure-volume

conductance catheter (SPR-869; Millar Instruments, Inc.).

(P-V)

The catheter was

calibrated via 5 point cuvette linear interpolation with parallel conductance
subtraction by the hypertonic saline method. Rats were anesthetized as above,
and the catheter was introduced into the LV utilizing a closed-chest approach via
the right carotid artery. Measurements were obtained before and during inferior
vena cava occlusion to produce static and dynamic P-V loops under varying load
conditions. Data were recorded and analyzed with LabChart version 6 software
(AD instruments) and ARIA Pressure Volume Analysis software (Millar
Instruments, Inc). Finally, cardiac output was assessed by placing a 2.5mm periaortic Doppler flow probe (Transonic Systems, Ithaca, NY) around the ascending
aorta.
In-vivo ESA release
In a subset of 6 animals from the hydrogel/ESA group, in vivo
fluorescence of ESA was quantified using a Pearl Impulse small animal imaging
system (LI-COR) on post injection day 1, and every 4 days thereafter through the
4 week time point in order to visualize intramyocardial ESA.

Animals were

anesthetized with 1% isoflurane via nose cone, the left chest was shaved, and
the animals were placed in the right lateral decubitus position on the imaging
platform with the left chest closest to the camera.
obtained

using

the

800nm

channel

of

the

Dynamic images were
instrument

(785/820nm

excitation/emission), with standardized parameter settings scaled to the same
maximum values. Estimates of the fluorescence of ESA were determined by
fixed regions of interest (ROI) over the heart, and signal intensity was calculated
using the manufacturer’s software.

Signal intensity for each time point was

normalized to the peak signal observed for each animal, and the ratio for each
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time point was averaged for all 6 animals. Animals from the saline group (n=3)
served as negative controls.
Histologic Analysis and Immunohistochemistry
In order to assess ventricular geometry, infarct size, and microvascular
angiogenesis, hearts were explanted in a subset of 11 animals after the invasive
hemodynamic assessment was performed (saline, n=3; hydrogel, n=4;
hydrogel/ESA, n=4) and flushed with PBS, then injected retrograde with Tissue
Tek OCT compound (Sekura, Netherlands) through the aorta and pulmonary
artery. Hearts were submerged in OCT, frozen, and stored in a -80ºC freezer.
Orientation of hearts during freezing was standardized so as to result in
consistent positioning during the sectioning process. Eight, 10!m thick sections
were prepared from each heart at the level of the papillary muscles and stained
with hematoxylin and eosin or Masson’s Trichrome.

Standardized digital

photographs were taken with a Nikon D5100 SLR camera (Nikon, Tokyo, Japan).
Photographs were uploaded to ImageJ (v1.46b) and the size of the infarct
assessed with digital planimetry.
Two, 10!m thick sections from each animal were co-stained with
antibodies directed against von Willebrand Factor (vWF) in order to quantify
capillary density. Sections were fixed with HistoChoice (Amresco, Solon, OH),
blocked in 10% FBS, and incubated with sheep anti-VWF (conjugated to FITC,
1:100 dilution, Abcam) for 2 hours.
Vectashield (Vector Laboratories).

Slides were washed and mounted with
Quantitative analysis of capillary density

within the borderzone was conducted under the 20x objective of a Zeiss LSM
710 confocal microscope (Zeiss, Germany).

Group blinded counts were

averaged over 4 fields per specimen. Sections were also stained with antibodies
directed towards CXCR4. Sections were fixed with ice cold acetone, blocked in
10% FBS, and incubated with goat anti-CXCR4 (Abcam 1671, 1:300) for 2 hours.
Donkey anti-goat antibody-FITC (Abcam 7121, 1:1000) was used as a secondary
reagent, and sections were counterstained with DAPI to visualize nuclei.
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Immunofluorescent images were acquired and analyzed as above.
Statistical Analysis
Continuous variables were reported as means ± standard deviation. The
Student’s t-test was used to compare continuous variables.
significance was set at p < 0.05.

Statistical

Analyses were preformed with STATA

(StataCorp, College Station, TX) statistical software package, version 12.1.
5.3. Results
Hydrogel Formation
HEMA-HA gels formed rapidly through the mixing of two solutions that
each contain components of the APS/TEMED free-radical initiator system (Figure
5.1). Gelation occurred within 1 minute and the crosslinking reaction reached a
plateau within 30 minutes. By using this crosslinking route, we are able to inject
the liquid precursor solution through a syringe and form solid gels under
physiologic conditions.
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Figure 5.1. Hydrogel formation. (A) HEMA modified HA macromers synthesized with terminal
vinyl double bonds for free-radical initiated crosslinking into gels and ester groups to introduce
hydrolytic degradation of the gels. (B) Monitoring storage (G’, elastic component) and loss (G’’,
viscous component) moduli over time with rheometry shows that solid gels form from an
injectable liquid solution within minutes upon addition of APS/TEMED initiators.
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Hydrogel Degradation and ESA Release Kinetics
ESA release was sustained for over 28 days in vitro when encapsulated in
degradable HEMA-HA hydrogels (Figure 5.2 A). An initial burst release of ESA
was observed during the first few days due to ESA that was not encapsulated
during gel formation or encapsulated in the periphery of the gels. Similarly, an
initial burst release of HA was observed due to HEMA-HA polymers that were not
incorporated into the gels during the crosslinking reaction. After this initial period,
ESA release was steady for approximately 20 days while the gels remained
intact. The retention of ESA within the hydrogels was surprising considering the
small size of ESA (~4kDa).

Upon closer examination, microscale ESA

aggregates were observed within the gel (purple due to the fluorescent tag)
which would account for the reduced diffusion of the peptide within the hydrated
gel (Figure 5.2 C). As the gels began to hydrolyze and HA was released, the
rate of ESA release increased due to less restricted diffusion of the particles
within the gels (Figure 5.2 D).
Hydrogel Release of ESA Remains Functional
Using a transwell migration assay, EPCs showed significant chemotaxis
towards ESA released from the gels, indicating that the peptide remains active
after gel encapsulation and release (Figure 5.2 B).

Importantly, the ESA

remained active throughout the entire 28 day in vitro study. Significant increases
in EPC chemotaxis were also observed in samples from the hydrogel alone when
compared to PBS, which is attributed to the HA degradation products being
released from the material.
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Figure 5.2. Molecule release from hydrogels. (A) ESA release from the gels was sustained for
28 days in vitro and correlated with gel stability (n=3 gels, mean±SD). (B) Released ESA and HA
stimulated EPC chemotaxis throughout the 28 day study (n=5-6 wells/condition, mean±SD,
*p<0.05 compared to saline control. Dotted line represents saline control). (C) Representative
bright field images of ESA aggregates (purple due to fluorescent tag) encapsulated in the
hydrogel at Days 1, 5, 14, and 23 (scale bar = 200 µm). (D) Schematic of diffusion controlled
release of encapsulated ESA from degradable HA gels.

Tracking ESA within the Heart post MI
By utilizing ESA that had been conjugated with a near IR wavelength
fluorophore (i.e., HiLyte Fluor 750, 753/778nm excitation/emission), we were able
to image ESA in the heart to quantify the dynamics of ESA release from
hydrogels.

Rats treated with the fluorescently tagged ESA encapsulated in

hydrogels manifested a strong fluorescent signal for the first 10 days, followed by
a steady decline in signal until a plateau at day 24, when there was no difference
in signal compared to the saline control group (Figure 5.3). The quantitative data
for ESA localized to the heart is shown in Figure 5.3 and demonstrates that ESA
is released over a 24 day time period in-vivo.
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Figure 5.3. In vivo ESA tracking.
After undergoing LAD ligation and injection with
hydrogel/ESA, animals underwent in vivo imaging to visualize ESA fluorescence. Animals
receiving saline injections served as a negative control. (A) Representative images of
hydrogel/ESA injection group. (B) Quantitative analysis of fluorescent images showed a
fluorescent ESA signal in the heart out to day 24, after which fluorescence was not different than
background (dotted line denotes fluorescence of saline control) (Saline n=3; hydrogel/ESA, n=6;
mean±SD).

Hydrogel + ESA Improves Hemodynamics post-MI
Echocardiographic assessment of cardiac structure and function revealed
significant benefits with hydrogel injection and ESA delivery (Figure 5.4 A-B). At
4 weeks post MI, LV inner diameter at end diastole (LVIDd) was reduced in the
hydrogel groups compared to the saline control group; however, there was no
statistical difference between hydrogel and hydrogel/ESA groups (Figure 5.4 A).
LV ejection fraction was preserved and significantly greater in the hydrogel/ESA
group compared to the saline and hydrogel alone groups (Figure 5.4 B).
Additionally, hemodynamic assessment of LV function revealed significant
improvements with hydrogel injection and ESA delivery (Figure 5.4 C-D).
Cardiac output was significantly greater in the hydrogel/ESA group compared to
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saline and hydrogel alone groups (Figure 5.4 C).

In addition, there was a

significant increase in the LV end systolic pressure-volume relationship (ESPVR)
in the hydrogel/ESA group compared to the saline and hydrogel alone groups
(Figure 5.4 D).
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Figure 5.4. LV functional assessment. LV function was quantified using echocardiography (AB) and hemodynamic analysis (C-D) 28 days following experimental MI and injections in rats. (A)
Injection of hydrogels significantly reduced LV dilation as indicated by LV internal diameter and
diastole (LVIDd). (B) A significant improvement in LV ejection fraction was observed with
hydrogel delivery of ESA. (C) Significant improvements in cardiac output were observed with
hydrogel injections, and further improvement was observed with encapsulation of ESA. (D)
Significant improvements in LV end systolic pressure-volume relationship (ESPVR) were
observed with gels injection, and further improvement was observed with encapsulation of ESA.
(Saline, n=8; HA Gel, n=10; HA Gel/ESA, n=9; mean±SD; #p<0.025 versus control, *p<0.025
between groups, student’s t-test with Bonferonni correction).

Hydrogel + ESA Results in Preservation of Ventricular Geometry, Smaller
Infarcts, Greater Borderzone Capillary Density, and Upregulation of CXCR4+
Cells
Histologic analyses showed smaller LV areas in the hydrogel/ESA group
when compared to saline control, but was statistically similar to the hydrogel
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alone group, while the infarct fraction of theLV was significantly smaller in the
hydrogel/ESA group compared to controls. Representative images are shown in
Figure 5.5. Analysis of immunofluorescently labeled vWF showed a significant
increase in capillary density in the hydrogel/ESA group and hydrogel alone group
when compared to the saline group (Figure 5.6 A). Additionally, there were
significantly more CXCR4+ cells in the hydrogel /ESA group compared to
hydrogel and saline groups (Figure 5.6 B).
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5.4. Discussion

fu

Over the past five years, investigations into intramyocardial injection of

bioengineered, chemically modified materials after MI have showed promising
results, causing thicker, stiffer infarcts, limiting infarct expansion and preserving
LV geometry22-26" Although promising, it may be very useful to improve on these
techniques through further biological targets, such as stimulating a robust

'
angiogenic
response and localizing progenitor cells to the site of infarction. HA
based hydrogels offer an intriguing benefit as they are able to provide both
support to the infarcted myocardium during the acute phase and a platform for
the delivery of potent chemokines, where release is controlled with diffusion and
hydrolytic degradation.
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In the present study we utilized a HA based hydrogel to encapsulate an
engineered SDF-1 analog (ESA) to sustain release of this polypeptide over 28
days. The hydrogel was chemically engineered to degrade in about 28 days,
which was confirmed in vitro by a uronic acid assay. We were able to show that
functional ESA can be released from the hydrogels over the entire 28 days study,
recruiting EPCs in a transwell migration assay across all time points.
Interestingly, the hydrogel alone group also stimulated migration of EPCs, albeit
to a lesser extent than hydrogel/ESA, a finding that is supported by prior studies
and likely due to the interaction of HA with the membrane protein CD44 on
EPCs19, 27, 28.
Our in vivo studies demonstrated that treatment with hydrogel/ESA
resulted in smaller infarcts, stimulated angiogenesis at the borderzone, and
preserved LV geometry and function. Again, we observed that treatment with
hydrogel alone stimulated a moderate amount of angiogenesis at the borderzone
and maintained LV geometry, findings which are consistent with previous
literature showing that injectable hydrogels can limit infarct expansion by
providing structural support to the myocardium, resulting in improved
hemodynamic functioning24, 25. Lastly, we were able to successfully track ESA in
the heart over 24 days using fluorescent imaging, confirming that our hydrogels
sustained release of ESA in vivo as we originally proposed.
It is noteworthy the degree to which the hydrogel alone group derived
structural and functional benefit in this study. Although this is not a new finding, it
is interesting that HA hydrogels can limit infarct expansion and preserve
ventricular geometry, causing improved hemodynamics. It is likely that these
benefits are multifactorial in nature, resulting from the structural properties of the
gel itself as well as HA interaction with CD44 on bone marrow progenitor cells.
Ultimately, however, we have shown that hydrogel/ESA has a synergistic effect
on the heart following MI, resulting in improved structure and function of the
myocardium and upregulation of CXCR4+ cells.

Despite the similarities in

angiogenesis between the hydrogel and hydrogel/ESA groups, improved
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hemodynamic function was observed in the hydrogel/ESA group. This is most
likely due to the fact that the role of ESA is not merely to attract bone marrow
progenitor cells, but also recruit endogenous cardiac progenitor cells to the
infarct borderzone. Through its interaction with CXCR4+ cardiomyocytes, ESA
may lead to preservation of cardiac cells through reduced apoptosis via CXCR4
pathways, leading to improved hemodynamics.

In a very eloquent knockout

model, Dong and colleges were able to show that the SDF-1:CXCR4 axis is
vitally important for preservation of cardiac function following MI, specifically
showing SDF-1 binding to CXCR4+ cardiac cells leads to retention of
cardiomyocytes, reduction in infarct size and localization of cardiac stem cells at
the borderzone – and all without altering vascular density29"
One limitation of this study is that it was performed in an acute model of
MI, where the treatment was given immediately after coronary artery ligation.
Although this satisfies our scientific search for how hydrogel encapsulated ESA
interacts with ischemic myocardium, the positive findings reported here may not
be generally applied to clinical situations where treatment modalities must be
effective in the setting of chronic heart failure. Chronic post-ischemic changes
offer a complex problem to the investigator, where deleterious remodeling and a
diminutive stem cell supply must be overcome. However, as a proof of principle
study and a starting point, we have effectively shown that sustained release of
ESA by injectable hydrogels is possible in the heart.
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CHAPTER 6
Local hydrogel delivery of recombinant tissue inhibitor of
metalloproteinase-3 attenuates adverse left ventricular remodeling after
myocardial infarction
(Adapted from: S.R. Eckhouse, B.P. Purcell, J.M. Oelsen, C.B. Logdon, W.F.
Rawls, R.K. Patel, K.N. Zellars, R.E. Stroud, J.A. Jones, R. Mukherjee, R.C.
Gorman, R.A. Black, J.A. Burdick, F.G. Spinale, Sci Trans Med, in revision)
6.1. Introduction
A structural milestone in the progression of heart failure following a
myocardial infarction (MI) is left ventricular (LV) remodeling, defined as changes
in LV geometry and structure1-10. While post MI remodeling is a multifactorial
process, one ubiquitous event is infarct expansion4-10. Specifically, infarct
expansion is the regional process by which continuous turnover of the
extracellular matrix (ECM) results in the LV wall thinning and the loss of structural
support8-13. One biological system that is active in the post MI context is a family
of ECM proteases, the matrix metalloproteinases (MMPs)13-25.

MMPs are a

family of enzymes involved in proteolytic processing of interstitial structural
proteins, signaling molecules and growth factors13,26,27. The induction and
release of MMPs have been demonstrated in patients post MI, and were
associated with adverse LV remodeling and the development of heart failure22-25.
Moreover, direct measurement of interstitial MMP activity through microdialysis
techniques have established that MMP activation occurs within the ischemic
myocardium21,28. Thus, localized control of MMP activity within the MI region is a
potential therapeutic target for the purposes of interrupting the maladaptive
process of infarct expansion.
The cause-effect relationship between MMP activity and adverse LV
remodeling

has

been

established

in

experimental

models

through

pharmacological MMP inhibition, as well as transgenic constructs13-20.

For
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example, continuous, systemic adminstration of pharmacologic MMP inhibitors
reduced the extent of infarct expansion and LV dilation following experimental MI
in adult pigs14. However, translation of systemic pharmacologic MMP inhibition
to clinical application has encountered problematic issues, including concerns
surrounding dosing and potential side-effects29-32. Under ambient physiologic
states, endogenous MMP inhibition is achieved through the synthesis and
release of the tissue inhibitors of MMPs (TIMPs)13,33-35. In contradistinction to the
induction of MMPs in the early post-MI period, a concomitant increase in relative
TIMP levels does not occur, causing an imbalance between endogenous
proteolytic activity and inhibition, which in turn would facilitate early adverse LV
remodeling and infarct expansion13-15,22-25. It is now becoming recognized that
the biological effects of TIMPs may not be uniform, and studies have identified
unique functionality34-38. Of particular relevance, TIMP-3 levels are reduced in
patients post MI22,

and transgenic deletion of TIMP-3 causes adverse

remodeling and acceleration to heart failure39-41. Unique biological features of
TIMP-3 include a high affinity to bind to the ECM through interactions with
glycoasaminoglycans34,42,43,

influences on cytokine processing41,44,

and

alterations in fibroblast phenotype in-vitro36,45. However, localized augmentation
of TIMP-3 in the context of post-MI remodeling has not been examined.
Accordingly, the central hypothesis of this study was that local delivery of
exogenous TIMP-3 within the MI region would reduce infarct expansion and alter
the course of post-MI remodeling.

Polymers that form solid water-swollen

hydrogel matrices from liquid precursor solutions upon injection through a syringe
have been applied in order to localize and sustain the release of macromolecules
to the MI region46. Past studies have demonstrated that composite materials
such as hydrogels containing hydroxyapatite or fibrin-alginate can be safely
injected into the MI region47-51.

Moreover, injectable hydrogels based on

hyaluronic acid (HA), a glycosaminoglycan found abundantly in the ECM, have
been deployed in large animal models of MI47. Thus, the first aim of the present
study was to develop a method by which to incorporate a recombinant TIMP-3
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(rTIMP-3) within a degradable HA hydrogel construct for localized myocardial
delivery in a large animal model of MI. The second aim of the present study was
to locally place the Hydrogel/rTIMP-3 system within the MI region and quantify
the effects on regional interstitial MMP activity, infarct expansion, and LV
geometry and structure within the early post MI period.
6.2. Methods
Animals
All animals were treated and cared for in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals (Eighth
Edition. Washington, DC: 2011), and all protocols were approved by the Medical
University of South Carolina’s Institutional Animal Care and Use Committee.
rTIMP-3 Synthesis
A stable human TIMP-3 poly-His (rTIMP-3) expressing Chinese hamster
ovary cell line was established using a vector with a Cytomegalovirus promoter,
whereby 60 L of conditioned medium were concentrated to 8 L via Tangential
Flow Filtration (TFF) (Millipore, 10kD MWCO). The full length human TIMP-3
sequence was utilized52. The concentrated supernatant was filtered and applied
to Fractogel EMD SO3 (Merck KGaA, Darmstadt, Germany), and protein was
eluted with a 0.1 M sodium chloride (NaCl) gradient. The TIMP-3 containing
fractions were applied to Ni-NTA resin (Qiagen, Valencia, CA), and poly-His
tagged protein was eluted with 300 mM Imidizol.

To further remove

contaminants, the protein was then subjected to size-exclusion chromatography.
TIMP-3 containing fractions were concentrated by TFF and buffer exchanged to
10 mM Na Acetate pH 5.2, 9% Sucrose. The material was then lyophilized for
later reconstitution. Using a previously validated global MMP fluorogenic peptide
assay, 10 µM of the MMP substrate (Cat no. ES001, R&D Systems) and 4 nM of
a recombinant active MMP-2 (Cat no. 902-MP R&D Systems) were incubated in
the presence and absence of increasing concentrations of rTIMP-3.
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Fluorescence of the cleaved substrate was measured at an emission/excitation
wavelength of 320/405 nm. An exponential decay in MMP activity occurred with
increasing concentrations of rTIMP-3, with a computed half maximal inhibitory
concentration of approximately 26 ng/mL (Figure 6.1 A).
Hydrogel Synthesis
A degradable hydrogel was fabricated by synthesizing HA macromers as
described previously48-49.

Briefly, HA (74kDa, Lifecore) was modified with

hydroxyethyl methacrylate (HEMA) to incorporate a terminal methacrylate group
for free-radical initiated crosslinking as well as ester bonds to introduce hydrolytic
degradation (Figure 6.1 B). Briefly, HEMA was reacted with succinic anhydride
via a ring opening polymerization in the presence of N-methylimidazole to obtain
HEMA-COOH, which was then coupled to a tetrabutylammonium salt of HA in
the presence of 4-dimethylaminopyridine.

The resulting HA macromer with

HEMA group modification (HEMA-HA) was purified with dialysis, lyophilized and
characterized by 1H NMR.

For hydrogel formation upon injection, a redox

initiator system consisting of ammonium persulfate (APS) and N,N,N!,N!tetramethylethylenediamine (TEMED) was utilized.

10 mM APS and 10 mM

TEMED were mixed with a 4 wt% (w/v) HEMA-HA solution in phosphate buffered
saline (PBS) to form hydrogels.

Kinetics of hydrogel formation were

characterized with rheometry by monitoring the storage (G’) and loss (G”) with
time (20mm 1o cone geometry, 1% strain, 1Hz, Texas Instruments AR 2000ex).
rTIMP-3 Binding Affinity to HEMA-HA
Binding affinity between rTIMP-3 and HEMA-HA was quantified using an
intrinsic protein fluorescence quenching technique. Fluorescence titration
experiments were performed on a Tecan infinite m200 plate reader (Grödig,
Austria) at 25°C.

The fluorescence of a 2 µM rTIMP-3 solution in 100 mM

HEPES buffer (pH 7.4) was recorded at 280/350nm excitation/emission.
Fluorescence quenching was monitored by increasing the concentration of
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HEMA-HA in rTIMP-3 solution in 0.64 µM increments. 2 µL of concentrated
polymer solution in HEPES was added to 1 mL rTIMP-3 solution for each
titration, mixed, equilibrated for 2 min and fluorescence was measured. The
normalized changes in fluorescence with each HEMA-HA titration were plotted
against HEMA-HA concentration and resulting binding isotherms were fit by
nonlinear regression to the equation describing bimolecular association:

where F is the change in fluorescence over initial fluorescence (-!F/Fo), Fi is the
initial value for (-!F/Fo), Ff is the final value for (-!F/Fo), and Kd is the dissociation
constant.
Hydrogel Encapsulation of rTIMP-3 and in vitro Release Kinetics
rTIMP-3 was mixed with a 4 wt% HEMA-HA macromer solution in PBS,
and hydrogels were formed upon mixing 10mM APS/TEMED initiators as
described above. 50 µL hydrogels containing 10 µg rTIMP-3 were crosslinked in
cylindrical molds for 30 minutes at 37°C and then transferred to eppendorf tubes
containing 1mL PBS supplemented with 1% (w/v) bovine serum albumin (BSA).
Hydrogels were incubated in buffer at 37oC, and samples were collected for up to
14 days. At each time point, buffer was collected and replaced and analyzed for
released molecules. rTIMP-3 was quantified with a His ELISA (QUAexpress, NiNTA HisSorb, Quiagen Inc) using rTIMP-3 standards (0.7-25 ng) and HA
degradation products were quantified using a uronic acid assay47,48. After 14
days, hydrogels were enzymatically degraded by overnight incubation with
hyaluronidase (800 units/mL, Sigma Aldrich), and evaluated for remaining rTIMP3 and HA.
In vivo Validation of rTIMP-3 Releasing Hydrogel
Hydrogel/rTIMP-3 injections were performed within the LV free wall of
Yorkshire pigs (n=3, 25 kg, Hambone Farms, Orangeburg, SC). The pigs were
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anesthetized with isoflurane (2%), and through a left thoracotomy, the LV free
wall was exposed. A 2 cm square calibrated grid was sutured below the origin of
the first two obtuse marginal arteries of the circumflex artery (OM1 and OM2)14,50,
which provided for a total of 9 distinct injection sites within a targeted 2X2 cm
region of myocardium (Figure 6.1 E).

The hydrogel precursors containing

initiators and rTIMP-3 (20 µg rTIMP-3/100 µL hydrogel) were mixed in a sterile
fashion, drawn into micro-syringes, and injected into the mid-myocardium of each
target site. This volume of hydrogel and concentration of rTIMP-3 was
determined during initial titration studies, which provided the optimal ratio of
volume and concentration. The duration of time from final polymer mixing to
completion of the 9 injections was 3 minutes.

Successful injections were

confirmed by visualization of an opacification of the epicardial surface at the point
of myocardial injection. The perimeter of the injection grid was marked at each
corner with radiopaque markers (1.6mm diameter, VNUS Medical Systems,
Sunnyvale, CA) and the grid removed14. At 7 days post injection, the pigs were
again anesthetized, the LV harvested, the myocardial tissue isolated and
sectioned into 9 regions, and immediately processed. The LV samples were
prepared in an ice cold extraction/homogenization buffer (QUAexpress, Ni-NTA
HisSorb, Quiagen Inc) and subjected to the His ELISA technique described in the
previous section.
MI Induction and Hydrogel Injection Protocol
Pigs were randomized to one of three different groups: MI and no
injections (MI only, n=6), MI and hydrogel injections (MI/Hydrogel, n=8), and MI
and hydrogel with rTIMP-3 injections (MI/Hydrogel/rTIMP-3, n=8).

Non-

instrumented pigs were used as referent, non-MI controls (n=8). The pigs were
anesthetized and markers placed as described in the previous section. OM1 and
OM2 were ligated to induce an MI, and characteristic ECG changes occurred, but
electrical cardioversion and/or defibrillation were not required, and past studies
demonstrated that this technique creates a uniform and consistent MI involving
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22% of the LV free wall14,50. For pigs assigned to either hydrogel groups, nine
injections were performed as described in the previous section.
Measurements of Infarct Expansion, LV Geometry and Function, In-vivo MMP
Activity
Two weeks after chronic instrumentation, the animals were sedated and
two-dimensional echocardiographic studies (ATL Ultramark VI, 2.25MHz
transducer, Bothell, WA) were performed to calculate LV volume and
dimensions14,22,50. In addition, LV short-axis images gated to end-diastole were
digitized and used to compute regional wall stress as previously described14,50.
Following which, fluoroscopic images of the myocardial markers were recorded
with a high-speed cinefluoroscopy (Philips Cardiac-Diagnostic) and were
digitized (ATI Radeon). Using projections of the markers from two orthogonal
planes, intermarker distances were computed in three-dimensional spaces and
used to determine the area circumscribed by the markers14.
Following imaging studies, the pigs were anesthetized with sufentanyl (2
µg/kg IV, Baxter Healthcare), morphine sulfate (3 mg/kg/h IV, Elkin-Sinn), and
isoflurane (1%, 3 L/min O2, Baxter Healthcare), and mechanically ventilated. The
LV was exposed through a sternotomy, a microdialysis probe (20 kDA, outer
diameter of probe shaft 0.77 mm; CMA/Microdialysis, North Chelmsford, MA)
placed within the MI region, and infused with the MMP fluorescent substrate (5
µL/min) described in the previous section and validated previously21,28.

The

dialysate was then subjected to fluorometry which reflected interstitial MMP
activity. Following these measurements, the LV was harvested, separated into
MI and remote regions (area served by left anterior descending artery), and
prepared for biochemical and histological measurements.
Ex vivo Measurements of TIMP-3, LV Histology, and Cytokine Assay
Immunoblotting. Immunoblotting was performed for total myocardial TIMP3 levels using approaches described in detail previously14,15,28,50,51. LV extracts
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(80 µg of total protein) underwent electrophoretic separation, transferred to a
nitrocellulose, incubated with anti-TIMP-3 (1:2000, Cat#AB6000, Millipore,
Billerica, MA, overnight 4°C), the immune-positive signal detected by
chemiluminescence (Western Lighting, Perkin Elmer), and digitally quantified
(Gel-Pro Analyzer, v3.1.14, Media Cybernetics Inc., Silver Spring, MD). In order
to confirm the presence and absence of rTIMP-3 within the LV targeted regions,
immunoblotting was performed using anti-polyHis (1:1000, Cat#ab27025,
Abcam, Cambridge, MA, overnight 4°C).
Histomorphometry.

The formalin fixed full thickness LV samples were

embedded, sectioned (7 µm), and stained with picrosirius red for fibrillar collagen,
and the percent area of collagen within the remote and MI regions were
computed using computer assisted morphometry14-16,51,53. Immunostaining was
used to colocalize with cells that stained positive for !-smooth muscle actin
(1:100; !-smooth muscle actin: Sigma A5228), a marker for actin present in
vascular smooth muscle cells as well as myofibroblasts, using approaches
described previously53. Additional LV sections were stained with hematoxylin
and eosin, and histopathological examination was performed.
Cytokine Assay. LV myocardial homogenates were subjected to cytokine
analysis using a 2-laser flow cytometric detection system (Bio-Plex 200, BioRad
Laboratories)

and

a

previously

validated

MPXHCYT060KPMX39, Millipore, Billerica, MA)21.

platform

(Cat.

no.

Using pre-calibrated

standards and regression modeling, the fluorescence emission was converted to
an absolute cytokine concentration.
Computation and Data Analysis
Statistical analyses were performed using STATA statistical software
(STATA Corp, College Station, TX). LV geometry, function, and area within the
markers were compared between the control and MI groups using a one-way
analysis of variance (ANOVA).

Post-hoc separation following ANOVA was

performed using pairwise comparisons with a Bonferroni analysis (prcomp
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module, STATA). The interstitial global MMP activity was evaluated by ANOVA
and subsequently compared against the control values of 100% by a Student’s ttest. For TIMP-3 levels and myocardial cytokine concentrations, values from
each group were first evaluated by ANOVA, and then a post-hoc separation
following ANOVA was performed using pairwise comparisons with a Bonferroni
analysis. For morphometric measurements, a multi-way ANOVA (MANOVA) was
performed, evaluating for treatment dependent, MI dependent, and region
dependent effects.

Post-hoc separation following MANOVA was performed

using pairwise comparisons with a Bonferroni analysis. Results are presented as
a mean ± standard error of the mean (SEM), and values of p<0.05 were
considered to be statistically significant.
6.3. Results
Hydrogel Formation and rTIMP-3 Release
HEMA-HA macromers were synthesized with a modification of ~20% as
determined by 1H NMR analysis. The negatively charged HEMA-HA macromers
bound rTIMP-3 with a dissociation constant (KD) of 3.8±0.03µM (Figure 6.1 B).
Solutions of the HEMA-HA macromer and APS/TEMED initiators (4 wt% HEMAHA, 10 mM APS/TEMED) were mixed together for hydrogel formation, with
gelation occurring approximately 1 minute after mixing, and a plateau of
crosslinking reached within 30 minutes (Figure 6.1 C). Upon mixing APS and
TEMED, a free-radical is generated, which initiates the growth of kinetic chains
between methacrylate groups on the HEMA-HA macromers, covalently
crosslinking the hydrogel.

The crosslinked hydrogels steadily degraded in

aqueous solution throughout the 14 day period, as determined by release of
uronic acid, although the gels remained intact at day 14 (Figure 6.1 D). rTIMP-3
was successfully encapsulated in the hydrogel and released at a nearly uniform
rate throughout the 14 day period (Figure 6.1 D). A significant amount of rTIMP3 remained in the hydrogels after the 14 day study. When injected into the
myocardium, the hydrogels maintained the levels of rTIMP-3 above remote
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background levels over a 7 day period. Specifically, a consistent signal for
rTIMP-3 was detected at each of the targeted injection sites, but no signal was
obtained in non-targeted injection sites (Figure 6.1 F).
LV Geometry, Infarct Expansion, and Wall Stress
LV end-diastolic volume, ejection fraction, and regional infarct expansion,
defined as the area of myocardium within the markers (MI marker area), are
summarized in Figure 6.2. At 14 days post MI, LV volumes increased in all three
MI groups but were reduced in the MI/rTIMP-3/Hydrogel group.

LV ejection

fraction fell in all MI groups but was higher in the MI/rTIMP-3/Hydrogel group
when compared to the MI only group. Regional infarct expansion increased in
the MI only and MI/Hydrogel groups at 14 days post-MI, whereas this index of MI
expansion was significantly attenuated in the MI /Hydrogel/rTIMP-3 group. In
light of the changes in LV global geometry and MI expansion, LV regional wall
stress was computed in all groups (Figure 6.3 A).

LV regional wall stress

increased in all MI groups when compared to referent controls but was reduced
in both the MI/Hydrogel and the MI/Hydrogel/rTIMP-3 groups when compared to
MI only values.

However, the greatest reduction in LV regional wall stress

occurred in the MI/Hydrogel/rTIMP-3 group.
In vivo interstitial MMP activity and ex-vivo TIMP-3 levels
Myocardial interstitial MMP activity was quantified within the MI region at
14 days post-MI using a validated microdialysis-fluorogenic approach21,28,53, and
the results are summarized in Figure 6.3. Interstitial MMP activity was higher in
the MI only and the MI/Hydrogel groups, and was significantly reduced in the
MI/Hydrogel/rTIMP-3 group. LV myocardial extracts were subjected to antipolyHis immunoblotting, whereby only apositive signal corresponding to rTIMP-3
could be identified within the MI region at 14 days post-MI (Figure 6.4 A).
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Figure 6.1. Hydrogel fabrication for targeted rTIMP-3 delivery. (A) rTIMP-3 inhibits rMMP-2
activity in a dose-dependent manner with a half maximal inhibitory concentration, IC50=26±2
ng/mL. (B) Synthesized HA macromer with reactive methacrylate group for gel crosslinking and
hydrolytically unstable ester groups for gel degradation. This negatively charged macromer binds
to rTIMP-3 with a KD=3.8±0.3µM through electrostatic interaction. (C) Gel crosslinking was
quantified with rheometry by measuring the storage (G’) and loss (G’’) moduli over time.
Crosslinking of 4wt% macromer (20% HEMA modification) reaches a gel point within 1 min after
adding 10mM APS/TEMED free-radical initiators and plateaus by 30 min. (D) Encapsulated
rTIMP-3 (10µg/gel) diffuses from the gels in a steady fashion for 14 days as the gels degrade in
aqueous buffer. A significant amount of rTIMP-3 remained in the gels after the 14-day study. (E)
Gels containing rTIMP-3 (20µg/100µL gel) were delivered to the MI region through a syringe
immediately following ligation of obtuse marginal arteries 1 and 2 (OM1 and OM2) in pigs. (F)
rTIMP-3 was quantified locally at the 9 injections sites 1 week after MI with no spillover to remote
sites.
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Figure 6.2. LV end-diastolic volumes and ejection fraction were computed by echocardiography
and the area within the radiopaque markers (MI marker area) by fluoroscopy at 14 days post MI.
LV dilation, as measured by LV end-diastolic volume, increased in all 3 groups post MI when
compared to referent control values. However, the degree of LV dilation was significantly reduced
in the MI/Hydrogel/rTIMP-3 group. LV ejection fraction significantly fell in all 3 groups at 14 days
post-MI. However, LV ejection fraction was significantly higher in the MI/Hydrogel/rTIMP-3 group
when compared to the MI only group. MI marker area, indicative of infarct expansion, increased
in the MI only and MI/Hydrogel groups, but was significantly reduced to control values in the
MI/Hydrogel/rTIMP-3 group. (*p<0.05 vs referent control, +p<0.05 vs MI only, #p<0.05 vs
MI/Hydrogel).
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Figure 6.3. (A) Regional peak systolic wall stress at the LV anterior wall (targeted MI region) was
computed using LV short axis dimensions, and wall thickness measurements as described in the
Methods section. LV regional wall stress increased within the targeted MI region in all 3 groups at
14 days post-MI when compared to referent controls. However, LV regional wall stress was
reduced in the MI/Hydrogel group when compared to MI only values. Moreover, LV regional wall
stress was reduced even further in the MI/Hydrogel/rTIMP-3 group. (B) Interstitial MMP activity
within the MI region was determined using microdialysis and a fluorogenic peptide, as described
in the Methods section, and normalized to referent control values (dashed line). Interstitial MMP
activity increased in the MI only and MI/Hydrogel groups at 14 days post MI and was reduced in
the MI/rTIMP-3/Hydrogel group. (*p<0.05 versus referent control, +p<0.05 versus MI only,
#p<0.05 versus MI/Hydrogel)
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Using anti-TIMP-3 targeted against both native TIMP-3 and rTIMP-3, quantitative
immunoblotting was performed and summarized in Figure 6.4 B. Total TIMP-3
levels fell within the MI region in both the MI only and MI/Hydrogel groups, but
increased in a robust fashion within the MI region of M/Hydrogel/rTIMP-3 group.
Total myocardial TIMP-3 levels were similar across groups in the LV remote
region.
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Figure 6.4. (A) Representative
immunoblot for the His-tagged
rTIMP-3 within the targeted MI region
at 14 days post MI. A strong positive
signal was identified within the
MI/rTIMP-3/Hydrogel samples and
was absent in the referent control, MI
only, and MI/Hydgrogel groups. (BTop
Panel)
A
representative
immunoblot for TIMP-3, using an
antibody which reacted against both
rTIMP-3 and native TIMP-3. The
signal for total TIMP-3 was reduced
within the MI region in the MI only
and MI/Hydrogel groups. (B-Bottom
Panel) Quantitative immunoblotting
for total LV myocardial TIMP-3 levels
within the MI and remote regions was
performed at 14 days post MI as well
as in referent control samples (the
mean is represented by the solid line,
and the SEM is represented by the
dashed lines). Within the MI region,
total TIMP-3 was reduced in the MI
only and MI/Hydrogel groups, and
was significantly increased from both
MI groups and referent control values
in the MI/Hydrogel/rTIMP-3 group.
(*p<0.05 versus referent control,
+p<0.05 versus MI only, #p<0.05
versus MI/Hydrogel)

Cytokine levels relative to referent control values are summarized in Figure 6.5.
LV myocardial levels of interleukin-6, -9, and -12 increased in both the MI only
group and the MI/Hydrogel group. Interestingly, the myocardial concentrations of
IL-6, -9, -12 were significantly reduced in the MI/Hydrogel/rTIMP-3 group.
Monocyte chemoattractant protein-1 (MCP-1) concentrations were similar in
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the MI only and MI//Hydrogel groups, and actually fell below referent control
values in the MI/Hydrogel/rTIMP-3 group.
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Figure 6.5. Significant changes in specific inflammatory cytokines were detected within the MI
region at 14 days post MI, which included interleukin-6,-9,-12, and monocyte chemoattractant
protein-1 (MCP-1) when compared to referent control values. Interleukin-6, -9, and -12 increased
significantly in the MI only and MI/Hydrogel groups, whereas these cytokine levels were
significantly reduced in the MI/Hydrogel/ rTIMP-3 group. MCP-1 were similarly increased in the MI
and MI/Hydrogel groups and actually fell below referent control values in MI/Hydrogel/rTIMP-3
group. (*p<0.05 versus referent control, +p<0.05 versus MI only, #p<0.05 versus MI/Hydrogel)

Myocardial Histology and Fibrillar Collagen Content
Histological examination of LV sections taken from the referent control and
MI region revealed significant myofibrillar loss and an influx of inflammatory cells
(Figure 6.6 B-D). The presence of remnant hydrogel was observed within the
MI/Hydrogel and MI/Hydrogel/rTIMP-3 groups. Collagen content increased in all
MI groups when compared to controls (Figure 6.6 E). Collagen content was
further increased in the MI/Hydrogel and MI/Hydrogel/rTIMP-3 groups when
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compared to the MI only group. LV mid-myocardial sections devoid of large blood
vessels were examined with respect to immunolocalization for smooth muscle
actin (SMA), and representative photomicrographs are shown in Figure 6.6 F.
While in the referent control and remote regions, SMA staining predominated
around arterioles and venules. The predominant staining pattern within the MI
region was that of interstitial cells, consistent with myofibroblasts. This
myofibroblast positive staining was increased in the MI/Hydrogel group and
increased further in the MI/Hydrogel/rTIMP-3 group (Figure 6.6 F).
6.4. Discussion
Targeting Myocardial Infarct Expansion
While a number of pathophysiological events contribute to adverse
remodeling following MI, the myocardial process generically termed as infarct
expansion is a significant contributing factor5-10.

In the early post MI period

(hours-days), an influx of inflammatory cells, cytokine release, and activation of
multiple signaling pathways occurs, and results in heightened MMP activation
and matrix degradation12,13. While this early MMP induction may be an adaptive
biological response to myocardial injury, the persistently elevated MMP activation
which can occur in the later post MI period (days-weeks) can result in matrix
instability and abnormalities in stress-strain patterns, which in turn cause thinning
of the MI region as well as jeopardize the cellular and extracellular structure and
function of the viable border zone9-13. In contrast to the robust MMP induction
and activation in the post MI period, animal and clinical studies have
demonstrated that there is not a parallel increase in TIMPs, which in turn would
further potentiate interstitial MMP proteolytic activity14,15,22,24,25,51,53.. Moreover,
transgenic models have underscored the importance of TIMPs in terms of the
adverse LV remodeling process16. Thus, targeting MMPs remains an area of
active therapeutic investigation and development29-32 and would be particularly
relevant in terms of the infarct expansion process.
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Figure 6.6. (A-D) Representative photomicrographs of LV sections taken from the MI region
stained with hematoxylin and eosin: (A) a referent control and 14 days post-MI for (B) MI only, (C)
MI/Hydrogel, and (D) MI/Hydrogel/rTIMP-3. In contrast to the organized distribution of myofibrils
within the referent control LV myocardium, an influx of inflammatory cells and myofibril disruption
could be appreciated within the MI region, but to a lesser extent in the MI/Hydrogel/rTIMP-3
sections. Histological features consistent with islands of remnant Hydrogel were observed within
the MI region of the MI/Hydrogel group and the MI /Hydrogel/rTIMP-3 (black arrows). Scale bars
are 50 µm. (E) Computer assisted morphometric measurements of picro-sirius stained sections
from referent controls and the MI region were used to compute relative fibrillar collagen content.
Collagen content was increased in all MI groups when compared to referent control values
(F=3.07, p=0.04). Collagen content was further increased in the MI/Hydrogel group and the
MI/Hydrogel/rTIMP-3 group when compared to the MI only group. (F) Top Panels- Representative
smooth muscle actin staining within the referent control and MI sections. In the referent control as
well as the remote sections, smooth muscle actin staining was primarily associated with small
vascular structures (arterioles/venules), whereas in the MI region the staining pattern was
primarily associated with interstitial cells – i.e. myofibroblasts. Quantification using densitometry
revealed a substantial increase in this pattern of smooth muscle actin staining within the MI
region of the MI/ Hydrogel/rTIMP-3 group. (*p<0.05 versus control group, +p<0.05 versus MI only
group, #p<0.05 versus MI/Hydrogel)
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The present study was built upon these past clinical observational studies,
transgenic model systems, and broad based systemic pharmacological inhibitors,
through directly targeting the region of the LV myocardium where a clear
imbalance exists between MMPs and TIMPs. Using a clinically relevant model of
post MI remodeling54, the present study demonstrated that targeted TIMP
delivery is feasible and effective in interrupting the infarct expansion process.
These findings underscore the importance of developing therapeutic strategies
focused upon restoring the balance between MMP/TIMPs following MI.
Specifically, the new and unique findings from the present study were three-fold:
(1) regional Hydrogel/rTIMP-3 injections abrogates infarct expansion, reduces LV
dilation and regional wall stress, and improves systolic function in the early postMI period; (2) local Hydrogel/rTIMP-3 delivery augments total TIMP-3 levels
within the MI region and reduces myocardial interstitial MMP activity without
causing significant collagen accumulation over and above that of hydrogel
delivery alone; and (3) rTIMP-3 delivery within the MI region reduces local proinflammatory cytokine levels and increases myofibroblast density. This unique
translational study provides the first proof of concept that local and sustained
delivery of a recombinant TIMP effectively interrupts infarct expansion and
improves LV geometry, likely through modifying biological mediators of the
adverse post MI remodeling process.
LV Remodeling and Function: Effects of rTIMP-3
LV remodeling following MI invariably includes LV dilation, whereby the
progression and extent of post MI LV dilation is an independent risk factor for
morbidity and mortality1-7. In the present study, regional injection of rTIMP-3 into
the MI region reduced the degree of LV dilation when compared to MI only
values as well as to that of Hydrogel injection alone. It is important to note that a
range of hydrogels have been investigated to alter local tissue bulking and to
reduce stress profiles in the myocardium, leading to changes in LV dilation,
without the delivery of biological molecules47. Here, there is a clear improvement
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in outcomes with the addition of rTIMP-3. Also, LV ejection fraction increased in
the rTIMP-3 group in the post MI period. LV ejection fraction, as with any index of
LV pump function, is influenced by loading conditions and intrinsic contractile
performance.
In the present study, rTIMP-3 injection resulted in increased MI thickness,
and when considered in conjunction with the changes in chamber radius, caused
a net reduction in regional LV peak wall stress. Since LV peak wall stress is a
fundamental measure of LV afterload and is inversely related to LV ejection
performance, one likely mechanism for the improved LV ejection fraction with
rTIMP-3 injection was favorable effects on regional LV afterload. However, it
must be recognized that these measures of LV global and regional geometry
were taken at only one time point post MI, and whether these improvements with
rTIMP-3 are due to changes in the trajectory of adverse post-MI remodeling, or
actually represent a complete cessation of this process, will require future serial
studies. Significantly increased collagen accumulation within the LV myocardium
can contribute to increased myocardial stiffness properties13.

One critical

observation was that while rTIMP-3 release into the MI region, while significantly
reducing interstitial MMP activity, was not associated with excessive collagen
accumulation. These findings would suggest that localized rTIMP-3 augmentation
did not disproportionally alter ECM turnover and accelerate fibrosis.
Potential Biological Effects and Mechanisms of rTIMP-3 Delivery Post-MI
In the present study, interstitial MMP activity was reduced within the MI
region with rTIMP-3 delivery, demonstrating a localized MMP inhibitory effect,
and therefore, the hydrogel mediated delivery strategy released an active protein.
However, multiple substrates and biological pathways are influenced by
MMPs58,59, and therefore, it would be an oversimplification to assume that rTIMP3 delivery merely inhibited matrix proteolysis. In addition, it has been
demonstrated that TIMP-3 can induce direct biological effects, which include
influencing

fibroblast

growth

and

function,

cell

survival,

and

cytokine
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processing36,42,44.

The present study provides evidence to suggest that the

reduction in MI wall thinning and infarct expansion that occurred with rTIMP-3
delivery was likely due to a summation of these biological effects.
One unique finding from the present study was that rTIMP-3 delivery
resulted in a significant reduction in pro-inflammatory cytokines within the MI
region. This effect may have been due to several factors, which include
interference of MMP matrix proteolysis and egress of inflammatory cells, MMP
mediated cytokine processing, and/or direct effects of TIMP-3 on cytokine
induction.

Nevertheless, it is likely that the attenuation of cytokine signaling

within the MI region with rTIMP-3 delivery influenced the post MI remodeling
process. Another observation from the present study was that rTIMP-3 caused a
significant increase in !-smooth muscle actin, predominantly in interstitial cells
(i.e. myofibroblasts)58,59. Since myofibroblasts are critical in the wound healing
context and provide significant contractile force across the ECM13,58,59, it is likely
that the increase in this fibroblast phenotype with rTIMP-3 delivery influenced
regional tissue geometry and structure within the MI region. While this potential
contributory mechanism for the effects of rTIMP-3 remains associative, what is
clear from the present study is that regional TIMP-3 delivery within the MI region
likely altered biological signaling pathways as well as fibroblast phenotype.
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CHAPTER 7
Incorporation of sulfated hyaluronic acid macromers into degradable
hydrogels for controlled presentation of proteins through electrostatic
interactions

7.1. Introduction
Hyaluronic acid (HA) based hydrogels have been used widely in recent
years for applications in drug delivery and tissue engineering1.

HA is a

ubiquitous biological polymer composed of repeating D-glucuronic acid [!-1-3]
and N-acetyl-D-glucosamine [!-1-4] disaccharides and is found abundantly in the
extracellular matrix (ECM) of tissues. During endogenous tissue remodeling, HA
plays a critical role in regulating cell motility through CD44 receptor interactions
and provides a hydrated microenvironment for growth factor and cytokine stability
and diffusion2.
HA is unique among glycosaminoglycans (GAGs) in that it is produced
and secreted from cells as a linear polymer unattached to a polypeptide. This
feature makes HA production amendable to typical genetic engineering
approaches using microbial fermentation3.

These recombinant HAs are

nonimmunogenic, available in a wide range of well-defined molecular weights,
and have been used in numerous biomedical applications. Further, due to the
abundance of hydroxyl and carboxylic acid groups, HA is readily modified with
reactive groups to form hydrogels1. In particular, modification of HA with vinyl
groups permits gel formation through free-radical initiated crosslinking.

This

approach has allowed spatiotemporal control of network architectures to direct
stem cell differentiation in vitro4,5, as well as in situ gelation to localize therapeutic
protein delivery in vivo6.
While protein binding to vinyl modified HA macromers has been
observed6, HA lacks the sulfate groups typically associated with high protein114!
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ECM binding affinities. For example, heparin has been shown to bind, stabilize,
and in some cases enhance the activity of hundreds of heparin binding proteins
(HBPs) through electrostatic interaction between sulfates and basic amino acid
residues7.

These interactions are critical to regulating tissue remodeling

processes by localizing HBP activity in a temporally controlled fashion (i.e., HBP
presentation)8,9. A variety of conjugation techniques have been developed to
covalently incorporate heparin into scaffolds, and these systems have been used
to control HBP presentation and subsequent cellular processes10-12. However,
since heparin is normally present in tissues attached to a core protein (i.e.,
proteoglycan), production of heparin is limited to crude isolation from animal
tissues.

As a result, commercially available heparin is a heterogeneous

distribution of polysaccharides with diverse protein binding specificities and some
polysaccharide contaminants found in heparin have caused a sudden increase of
severe side effects in patients undergoing antithrombotic treatment13.
To minimize contaminants and provide a higher level of HBP specificity,
there has been a growing interest in producing well-defined heparin mimetics
through synthetic routes14. Heparin mimetics are highly sulfated polymers that
are structurally distinct from naturally occurring GAGs, but perform some of the
same functions as heparin (e.g., HBP binding)7. These sulfated polymers have
been shown to bind HBPs with high affinity and when delivered in vivo they
significantly enhance tissue repair, presumably by replacing degraded heparin
and increasing the bioavailability of HBPs15. While HA is unique among GAGs in
that it lacks sulfate groups, researchers have demonstrated synthetic sulfation of
HA through nucleophilic substitution of primary hydroxyl hydrogens on HA with
SO3 by simply reacting SO3 complexes with HA in an organic solvent16-18.
Reaction of an SO3/DMF complex with HA results in a specific sulfation pattern
that binds HBPs with a high affinity17,19. Further, sulfated HA polymers exhibit
good cytocompatibility and enhance HBP presentation to cells in vitro20. Also,
sulfated HA polymers themselves have been shown to influence cell activity in
vitro including stimulating Wnt and Notch signaling16, as well as increasing cell115!
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cell junctions18.

However, sulfated HA has not previously been modified for

covalent incorporation into hydrogels to alter features such as protein interactions
and diffusion.
Here, we synthesized sulfated and vinyl modified HA macromers to
incorporate protein-binding features into radically crosslinked HA hydrogels.
Further, we incorporated hydrolytically unstable ester groups between the
reactive vinyl group and the sulfated HA backbone to liberate bound proteins in a
controlled fashion. We show that these macromers bind a HBP with an affinity
comparable to heparin, can be readily incorporated into unsulfated HA hydrogels
without significantly altering hydrogel crosslinking, and therefore can be used to
control the presentation of HBPs for drug delivery and tissue engineering
applications.
7.2. Methods
Materials.
Sodium hyaluronate (NaHy) was purchased from Lifecore (100 and 440
kDa, as measured with GPC). ELISA kit and reagents were purchased from
R&D Systems. Recombinant human TIMP-3 with a 6x His tag was provided as a
gift from Amgen, Inc.

Anti-6x His antibodies were purchased from Abcam.

Heparin binding plates were purchased from BD Biosciences.

Polyethylene

glycol standards were purchased from Waters. All other materials and chemicals
were purchased from Sigma Aldrich.
Macromer Synthesis.
NaHy (100kDa) was chemically modified with a hydroxyethyl methacrylate
(HEMA) group to incorporate methacrylate reactivity for free-radical initiated
crosslinking, as well as hydrolytic degradation through ester group hydrolysis as
previously described6. Briefly, HEMA was reacted with succinic anhydride via a
ring opening polymerization in the presence of N-methylimidazole to obtain
HEMA-COOH, which was then coupled to a tetrabutylammonium (TBA) salt of
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HA in the presence of 4-dimethylaminopyridine (DMAP) and di-tert-butyl
dicarbonate (BOC2O).

The resulting HA macromer with HEMA group

modification (HEMA-HA) was purified with dialysis and characterized by 1H NMR.
For HEMA-SHA synthesis, a 440kDa NaHy was first synthesized to
HEMA-HA as described above and then converted to a TBA salt through resin
exchange (Dowex 50x8w hydrogen form) and TBA-OH titration to pH 7.02 to
permit polymer solubility in DMF for the sulfation reaction. HEMA-HA TBA was
then frozen and lyophilized.

Dry HEMA-HA TBA was dissolved in N,N-

dimethylformimide (DMF) at 0.25% (w/v) under N2 at room temperature (RT).
SO3/DMF complex in DMF solution (10% (w/v)) was added to the reaction at a
20:1 (mol/mol) SO3/DMF:HA repeat unit ratio and reacted for 1 hr at RT under
N2. The reaction solution was then dialyzed against DI H2O for 14 days at 4°C to
remove solvent and TBA salts, frozen and lyophilized.
Gel Permeation Chromatography.
Molecular weights were determined with gel permeation chromatography
(GPC) analysis using a Waters 1525 Binary HPLC Pump, Waters 2414
Refractive Index (RI) Detector, and Waters Ultrahydrogel 1000 columns. The
eluent was PBS buffer and the flow rate was 0.5 mL/min. Size calibrations for
molecule weight determination were made with polyethylene glycol standards
(Polymer Standard Services USA, Inc).
Zeta Potential Measurements.
Polymers were dissolved in MilliQ H2O at 3.5wt% for HEMA-HA and 4wt%
for HEMA-SHA and loaded into folded capillary cells (Malvern).

Zeta Potential

measurements were made on a ZetaSizer Nano ZS (Malvern).
Dimethylmethylene Blue Assay.
Serial dilutions of each polymer were prepared in MilliQ H2O
(50µg/mL!0µg/mL) and assayed for the presence of sulfate groups using a
117!
!

previously developed dimethylmethylene blue (DMMB) assay21. Absorbance at
520 nm was measured using a cuvette reader (Tecan). To visualize sulfate
groups, 50µL hydrogels were formed (see subsequent methods), washed for 2
days in PBS, incubated in DMMB solution overnight at 37°C, rinsed and
photographed.
Solid-phase Binding Assay.
HEMA-HA, HEMA-SHA and heparin at 2.5µM in PBS were coated
overnight at 25°C onto heparin binding plates (BD Life Sciences)22. Wells were
washed in TNC buffer (50 mM Tris/HCl, 150 mM NaCl, 10 mM CaCl2, 0.05 %
Brij-35 and 0.02 % sodium azide) containing 0.1 % Tween 20 between each
subsequent incubation. Wells were blocked with 0.2% gelatin in TNC buffer and
then incubated with rTIMP-3-His (0.02-3µg/mL in blocking solution for 3 h at
37°C). Bound rTIMP-3-His was detected using a biotin labeled antibody against
the 6xHis tag on rTIMP-3 (Abcam, ab27025, 3 hr incubation at 37!C), followed by
streptavidin coupled to horseradish peroxidase (R&D Systems) for 1h at 37°C.
Hydrolysis of a 1:1 mixture of H2O2 and tetramethylbenzidine (R&D Systems)
was measured at 450 nm using a microplate reader (Tecan infinite m200).
Hydrogel Formation.
For crosslinking, a redox initiator system consisting of ammonium
persulfate (APS) and N,N,N",N"-tetramethylethylenediamine (TEMED) was
utilized. APS and TEMED were mixed with polymers dissolved in phosphate
buffered saline (PBS) to initiate crosslinking at final concentrations of 10mM
APS, 10mM TEMED, and 4wt% (w/v) polymer. HEMA-HA/HEMA-SHA blends
were formed by mixing different volumetric ratios of the respective polymers
dissolved at the same concentrations in PBS.

Kinetics of the crosslinking

reaction were characterized with rheometry by monitoring the storage (G’) and
loss (G”) moduli with time (20mm 1° cone geometry, 1% strain, 1Hz, TA
Instruments AR 2000ex).
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Hydrogel Swelling.
50µL hydrogels (4wt% polymer, 10mM APS/TEMED) were formed in
cylindrical molds at 37°C for 30 min after mixing APS/TEMED initiators.
Hydrogels were then incubated in PBS for 2 days at 37°C. Gel diameters were
measured after 30 min crosslinking and again after 2 days in PBS. Swelling
ratios were reported as a percent change in diameter after 2 days in PBS.
Protein Release Studies.
rTIMP-3 or FITC-BSA were dissolved in the polymer solutions at 10µg of
protein/50µL gel.

50µL hydrogels (4wt% polymer, 10mM APS/TEMED) were

formed in cylindrical molds at 37°C for 30 min after mixing APS/TEMED initiators.
After a wash in PBS, hydrogels were incubated in PBS supplemented with 1%
BSA (R&D Systems) at 37°C. Hydrogels were moved to fresh buffer every 2
days and samples were stored at -20°C until the end of the study. After the final
time point, hydrogels were degraded in 0.3 mg/mL hyaluronidase to release
remaining protein. FITC-BSA was quantified using fluorescence while rTIMP-3
was quantified using ELISA (R&D Systems).
Statistical Analysis.
Statistical comparisons between groups were performed with a two-tailed
student’s t-test, followed by a Bonferroni correction for multiple comparisons;
p<0.05 were considered statistically significant for comparison between two
groups, while p<0.025 were considered statistically significant for comparison
between three groups. The results are reported as mean values ± standard
deviations.
7.3. Results and Discussion
Sulfation of HEMA Modified HA.
HA has been previously modified with sulfate groups through nucleophilic
substitution of primary hydroxyls along the HA backbone17. When the reaction
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was performed with the SO3/DMF complex at a 20:1 SO3/DMF:HA ratio, a high
degree of sulfation was observed, estimated at 2.8 sulfate groups per HA
disaccharide, in a specific pattern that resulted in high protein binding affinities.
We

applied

this

sulfation

reaction

to

our

previously

developed

hydroxyethylmethacrylate (HEMA) modified HA (HEMA-HA) in order to
incorporate protein-binding features into a degradable, radically crosslinked
hydrogel.

Using this strategy, sulfated HEMA-HA macromers (HEMA-SHA)

could be blended with non-sulfated HEMA-HA macromers at any desired ratio
and crosslinked using a variety of free-radical initiator systems (Figure 7.1).
Further, the degradation kinetics of the system can be controlled through HEMA
group modification to release bound proteins in a temporally controlled fashion.
HEMA-HA was synthesized as previously reported by first converting
sodium hyaluronate (NaHy, 100kDa) to a tetrabutylammonium (TBA) salt and
then coupling HEMA succinate to primary hydroxyls on HA through an
esterification reaction6 (Figure 7.2 A). The modification process decreased the
number average molecular weight (Mn) of the HA polymer by 20% and slightly
increased the HA polydispersity, as determined by GPC (Figure 7.2 B). The
decrease in Mn is likely due to acid hydrolysis
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Figure 7.1. Incorporation of sulfated hyaluronic acid (HA) macromers into hydrogels
through free-radical initiated crosslinking. Hydroxyethylmethacrylate (HEMA) modified HA
macromers were synthesized with or without sulfate groups to control sulfated polymer
concentration in hydrogels by simply blending the two macromers together and crosslinking with
free-radical initiators. Release of encapsulated proteins in these networks is controlled by
electrostatic interactions with the negatively charged polymers and by gel degradation through
ester group hydrolysis of the HEMA crosslinks.
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of the polysaccharide backbone during HA-TBA synthesis as a proton-rich
exchange resin was used for protonation of NaHy. The final HEMA-HA had a Mn
of ~80kDa and a HEMA modification of ~16%.
To synthesize HEMA-SHA, HEMA-HA was synthesized starting with NaHy
of 440kDa and converted to a TBA salt through a protonated resin exchange.
This step did not affect the HEMA modification as indicated by peak integration of
vinyl protons on the methacrylate group (approximately 5.8 and 6.2 ppm) via 1H
NMR (Figure 7.3 A). Next, the TBA salt of HEMA-HA was reacted with SO3 in
DMF, which also did not affect HEMA modification as indicated by the vinyl
proton integrations before and after the reaction (Figure 7.3 A). Also, there was
an obvious shift in hydroxyl proton peaks along the HA backbone (approximately
3 to 4 ppm) following the sulfation reaction as expected due to substitution of
these protons with sulfate groups (Figure 7.3 A).
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Figure 7.2. Synthesis of HEMA modified HA. (A) Sodium hyaluronate (NaHy) was converted
to a tertbutylammonium (TBA) salt and reacted with HEMA-succinate in dimethyl sulfoxide using
dimethylaminopyridine (DMAP)/di-tert-butyl dicarbonate (BOC2O) catalyzed esterification. HEMA
modification was quantified by methacrylate group 1H NMR peaks (green circle). (B) This
modification slightly reduced the number average molecular weight (Mn) and increased the
polydispersity index (PDI) as measured with GPC when compared to unmodified NaHy.

121!
!

A

B
/>?-@/-$
67368$9":$

234$

734$

;34$

=34$

<34$

534$

634$

119$

!"#$%&'()#*%$
+,-./0$1/$2345$

/>?-@/-$+,-$

H%IJ)'EK%$L#:%&$F#"J9G$

635$

734$

43B$
437$
43=$
435$
4$
5;$

67328$9":$

234$

634$

;34$

=34$

<34$

534$

634$

119$

<4$

<;$

=;$

;4$

;;$

>CDE"#$+!9%$F9!#G$

P)/Q$
/>?-@/-$
/>?-@A/-$

/>?-@A/-$

=4$

?#$FMN)G$
==4$
<;4$
B4$

ONL$
632$
63R$
63B$

6;328$9":$

234$

734$

;34$

=34$

<34$

534$

634$

119$

Figure 7.3. Synthesis of sulfated HEMA-HA. (A) HEMA-HA was converted to a TBA salt and
reacted with SO3/dimethylformamide (DMF) complex in DMF. This reaction altered hydroxyl
group 1H NMR peaks as expected, but did not affect methacrylate 1H NMR peaks (green circles).
(B) Sulfation reduced the Mn of HEMA-HA by almost 80% as measured by GPC, so a larger
440kDa NaHy was used to generate HEMA-SHA macromers with comparable Mn to HEMA-HA
macromers (80kDa).

Although there was no change in HEMA modification (~16%) there was an
expected and significant reduction of the macromer Mn following the sulfation
reaction, which is likely due to acid hydrolysis of HA from H2SO4 formed from
reaction of SO3/DMF and water vapor, or from non-specific nucleophilic
substitution (Figure 7.3 B). By starting with a 440kDa NaHy, the final Mn of
HEMA-SHA was maintained at ~80kDa so that HEMA-HA and HEMA-SHA could
be blended at approximately the same molecular weight and modification.
Naturally sulfated GAGs are typically much smaller than 80kDa; therefore, our
approach allows generation of sulfated and crosslinkable polymers with larger
molecular weights for covalent incorporation into hydrogels. Using this approach,
the sulfate group content within hydrogels can be easily controlled by blending
sulfated and non-sulfated polymers at the desired ratios.
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Sulfating HEMA-HA Alters Polymer Charge and Increases Binding to a HBP.
Heparin has been shown to bind hundreds of proteins through
electrostatic interaction between negatively charged sulfate groups on heparin
and positively charged amino acid residues on proteins7. While intermolecular
forces such as hydrogen bonding and van der Waals interactions involving other
chemistries on heparin have been shown to contribute to some highly specific
binding events23, charge interactions from sulfate groups are the major force
driving heparin-protein binding24. Similarly, the addition of sulfate groups to HA
has been shown to dramatically increase binding of proteins that are rich in basic
amino acid residues17,19. While the degree of sulfation of HA was shown to
directly correlate with protein binding affinity, oversulfation of polysaccharides
can inhibit protein binding

25

and the distribution of sulfate groups along the

polysaccharide is important in protein binding affinity17,19.
The sulfate content on HEMA-SHA macromers was compared to HEMAHA and heparin using a modified dimethylmethylene blue (DMMB) assay21.
Using this assay, a significant increase in sulfate content was observed on
HEMA-SHA compared to HEMA-HA, confirming success of the sulfation reaction
(Figure 7.3 A). Further, the sulfate content on HEMA-SHA was comparable to
that of heparin. To quantify the effect of the sulfate groups on polymer charge,
an important contributor to protein binding affinity, zeta potentials of the polymers
were measured from pH 2 to 10.

HEMA-SHA polymers possessed a more

negative charge when compared to HEMA-HA polymers across all pHs (Figure
7.3 B).

Further, a clear difference was observed in the protonation states

characteristic of sulfate groups on HEMA-SHA polymers compared to
carboxylate groups on HEMA-HA polymers.

The sulfate groups remained

deprotonated across all pHs, while the carboxylate groups were protonated at
lower pH.
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Figure 7.4. Characterization of HEMA-SHA macromers. (A) Sulfate content was significantly
increased in HEMA-SHA macromers when compared to HEMA-HA macromers, as determined by
dimethylmethylene blue assay. Sulfate content of HEMA-SHA macromers was comparable to
that of heparin. (B) Addition of sulfate groups significantly enhanced the negative charge of
carboxylic acid-containing HEMA-HA macromers via zeta potential measurements, and (C)
significantly enhanced binding to the heparin binding TIMP-3 protein. TIMP-3 binding of HEMASHA macromers was comparable to that of heparin, though with a significantly different binding
profile. (n=3 replicates per group, mean±SD, *p<0.025 compared to HEMA-HA, #p<0.025
compared to heparin).

To assess the protein-binding characteristics of the polymers, a
recombinant tissue inhibitor of matrix metalloproteinases (TIMP-3) was used as a
model HBP. TIMP-3 is unique among the four known TIMPs in that it binds
sulfated polymers with a high affinity26,

27

. It naturally associates with sulfated

GAGs in the ECM, so matrix presentation is thought to be important in controlling
TIMP-3 activity28. TIMP-3 was incubated in wells with polymers adsorbed to the
surface and TIMP-3 bound to the polymer-coated wells was quantified using
ELISA.

Using this technique, a significant increase in TIMP-3 binding was

observed with HEMA-SHA polymers compared to non-sulfated HEMA-HA
polymers (Figure 7.3 C). Further, HEMA-SHA polymers had comparable TIMP-3
binding to heparin, although more TIMP-3 was bound to HEMA-SHA at higher
TIMP-3 concentrations. This observation could be explained by the greater Mn of
HEMA-SHA compared to heparin (80kDa vs. 20kDa by GPC) as both polymers
were adsorbed to the wells at the same molar concentration.
differences in the sulfation pattern could affect HBP binding.

In addition,
For example,

Hintze and coworkers showed that sulfated HA binds human transforming growth
factor beta-1 (TGF-!1) with a stronger affinity than synthetically sulfated
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chondroitin sulfate, despite having the same degree of sulfation19.

Further,

sulfated HA was shown to have different binding specificities for human plasma
proteins than heparin29. Therefore, while HEMA-SHA was shown to bind a HBP
(TIMP-3) in this study, further investigation into protein binding specificity of
HEMA-SHA polymers is warranted for specific HBPs.
HEMA-SHA Incorporates into Radically Crosslinked Hydrogels and Alters HBP
Presentation.
While a number of heparin mimetics have been developed as
antithrombotic therapeutics, very few have been crosslinked into hydrogels for
application in drug delivery or tissue engineering30-32.

After demonstrating

successful synthesis of a methacrylate modified and sulfated HA macromer and
its ability to bind a HBP, we crosslinked these polymers into hydrogels to
encapsulate and localize HBPs.

HEMA-SHA polymers were blended with

HEMA-HA polymers at 10% HEMA-SHA, 90% HEMA-HA with a total polymer
concentration of 4 wt% (w/v), then crosslinking was initiated with APS and
TEMED redox initiators. Rheometry was used to quantify gelation, and HEMASHA blended hydrogels were compared to 100% HEMA-HA hydrogels.
Incorporation of 10% HEMA-SHA did not significantly alter gelation, as both
groups had similar storage modulus (G’) profiles over time and crosslinking
reached the same G’ plateau after 30 min (Figure 7.5 A-B). Other ratios were
also investigated (higher HEMA-SHA content); however, they led to hydrogels
with statistically different mechanical properties, likely due to extensive sulfate
charge repulsion and were not pursued further (results now shown).
To visualize incorporation of sulfate groups into the HEMA-SHA blended
hydrogels, they were incubated with DMMB after a 2-day wash in PBS. HEMASHA blended hydrogels exhibited a purple color compared to blue HEMA-HA
hydrogels, indicating the presence of sulfate groups (Figure 7.5 C). Further,
HEMA-SHA blended hydrogels swelled significantly more than HEMA-HA
hydrogels, likely due to charge repulsion within the sulfate rich hydrogels or
125!
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increased water content due to sulfate hydrophilicity (Figure 7.5 D).
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Figure 7.5. Crosslinking of HEMA-HA/HEMA-SHA hydrogels. HEMA-HA/HEMA-SHA
hydrogels were crosslinked using APS/TEMED initiators and 4wt% macromers in PBS at 100/0 or
90/10 HEMA-HA/HEMA-SHA compositions (wt/wt). (A) Storage (G’) and loss (G’’) moduli profiles
over time with and without 10% HEMA-SHA incorporation. (B) Incorporation of 10% HEMA-SHA
did not significantly affect G’ after crosslinking had reached a plateau at 30 min. (C) Incorporation
of sulfate groups in the hydrogels was visualized using dimethylmethylene blue with purple
indicative of sulfate groups (scale bar = 5mm). (D) Incorporation of sulfate groups slightly
increased swelling of the hydrogels after 2 days in PBS. (n=3 replicates per group, mean±SD,
*p<0.05 between groups).

Finally, to illustrate the influence of sulfate group incorporation on HBP
presentation within the hydrogels, networks were formed that encapsulated either
a model HBP, TIMP-3, or bovine serum albumin (BSA) and protein release and
hydrogel degradation were monitored over 12 days.

HEMA-SHA blended

hydrogels degraded in a slightly more rapid fashion compared to HEMA-HA
hydrogels (Figure 7.6 A). This observation is likely due to the increased water
content of the hydrogels which enhances ester group hydrolysis of the HEMA
groups.

BSA release from HEMA-SHA blended hydrogels was significantly

reduced from HEMA-HA hydrogel release; however, both release profiles were
quite similar (~70% within 12 days), indicating little influence of sulfate groups on
BSA presentation and release (Figure 7.6 B). This is not surprising as previous
studies also found that albumin does not bind to sulfated HA with a high affinity29.
However, TIMP-3 release was drastically reduced with incorporation of HEMA126!
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SHA polymers into the network (Figure 7.6 C).

Less than 15% of the

encapsulated TIMP-3 was released from HEMA-SHA blended hydrogels,
whereas almost 60% was released from HEMA-HA alone hydrogels.

This

reduced release of TIMP-3 with the incorporation of HEMA-SHA polymers
demonstrates our ability to control HBP presentation within covalently crosslinked
and degradable hydrogels, simply through chemical modification of the gel
precursors. This approach can be used with a variety of radically crosslinked
scaffolds for drug delivery and tissue engineering applications.
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Figure 7.6. Gel degradation and
encapsulated protein release. (A)
Gel mass loss as determined by
uronic acid content. Incorporation of
HEMA-SHA macromers significantly
enhanced hydrolytic degradation of
the hydrogels over 2 weeks.
Encapsulated FITC-BSA (B) and
heparin-binding TIMP-3 (C) release
from hydrogels of HEMA-HA alone or
incorporating
HEMA-SHA
macromers. Encapsulated TIMP-3
release was reduced by over 40%
with incorporation of HEMA-SHA
macromers. (n=3 replicates per
group, mean±SD, *p<0.05 between
groups).
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CHAPTER 8
On-demand delivery of TIMP-3 from matrix metalloproteinase degradable
hydrogels attenuates post myocardial infarction remodeling
8.1. Introduction
Excessive

extracellular

matrix

(ECM)

proteolysis

by

matrix

metalloproteinases (MMPs) is a hallmark of many human disease states
including chronic inflammation, tumor progression, and cardiovascular disease1.
MMPs hydrolyze peptide bonds with a high level of amino acid specificity and
regulation.

Under normal physiological conditions, MMP activity is precisely

controlled to maintain a low level of structural protein, cell receptor, and growth
factor turnover. However, following a stimulus such as an injury, there is a loss
of control over MMP activity which causes maladaptive changes to tissue
architectures and functions, often resulting in the progression of disease2.

For

example, MMP levels are elevated in patients following a myocardial infarction
(MI) and are associated with adverse left ventricle (LV) remodeling3. Increased
MMP activity was directly measured within the human myocardium following
myocardial arrest and reperfusion4.
transgenic

deletion

of

specific

Further, experimental models involving

MMPs

and

systemic

administration

of

pharmacologic MMP inhibitors have demonstrated that MMPs are important
contributors to multiple aspects of adverse global LV remodeling including LV
wall thinning, volume dilation, and ultimately dysfunction5-8.

While systemic

administration of pharmacologic MMP inhibitors has shown efficacy in
attenuating post MI remodeling in pre-clinical animal models of MI, off-target
effects have limited their success in recent clinical trials9. Therefore, strategies
that localize physiological concentrations of MMP inhibitors to regions of MMP
overexpression and limit spill over into the systemic circulation would provide a
safe and effective strategy to attenuate post MI remodeling by targeting MMP
activity. !
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Wilson and colleagues recently showed that MMP elevation is highly
localized to ischemic tissue within the MI region following experimental MI in
pigs10. While MMP levels increased dramatically, levels of their inhibitors, tissue
inhibitors of MMPs (TIMPs), decreased significantly within the MI region. TIMPs
inhibit MMP activity by forming non-covalent complexes with MMPs in a 1:1
stoichiometry, blocking the MMP catalytic domain and preventing proteolysis.
With the exception of TIMP-1, TIMPs are known to inhibit all of the 25 known
MMPs, and studies have identified unique roles and functionalities of each of the
four TIMPs11. In the context of post MI remodeling, TIMP-3 has been shown to
play a particularly important role. For example, myocardial TIMP-3 levels were
significantly reduced in contradistinction to elevated myocardial MMP levels in
patients with end-stage heart failure12. In addition, transgenic TIMP-3 deletion in
experimental animal models caused adverse LV remodeling and accelerated
progression to heart failure following MI13-15.
We therefore chose to evaluate the ability of a recombinant TIMP-3 to
attenuate adverse LV remodeling through local MMP inhibition in a large animal
model of MI.

Critical to the success of this approach is a safe and flexible

delivery platform that locally releases TIMP-3 to the MI region while minimizing
systemic off-target effects. Injectable hydrogels have recently been developed
for the therapeutic delivery of molecules to the heart following MI16. In these
systems, therapeutic molecules are encapsulated in a polymer matrix and
released locally over time to sustain target levels of a molecule in the
myocardium.

Polymer

concentration,

polymer-molecule

interactions,

hydrophobic effects, and gel degradation collectively determine molecule
diffusion from the gel. While these parameters can be controlled to engineer a
gel formulation with a desired TIMP-3 release profile, studies have shown that
post MI MMP expression profiles are dynamic and vary from patient to patient. In
some patients, MMP expression was endogenously restored from day 1 to day 5
following MI, while in others a persistent or elevated MMP-9 signal from day 1 to
day 5 was accompanied by a 3-fold end-diastolic volume increase at day 283.
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Therefore, while MMP overexpression is an important target towards attenuating
post MI remodeling, it is difficult to choose a single TIMP-3 release profile
suitable for every patient. One way to overcome these limitations is to design
responsive gels that alter molecule release rates in response to external stimuli.
Specifically, hydrogels with MMP-cleavable crosslinks allow encapsulated
molecules to be released in response to local MMP activity17,18. Utilizing this
approach would effectively dose TIMP-3 release in response to MMP activity.
One challenge towards realizing on-demand TIMP-3 delivery is to
minimize passive TIMP-3 release from the gels (i.e., in the absence of MMP
activity). TIMP-3 is unique among the TIMPs in that it is found bound to the ECM
of tissues while the other three TIMPs are presented as soluble proteins19.
Specifically, TIMP-3 binds to sulfated glyocosaminoglycans with a high affinity
through an abundance of positively charged lysine and arginine residues
exposed on the protein surface20,21. TIMP-3 binding to the ECM is thought to
facilitate local MMP inhibition in tissues, and recent studies have shown that
sulfated polymers enhance TIMP-3 binding affinity for specific MMPs22.
Therefore,

we

developed

injectable

gels

with

a

negatively

charged

polysaccharide backbone to mimic native TIMP-3-ECM interactions and minimize
passive diffusion of TIMP-3 from the gels.

MMP-cleavable crosslinks were

incorporated to liberate bound TIMP-3 in the presence of local MMP activity.
Further, we utilized conjugation and crosslinking chemistries to form gels rapidly
upon injection into the myocardium that are stable in the absence of MMP activity
to further prevent the passive release of TIMP-3 from the injection site. We
demonstrate that this TIMP-3 delivery strategy effectively inhibits MMP activity
within the MI region without further damaging the myocardium or raising systemic
TIMP-3 levels.

Finally, we show attenuated post MI LV remodeling through

significant increases in LV wall thickness and ejection fraction in a large animal
model of MI.
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8.2. Methods
HA-maleimide synthesis.
74kDa sodium hyaluronate (NaHy, Lifecore) was first converted to a
tetrabutylammonium (TBA) salt of HA (HA-TBA) by mixing NaHy with an ion
exchange resin in DI water for 8hrs at RT. The resin was then filtered from the
aqueous solution and the solution was pH’d to 7.02 with TBAOH, frozen and
lyophilized.

HA-TBA was dissolved in DMSO and then reacted with N-(2-

aminoethyl)maleimide

trifluoroacetate

salt

(Sigma)

in

the

presence

of

benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate for
2hrs at RT. The reaction solution was then dialyzed against DI water for 14
days, frozen and lyophilized.

Percent maleimide modification of HA was

determined to be 35% of the HA repeat units by normalizing the area under the
maleimide 1H peak to the aminomethyl protons on the HA backbone.
Solid-phase peptide synthesis.
Peptides

were

synthesized

with

the

MMP-cleavable

sequence

GCNSGGRMSMPVSNGG-Hyd where C is the cysteine used for coupling to a
maleimide functionalized HA and Hyd is the hydrazide for gel crosslinking with an
aldehyde functionalized HA. The solid-phase resin (Rink Amide MBHA resin,
100-200 mesh, Novabiochem) was deprotected with 20% (v/v) piperidine in N,Ndimethylformamide

(DMF)

solution

and

Fmoc

protected

amino

acids

(Novabiochem) were activated with HBTU (Novabiochem) in 0.4 M Nmethylmorpholine in DMF prior to reaction with deprotected resin. Amino acids
were reacted at 4x excess to solid-phase resin using an automated solid phase
peptide synthesizer (PS 3, Protein Technologies, Inc.). After completion, the
polypeptide was cleaved from the resin with a 90% trifluoroacetic acid, 5% triisopropylsilane, 5% water solution for 3 hrs at room temperature.

The

polypeptide was then precipitated in ethyl ether solution at -80°C for 2 hrs, spun
down and dried against vacuum pump pressure overnight. Matrix-assisted laser
desorption/ionization-Time of Flight (MALDI-TOF) mass spectroscopy was used
133!
!

to verify successful polypeptide mass based on theoretical calculation.
Synthesis and characterization of polymers.
HA-peptide-hydrazide polymers were synthesized by coupling a cysteine
terminated peptide to HA-maleimide by mixing at a 4:1 molar ratio,
cysteine:maleimide in PBS for 4hrs at 4°C. The polymer was purified by dialysis
against a 20 mM NaCl solution for 4 days, then DI water for 3 days, frozen and
lyophilized.

HA-aldehyde was synthesized by mixing NaHy (350kDa, Lifecore)

at 1 % (w/v) and sodium periodate (IO4) in DI water at a molar ratio of 1:2 HA:IO4
for 2hrs at RT. The reaction was stopped by adding 10% (v/v) ethylene glycol to
the reaction, dialyzing against DI water for 5 days, freezing and lyophilizing. DSald was synthesized in a similar fashion except DS (Sigma) was reacted with IO4
at a molar ratio of 2:1 DS:IO4 for 5hrs at RT. Percent aldehyde modification was
quantified using a TNBS colorimetric assay as previously described24.
Rheometry.
To form gels, ALD (2.4% HA-ald, 1.4% DS-ald (w/v)) and HYD (3.2% (w/v)
HA-peptide-hyd) modified polymers were dissolved in PBS, mixed 1:1 and
gelation characteristics were quantified by monitoring the storage (G’) and loss
(G’’) moduli with time using an AR2000ex Rheometer (TA Instruments) at 37°C
under 1% strain and 1 Hz.
Gel degradation and molecule release studies.
FITC-BSA or rTIMP-3 was mixed with the ALD precursor solution and gels
were formed as described above in cylindrical molds for 30 min at 37°C. Gels
were incubated in PBS supplemented with 1% BSA for FITC-BSA studies or TTC
buffer (50mM Tris-HCl, 1mM CaCl2, 0.05% triton x-100, pH 7.5) for rTIMP-3
studies at 37°C. After a wash, enzymes (collagenase type 4, Worthington or
rMMP-2, R&D Systems) were added every 2 days and buffers were collected
and stored at -20°C prior to analysis.

Uronic acid content was analyzed to
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calculate gel mass loss25, FITC-BSA fluorescence was analyzed to measure
release, and an ELISA was used to measure rTIMP-3 content (R&D Systems).
rTIMP-3 activity and binding assays.
rTIMP-3-His (Amgen, Inc.) activity was quantified by its ability to inhibit
rMMP-2 (R&D Systems) activity using an MMP cleavable fluorogenic substrate
(R&D Systems). Serial dilutions of rTIMP-3 were added to 4nM activated rMMP2 in TTC buffer, incubated for 2hrs at 37°C, then the fluorogenic substrate was
added and fluorescence kinetics were measured over 5 min with a microplate
reader (Tecan). rTIMP-3 binding to polysaccharide polymers was evaluated with
a solid-phase binding assay. HA-ald, DS-ald, and heparin (Sigma) at 2.5µM in
PBS were coated overnight at 25°C on to heparin binding plates (BD Life
Sciences)26. Wells were washed in TNC buffer (50 mM Tris/HCl, 150 mM NaCl,
10 mM CaCl2, 0.05 % Brij-35 and 0.02 % sodium azide) containing 0.1 % Tween
20 between each subsequent incubation. Wells were blocked with 0.2% gelatin in
TNC buffer and then incubated with rTIMP-3-His (0.02-3µg/mL in blocking
solution for 3 h at 37°C). Bound rTIMP-3-His was detected using a biotin labeled
antibody against the 6xHis tag on rTIMP-3 (Abcam, catalogue number ab27025,
for 3 h at 37!C), followed by streptavidin coupled to horseradish peroxidase (R&D
Systems) for 1h at 37°C. Hydrolysis of a 1:1 mixture of H2O2 and
tetramethylbenzidine was measured at 450 nm using a microplate reader
(Tecan).
MI induction and gel injections.
Yorkshire pigs (n=7, 25kg, Hambone Farms, Orangeburg, SC) were
anesthetized with isoflurane (2%), and through a left thoracotomy, the LV free
wall was exposed. A 2 cm square calibrated grid was sutured below the origin of
the first two obtuse marginal arteries of the circumflex artery (OM1 and OM2),
which provided for a total of 9 distinct injection sites within a targeted 2X2 cm
region of myocardium. OM1 and OM2 were ligated to induce an MI, and
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characteristic ECG changes occurred, but electrical cardioversion and/or
defibrillation were not required, and past studies demonstrated that this
technique creates a uniform and consistent MI8.

Referent controls were

instrumented in a similar fashion with the exception of coronary artery ligation.
Pigs were randomized to receive injections of saline (MI only), gel alone (gel), or
gel with rTIMP-3 (gel/rTIMP-3). For gel injections, the ALD (2.4% HA-ald, 1.4%
DS-ald

(w/v))

and

HYD

(3.2%

(w/v)

HA-GCNSGGRMSMPVSNGG-hyd)

precursors solutions were mixed in a sterile fashion, drawn into separate 1mL
syringes, and injected into the mid-myocardium of each target site using a
FibriJet blending connector (Nordson Micromedics, SA-3670) with a 27G needle.
For gel/rTIMP-3 group, rTIMP-3 was mixed into the ALD precursor (20µg rTIMP3/100µL ALD). Successful injections were confirmed by visualization of an
opacification of the epicardial surface at the point of myocardial injection.
Blood analysis.
Pigs were instrumented as described in the preceding section with the
addition of a vascular access catheter placed in the descending aorta and
connected to a subcutaneous port (6 Fr., SlimPort,Bard Access Systems, Salt
Lake City). Blood samples (5 mL) were collected from the subcutaneous port 1,
3, 7 and 14 days post-MI. The referent controls were again instrumented in an
identical manner with the exception of MI induction. The collected blood samples
were centrifuged and the decanted plasma subjected to ELISA for troponin-I (Pig
Cardiac Troponin-I, KT-474, Kamiya Biomedical Co) and C-reactive protein
(CRP; Porcine CRP ELISA, IPGCRPKT, Innovative Research Inc.).
LV assessment with echocardiography.
Animals were sedated (20 mg valium, PO, Elkin-Sinn) and twodimensional echocardiographic studies (GE VIVID 7 Dimension Ultrasound
System: M4S 1.5-4.3 MHz active matrix array sector transducer probe) were
performed to calculate LV dimensions and ejection fraction. Echocardiography
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measurements were taken 1 day prior to MI induction, and then again 1, 3, 7 and
14 days following MI.
Interstitial MMP activity.
After 14 days post MI, the pigs were anesthetized with sufentanyl (2µg/kg
IV, Baxter Healthcare), morphine sulfate (3mg/kg/h IV, Elkin-Sinn), and isoflurane
(1%, 3 L/min O2, Baxter Healthcare), and mechanically ventilated. The LV was
exposed through a sternotomy, a microdialysis probe (20 kDa, outer diameter of
probe shaft 0.77mm; CMA/Microdialysis, North Chelmsford, MA) placed within the
MI region, and infused with the MMP fluorescent substrate (5 µL/min) as
previously validated3,4. The dialysate was then subjected to fluorometry, which
reflected interstitial MMP activity, and these values were normalized to referent
control values and expressed as a percent. Following these measurements, the
LV was harvested, separated into MI and remote regions (area served by left
anterior descending artery), and prepared for biochemical analysis.
Data and statistical analysis.
Statistical analyses were performed using STATA statistical software. LV
geometry, function, and area within the markers were compared between the
control and MI groups using a one-way analysis of variance (ANOVA). Post-hoc
separation following ANOVA was performed using pairwise comparisons with a
Bonferroni analysis (prcomp module, STATA).

The interstitial global MMP

activity was evaluated by ANOVA and subsequently compared against the
control values of 100% by a Student’s t-test. For TIMP-3 levels and plasma
troponin and CRP concentrations, values from each group were first evaluated
by ANOVA, and then a post-hoc separation following ANOVA was performed
using pairwise comparisons with a Bonferroni analysis. For PCR measurements,
a multi-way ANOVA (MANOVA) was performed, evaluating for treatment
dependent, MI dependent, and region dependent effects. Post-hoc separation
following MANOVA was performed using pairwise comparisons with a Bonferroni
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analysis. Results are presented as a mean ± standard error of the mean (SEM),
and values of p<0.05 were considered to be statistically significant.
8.3. Results and Discussion
Gel design for MMP-responsive rTIMP-3 delivery
The main criteria used in designing a gel formulation for rTIMP-3 delivery
were 1) a gel that crosslinks upon injection through a syringe, 2) stable gels that
degrade only in the presence of MMP activity, and 3) minimal passive release of
encapsulated rTIMP-3 (i.e., in the absence of MMP activity). To this end, we
developed a three-macromer system that utilizes the chemical versatility of
polysaccharide backbones (Figure 8.1 a).

Polysaccharides were chemically

modified to contain either aldehyde (ALD) or hydrazide (HYD) functional groups
to form gels in a one-step condensation reaction, with water as the only
byproduct (Figure 8.1 b). Hyaluronic acid (HA) was used as a template for both
ALD and HYD modifications due to the well-defined size ranges of commercially
available HA, the previous use of HA in biomedical applications, and the
abundance of diol and carboxylic acid groups necessary for ALD and HYD
modifications, respectively. Dextran sulfate (DS) was also incorporated into the
gels through ALD modification of its diol groups to act as a heparin mimetic to
immobilize encapsulated heparin-binding proteins23. ALD modification of HA and
DS were evaluated separately as each polysaccharide contains a different
number of diol groups amendable to aldehyde modification (Figure 8.2).
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Figure 8.1. Injectable hydrogels with peptide crosslinks. (a-b) HA and DS polymers were
modified with aldehyde (ALD) groups and HA polymers were modified with a peptide containing
an hydrazide (HYD) group to form hydrogels through stable hydrazone bond formation. (c) Upon
mixing ALD and HYD polymers, robust hydrogels formed rapidly as evidenced by development of
storage (G’) and loss (G’’) moduli over time.
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Figure 8.2. Aldehyde modifications. Aldehyde groups were synthesized on HA (a) and DS (b)
polymers using sodium periodate (NaIO4) oxidation of diols. Different reaction conditions were
chosen for each polymer due to differences in the amount of diol groups per polymer.
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Further, converting diols to aldehydes through periodate oxidation is known to
degrade polysaccharides, so a large molecular weight (MW) HA (~350kDa) was
chosen to provide sufficient HA-ald MW to allow formation of robust gels for
rTIMP-3 encapsulation. Reaction conditions for HA-ald were chosen to balance
aldehyde modification and macromer MW as periodate concentration both
increased aldehyde modification and decreased HA MW in a dose-dependent
manner (Figure 8.3). Reaction conditions for DS-ald were chosen to provide
sufficient aldehyde modification to crosslink DS-ald into the gel.

!D"#EF6#

G&#EF6# %%#EF6# C&#EF6#

'#

4,506)/718#9:;,5:6-<1#

=9#
=9>6)8?#'@$#AB$@=9#
=9>6)8?#'@C#AB$@=9#
=9>6)8?#'@'#AB$@=9#

!"#

$"#

%"#
()*+,-#./01#20/-3##

&"#

Figure 8.3. Periodate polymer degradation. HA polymers degraded due to non-specific
reactions during the oxidation reaction. Values reported are number-averaged molecular weights
(Mn) as determined by gel permeation chromatography.

MMP-specificity was incorporated into the gels by generating MMPcleavable peptides with a terminal HYD functional group using solid phase
peptide synthesis. In addition, a thiol containing cysteine was incorporated into
the MMP-cleavable peptides, opposite of the HYD group to facilitate thioether
linkage to a maleimide functionalized HA (MAHA) in a one-step click reaction
(Figure 8.1). Finally, hydrophilic serine (S) and asparagine (N) spacers were
incorporated between the reactive groups (cysteine and hydrazide) and the
MMP-cleavable peptides to improve solubility for passage through a syringe.
Successful synthesis of the designed peptide was verified with MALDI (Figure
8.4 a) and peptide coupling to MAHA was verified by complete consumption of
the characteristic maleimide peak from

1

H NMR (Figure 8.4 b).

Percent
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maleimide modification of HA (and therefore HYD modification) was controlled
through the concentration of N-(2-Aminoethyl)maleimide during MAHA synthesis.
The thioether coupling chemistry was chosen for its stability in water to prevent
non-specific hydrolysis of the gels.

The designed formulation enabled rapid

crosslinking of gels upon mixing ALD and HYD modified macromers as
evidenced by development of the elastic component (G’) of the complex modulus
using rheometry (Figure 8.1 c). The gels reached a plateau G’ of approximately
1.5 kPa, at which point the gels are robust, nearly elastic solids.

a

b

HA-TBA

HA-maleimide

HA-peptide-hydrazide

Figure 8.4. Peptide synthesis and coupling. (a) Peptide synthesized through solid-phase
peptide synthesis was analyzed using MALDI-TOF mass spectroscopy to verify mass. (b) Peptide
coupling to maleimide functionalized HA was verified by loss of peak characteristic of maleimide
protons using 1H NMR.

To demonstrate MMP-sensitivity, gels containing a peptide sequence that
is cleaved by MMPs (GGRMSMPV) were incubated in buffer with varying
concentrations of active MMPs and uronic acid content in the buffer was
measured over time to calculate gel mass loss. In the absence of active MMPs,
the gels were stable over the 12-day study (Figure 8.5 a). In a 20 U/mL enzyme
concentration, the gels degraded in a near-linear fashion with very little gel
remaining after 12 days. In 200 U/mL, the gels completely degraded in 2 days.
To evaluate the applicability of the gels for MMP-triggered release of
encapsulated molecules, FITC-BSA was encapsulated in the gels and release
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was quantified in buffer with varying concentrations of active MMPs.
Encapsulated FITC-BSA release followed the gel degradation behavior in a
similar MMP-dependent manner (Figure 8.5 b).
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Figure 8.5. MMP-trigged molecule release. Hydrogels with the MMP-cleavable GGRMSMPV
peptide in the crosslink were incubated in different concentrations of collagenase type 4. (a)
Hydrogels were stable in the absence of enzyme activity and degraded in response to enzyme
concentration. (b) Encapsulated FITC-BSA released in proportion to hydrogel degradation.
(mean±SD, n=3 hydrogels per condition).

rTIMP-3 delivery with MMP-cleavable gels
TIMP-3 was chosen for local delivery post-MI in part because of its unique
ECM-binding property.

This allowed us to design ECM mimetic gels to

encapsulate and immobilize rTIMP-3 until they are released by MMP-mediated
gel degradation. To this end, DS was incorporated into the gel formulation to
mimic sulfated GAGs, the major component of the ECM responsible for TIMP-3
binding, due to its susceptibility to aldehyde modification through diol oxidation.
Binding of rTIMP-3 to DS-ald was evaluated using a solid-phase binding assay.
rTIMP-3 bound to DS-ald with a much greater capacity than to HA-ald, and
approached the capacity of rTIMP-3 binding to heparin (Figure 8.6 a).
Importantly, rTIMP-3 binding to DS-ald did not reduce rTIMP-3 inhibition of active
MMPs (Figure 8.6 b).

rTIMP-3 inhibited 4nM rMMP-2 with a half maximal

inhibitory concentration of 17±4 ng/mL (0.7±0.2 nM) with 50 µg/mL DS-ald in
solution compared to 28±7 ng/mL (1.2±0.3 nM) without DS-ald in solution
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(p=0.07). Previous studies found that a stretch of basic amino acids responsible
for TIMP-3 binding to sulfated GAGs is opposite to the TIMP-3 reactive site that
interacts with MMPs

21

. Therefore, utilizing polysaccharides that mimic sulfated

GAGs allows localization of TIMP-3 without altering its inhibitory properties.
Indeed, encapsulating rTIMP-3 in the crosslinked polysaccharide gels limited
diffusion of rTIMP-3 from the gel (Figure 8.6 c), where less than 20% of
encapsulated rTIMP-3 was released over the 14-day study.
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Figure 8.6. Polymer binding to rTIMP-3. (a) rTIMP-3 bound to polymer coated wells detected
with ELISA. rTIMP-3 bound to DS-ald with a greater capacity than HA-ald, and approached
rTIMP-3 binding to heparin. (b) rTIMP-3 activity measured by its ability to inhibit a 4 nM rMMP-2
solution. rTIMP-3 binding to DS-ald did not affect rMMP-2 inhibition. (c) Release of rTIMP-3
encapsulated in ALD+HYD hydrogels was limited to less than 20% by incorporating sulfated DSald.

While using MMP activity to trigger release of molecules encapsulated in
gels has been performed previously17,18, using MMP activity to trigger release of
MMP inhibitors, and therefore using MMP activity to trigger its own inhibition, is a
novel concept. To investigate this unique feedback system, gels with and without
encapsulated rTIMP-3 were incubated in 20nM active rMMP-2. Gels without
rTIMP-3 degraded within 2 days in the MMP buffer, while gels with encapsulated
rTIMP-3 degraded in a linear fashion for over 14 days (Figure 8.7a).

This

reduction in gel degradation rate observed with rTIMP-3 encapsulation indicates
that encapsulated rTIMP-3 remains active and is inhibiting rMMP-2 activity as
rMMP-2 is degrading the gel (Figure 8.7 b). Further, as rMMP-2 was refreshed
every 2 days to account for enzyme stability (Figure 8.8), a sufficient amount of
active rTIMP-3 remained bound in the gel for the entire 14 day study, otherwise
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the gel would rapidly degrade in similar fashion to the gels without rTIMP-3.
These results demonstrate a novel approach of locally delivering rTIMP-3 by
designing injectable gels containing MMP-cleavable crosslinks, where the local
presence of active MMPs controls the release of encapsulated rTIMP-3, and
therefore MMP inhibition.
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Figure 8.7. MMP-triggered release of rTIMP-3. (a) Hydrogels with (filled symbols) and without
(open symbols) encapsulated rTIMP-3 were incubated with (squares) or without (triangles) rMMP2. rMMP-2 was added every two days (indicated by green arrows). Encapsulated rTIMP-3
attenuated MMP-2 mediated hydrogel degradation, confirming activity of rTIMP-3 across the 14day study. (b) In this system, rMMP-2 degrades the hydrogel crosslinks (1), liberating bound
rTIMP-3, inhibiting rMMP-2 activity (2), and attenuating further hydrogel degradation (3).
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Figure 8.8. rMMP-2 activity. Activity of
rMMP-2 decreases to less than 10% of its
initial level immediately after activation in
buffer.
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Effectiveness of rTIMP-3 delivery in vivo
To assess the effectiveness of our rTIMP-3 delivery system in the setting
of MI, a large animal model of MI was employed that allows for regional
quantification of MMP expression and activity, along with functional outcomes of
post MI LV remodeling10. Following MI induction in pigs, gels were injected
144!
!

at 9 equally spaced sites within a 2cm x 2cm grid in the MI region (Figure 8.9 a).
A dual-barreled syringe was utilized to blend ALD and HYD polymers in equal
ratios immediately prior to entering the tissue for in situ gelation.
Following rTIMP-3 delivery, blood samples were taken after 1, 3, 7, and
14 days and analyzed for TIMP-3 concentrations. Importantly, there was no
observed increase in systemic TIMP-3 levels with local delivery of rTIMP-3 to the
MI region using our injectable gels compared to MI only and gel injection alone
(Figure 8.9 b). To quantify MMP activity within the MI region, a previously
validated microdialysis technique was utilized that perfuses the myocardial
interstitium with an MMP cleavable substrate and measures fluorescence as the
substrate is cleaved4.

Using this technique, MMP activity was observed to

significantly increase in the MI region following MI induction (Figure 8.10).
Interestingly, injection of the MMP degradable gels alone significantly reduced
MMP activity within the MI region, potentially due to a “sink effect” where the
cleavable peptide substrate is cleaved by active MMPs, reducing substrate
hydrolysis elsewhere. However, rTIMP-3 delivery from the MMP degradable gels
further reduced MMP activity within the MI region.
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Figure 8.9. Hydrogel mediated rTIMP-3 delivery. (a) Hydrogels were formed in situ by utilizing
a dual barrel syringe to mix the ALD and HYD polymers at the injection site. (b) Hydrogel
mediated delivery of rTIMP-3 prevented a systemic increase in rTIMP-3 levels. (mean±SD; MI
n=5; MI/hydrogel n=6; MI/hydrogel/rTIMP-3 n=5; p>0.05 between groups across all time points;
horizontal lines represent non-MI control ± 95% CI, n=16;)
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Figure 8.10. Post MI MMP activity.
Interstitial microdialysis of a fluorogenic
MMP cleavable substrate showed a
significant increase in MMP activity in the
MI region of pigs. Injection of the hydrogel
alone significantly reduced MMP activity.
Encapsulation of rTIMP-3 further reduced
MMP activity. (mean±SD; control n=4; MI
n=5; MI/hydrogel n=6; MI/hydrogel/rTIMP-3
n=4; *p<0.05 vs. control; +p<0.05 vs. MI)
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Experimental MI induction caused a gradual reduction in LV function, as
indicated by a declining ejection fraction (EF) and a progressive increase in
pulmonary capillary wedge pressure (PCWP) (Fig 8.11 a-b). Coinciding with
declining LV function were significant changes in LV geometry as indicated by
progressive LV wall thinning and LV dilation (Fig 8.11 c-d). rTIMP-3 delivery
from the injectable gels significantly increased LV wall thickness compared to MI
only and significantly reduced LV end diastolic volume (LVEDV) compared to gel
alone. Further, rTIMP-3 delivery significantly improved LV function as evidenced
by significant increases in EF and decreases in PCWP compared to MI only and
gel alone control groups.
Our results demonstrate the utility of injectable gels to locally deliver
TIMPs and inhibit excessive MMP activity by restoring myocardial MMP/TIMP
balance following MI.

This is the first proof-of-concept demonstration of

designing MMP-degradable gels to release an MMP inhibitor in the presence of
MMP activity to limit off-target effects of MMP inhibitors, which have been
clinically problematic.

The successful demonstration of this technology in

attenuating post MI remodeling in a large animal model warrants further preclinical investigation as it could ultimately provide a safe and effective therapy to
treat patients in the clinical setting of acute MI.
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Figure 8.11. LV function and geometry post MI. Serial LV echocardiography measurements
were collected over the 14 day study to assess LV function (a-b) and geometry (c-d). (a)
Progressive decrease in ejection fraction (EF) was observed following MI induction, and rTIMP-3
delivery from injectable hydrogels significantly attenuated this decline. (b) Progressive increase
pulmonary capillary wedge pressure (PCWP) was observed following MI induction, which was
significantly attenuated with rTIMP-3 delivery. (c) Progressive thinning of the LV wall posterior
wall thickness at diastole (LVPWThd) was significantly attenuated with rTIMP-3 delivery. (d)
Progressive dilation of the LV end diastolic volume (LVEDV) was significantly attenuated
compared to injection of the hydrogels alone. (mean±SEM; MI n=5; MI/hydrogel n=6;
MI/hydrogel/rTIMP-3 n=5; +p<0.05 compared to MI; #p<0.05 compared to MI/hydrogel; horizontal
lines represent non-MI controls ± 95% CI)
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CHAPTER 9
Conclusions and Limitations
The work presented in this dissertation illustrated the utility of injectable
hydrogels based on the molecule hyaluronic acid (HA) to engineer the left
ventricular (LV) remodeling process that occurs following a myocardial infarction
(MI) by encapsulating and locally delivering therapeutic proteins to the MI region.
Specifically, HA hydrogels were designed and implemented for the delivery of
two therapeutic proteins: stromal cell-derived factor-1 alpha (SDF-1a) and tissue
inhibitor of matrix proteinases-3 (TIMP-3), and a range of in vitro and in vivo
studies were implemented to understand how the controlled delivery of proteins
through electrostatic interactions and hydrogel degradation influence therapeutic
outcomes. The following sections summarize the conclusions and limitations of
each Aim, as well as present a prospective on future directions for this area of
research.
9.1. Specific Aim 1: Demonstrate that local rSDF-1! delivery from HA
hydrogels homes mobilized bone marrow derived cells (BMCs) to the heart
following MI.
Conclusions:

Both rSDF-1! and the crosslinkable HA macromer

stimulated BMC chemotaxis up to 4-fold in vitro through CXCR4 and CD44
receptor signaling, respectively.

Moreover, the HEMA-HA macromer bound

rSDF-1! with a dissociation constant of 36±5 µM through electrostatic interaction.
When formed into hydrogels via photo-initiated crosslinking, release of
encapsulated rSDF-1! and crosslinked HA were sustained for over 7 days, and
these molecules significantly increased BMC chemotaxis in vitro. When applied
to the heart following experimental MI in mice, the HA hydrogel containing rSDF1! significantly increased the number of systemically infused BMCs in the heart
by ~8.5 fold after 7 days over untreated controls, likely through both systemic and
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local effects of released molecules.

We conclude that sustained release of

rSDF-1! and HA from our photo-crosslinked HA hydrogels enhances circulating
BMC homing to the remodeling myocardium better than delivery of rSDF-1!
alone.
Limitations: While our finding that SDF-1! release from HA hydrogels
enhances BMC homing through both SDF-1! and HA activities is significant,
several experimental variables limit the implications of this result. First, it was
necessary to deliver BMCs to the animals and this was completed 3 hrs following
MI induction. Although this was necessary to quantify homing to the heart, the
approach here was not intended to investigate injected cell therapies, but rather
the influence of the delivered molecule alone. Also, during this acute stage of
post MI remodeling, the endothelium of the coronary vasculature is activated with
adhesion molecules to regulate cell trafficking to the remodeling myocardium1.
While delivering SDF-1! and HA during this phase enhanced engraftment of
BMCs, whether or not SDF-1! and HA delivery at a more chronic stage would
have the same effect is unclear. Therefore this therapeutic strategy may be
limited to acute post MI remodeling. Further, since a heterogeneous population
of BMCs was used to model cell homing, it is unclear which populations of cells
responded to local molecule delivery and in this Aim, we did not investigate the
actual influence of the homed cells on LV remodeling. Therefore, we can only
speculate about what effect the responsive cells would have on post MI
remodeling. Finally, while recruiting endogenous populations of progenitor cells
to repair the heart is an attractive strategy to avoid ex vivo cell manipulations,
progenitor cell numbers have been shown to decline with age2-4, and therefore
the endogenous capacity for regeneration in older patients may be a limiting
factor in the translation of this approach.
9.2. Specific Aim 2: Assess the therapeutic benefit of engineered SDF-1!
analogue (ESA) delivery from injectable HA hydrogels post MI.
Conclusions: Encapsulating ESA in redox-initiated HEMA-HA hydrogels
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sustained ESA release for over 4 weeks as the hydrogels degraded in vitro.
Interestingly, aggregates of ESA were observed dispersed throughout the gel
suggesting the engineered protein is less water-soluble than native SDF-1!, but
remained active in enhancing progenitor cell chemotaxis over the 4-week in vitro
study.

Further, endothelial progenitor cell (EPC) chemotaxis to molecules

released from the hydrogel alone was significantly enhanced, consistent with the
finding in Aim 1 that HA released from the degradable HA hydrogels provides a
cue for cell migration. When delivered to the heart within injectable hydrogels
following MI induction in rats, near-IR tagged ESA was detected for over 3 weeks
in the heart using transthoracic optical microscopy, consistent with in vitro
release kinetics. Injection of the HA hydrogels alone significantly reduced LV
fibrosis and dilation and significantly improved cardiac output (CO) and LV endsystolic pressure volume relationship (ESPVR). Further, significant increases in
CXCR4+ cell and capillary densities were observed with hydrogel injection alone.
However, delivery of ESA from hydrogels further reduced adverse LV remodeling
with significant reductions in LV fibrosis and wall thinning, and significant
increases in CO, ejection fraction (EF) and ESPVR compared to gel injection
alone. Further, ESA delivery significantly increased CXCR4+ cell densities in the
myocardium.

We conclude that injectable HA hydrogels allow for sustained

delivery of ESA to the myocardium post MI, and this approach effectively
attenuates adverse LV remodeling in a rat model of MI through both hydrogel
bulking and SDF-1!/CXCR4 homing effects.
Limitations: While this study provided a strong proof-of-concept that
injectable HA hydrogel mediated delivery of ESA significantly attenuates post MI
remodeling in rats, several experimental variables limit the implications of this
finding. First, it is important to note that while a fluorescent ESA signal was
detected in the heart for over 3 weeks following hydrogel injection, this does not
confirm activity of delivered ESA for over 3 weeks in vivo. The engineered ESA
is still susceptible to protease degradation; therefore, additional studies are
warranted to investigate duration of active ESA in vivo. Second, the hydrogels
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with encapsulated ESA were delivered immediately following MI. As described in
the limitations to Aim 1, this time period may be optimal to enhance recruitment
of endogenous cells, and therefore the positive findings reported here may not be
generally applied to clinical situations where treatment modalities must be
effective in the setting of chronic heart failure. In addition to providing a SDF-1!
signal in the early stages of post MI remodeling, the injected hydrogels provide
mechanical support to the ischemic myocardium and therefore may be more
effective in attenuating LV remodeling when applied directly following MI
induction. Therefore, the results from this Aim must be considered in an acute
MI context.

For both Aims 1 and 2, a further limitation exists in that each

injection technique required direct injection either on or within the infarct tissue
from a syringe, rather than through a percutaneous delivery approach. This may
limit the patient population that could undergo such a process for hydrogel
injection.
9.3. Specific Aim 3: Investigate the effect of local TIMP-3 release from
injectable HA hydrogels on MMP activity and LV remodeling following MI
Conclusions: HEMA-HA macromers bound rTIMP-3 with a dissociation
constant of 3.8±0.3 µM through electrostatic interaction. When encapsulated in
redox-initiated HEMA-HA hydrogels, rTIMP-3 release was sustained for over 2
weeks in vitro. When delivered to the myocardium following experimental MI in
pigs, a detectable rTIMP-3 signal was still present at the injection sites after 7
days, indicating that rTIMP-3 release was sustained for at least 7 days from
injectable HA hydrogels in vivo. This delivery approach effectively inhibited MMP
activity within the MI region compared to MI only and hydrogel alone control
groups. By restoring the TIMP/MMP balance, infarct expansion was abrogated,
LV dilation reduced by ~20%, and ejection fraction increased by ~20% when
compared to MI only 14 days post MI (p<0.05). Further, smooth muscle actin
content indicative of myofibroblast proliferation increased and pro-inflammatory
cytokine levels were reduced within the MI region 14 days post MI with TIMP-3
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delivery.

These changes were not associated with a significant increase in

collagen accumulation compared to hydrogel delivery alone. We conclude that
these results provide the first proof of concept that local and sustained delivery of
a recombinant TIMP from injectable HA hydrogels can effectively attenuate the
adverse post MI remodeling process in a large animal model of MI by normalizing
MMP

activity

and

pro-inflammatory

cytokines,

and

inducing

contractile

myofibroblast proliferation.
Limitations: While it is clear from this study that local delivery of rTIMP-3
from injectable HA gels has beneficial effects on post MI remodeling, the
mechanism for this benefit remains associative. rTIMP-3 delivery inhibited MMP
activity, altered fibroblast phenotype, and attenuated cytokine signaling within the
MI region; therefore, it is difficult to speculate about which has the largest impact
on the remodeling process. Further, while observing these beneficial results in a
large animal model of MI is a significant step towards translating this therapeutic
approach to humans, the hydrogels were injected immediately following MI
induction, which may not be possible in a clinical scenario. However, since ECM
turnover is important for adequate wound healing following MI5,6, early MMP
inhibition may not necessarily be optimal.

Therefore, additional studies are

warranted that examine the optimal window for localized modulation of TIMP
levels within the MI region, with respect to providing maximal prevention of
adverse remodeling and minimal interference with the necessary wound healing
response. Further, rTIMP-3 was chosen for its strong binding to the ECM7-9 and
its critical role in post MI remodeling10-12, however the three other TIMPs could
also be suitable candidates for therapeutic delivery post MI. In addition, while
communications with collaborating laboratory (F.G. Spinale) revealed that
injections of rTIMP-3 alone had little effect of post MI remodeling, adding this
treatment group would better illustrate the importance of sustaining rTIMP-3
levels in the myocardium with injectable hydrogels.

Finally, additional dose-

titration studies will be required to determine the minimal threshold levels of
rTIMP-3 release in order to significantly affect LV regional geometry and function
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post MI while limiting off target effects.
9.4. Specific Aim 4: Develop sulfated HA macromers to incorporate high
TIMP-3 binding affinity into injectable HA hydrogels.
Conclusions: We developed sulfated and vinyl modified HA macromers
by first synthesizing HEMA-HA, then sulfating primary hydroxyls along the HA
backbone through nucleophilic substitution with SO3 (HEMA-SHA). The sulfation
reaction did not alter HEMA group modification and therefore HEMA-SHA
macromers could be readily incorporated into HEMA-HA gels by simply blending
the two macromers together at a desired ratio and initiating crosslinking with free
radical initiators.

Sulfate content of HEMA-SHA macromers was significantly

greater than HEMA-HA, and comparable to sulfate content of heparin.

In

addition, HEMA-SHA bound rTIMP-3 with an affinity comparable to heparin, and
could be covalently incorporated into hydrogels without altering hydrogel
crosslinking.

Once incorporated into the hydrogels, HEMA-SHA significantly

reduced encapsulated rTIMP-3 release (~15% compared to 60% total release)
over 14 days. We conclude that these sulfated HA macromers provide a useful
way to introduce heparin-binding features into radically crosslinked HA hydrogels
without altering hydrogel architectures, and can therefore be applied in a wide
range of radically crosslinked HA hydrogel systems, including injectable
hydrogels for localized rTIMP-3 delivery.
Limitations: While we showed comparable rTIMP-3 binding to sulfated
HA macromers and heparin, the differences in sulfation pattern between the two
polymers is likely to alter the library of proteins they bind13. Therefore, further
investigation into protein binding specificity of HEMA-SHA polymers is warranted.
In addition, these hydrogels would be exposed to a wide-range of proteins in
vivo, and binding endogenously expressed proteins could affect biological
processes. Therefore, demonstrating biocompatibility of injectable HEMA-SHA
blended gels in vivo in the context of the intended therapeutic application is
important. Further, the high concentration of highly acidic sulfate groups on the
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HEMA-SHA polymers could affect the viability of cells encapsulated in HEMASHA blended hydrogels. Therefore, cell viability studies in a range of HEMAHA/HEMA-SHA ratios is important towards cellular applications of these
hydrogels.
9.5. Specific Aim 5: Engineer injectable HA hydrogels with MMP sensitive
degradation to allow for localized TIMP-3 delivery as a function of MMP
expression within the MI region.
Conclusions:

In order to form HA hydrogels with MMP degradable

crosslinks upon injection through a syringe, a two component, aldehyde (ALD)
and hydrazide (HYD) macromer system was developed. This system allowed for
rapid crosslinking of stable hydrogels upon mixing ALD and HYD macromers,
and limited passive rTIMP-3 release by incorporation of ALD functionalized
dextran sulfate (DS) macromers for strong rTIMP-3 binding in the hydrogels. In
the presence of 20 nM rMMP-2, the hydrogels degraded over 14 days, releasing
encapsulated rTIMP-3 in response to MMP-2.

However, hydrogels without

encapsulated rTIMP-3 completely degraded in two days in 20 nM rMMP-2,
indicating that the encapsulated rTIMP-3 remains active as it is bound in the
hydrogel over the 14-day study as it attenuates MMP-mediated degradation.
Regional injection of the hydrogel alone immediately following MI induction in
pigs normalized MMP activity in the MI region to baseline values at 14 days post
MI, potentially by acting as a sink for active MMPs as the MMP-degradable
crosslinks were cleaved.

However, delivery of the hydrogel alone did not

significantly attenuate LV remodeling as measured by LV wall thickness, LV enddiastolic volume (LVEDV), pulmonary capillary wedge pressure (PCWP), and
ejection fraction (EF).

Regional delivery of rTIMP-3 encapsulated in the

hydrogels further reduced MMP activity within the MI region compared to
hydrogel alone injections, and significantly attenuated LV remodeling as
evidenced by significant increases in LV wall thickness, EF, and PCWP
compared to MI only and hydrogel alone controls, and a significant decrease in
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LVEDV compared to hydrogel alone controls. Further, these beneficial effects on
LV function were observed without an increase in systemic rTIMP-3 levels with
gel/rTIMP-3 delivery to the heart. We conclude that MMP-triggered release of
rTIMP-3 with injectable MMP-degradable hydrogels is an effective strategy to
attenuate adverse LV remodeling while avoiding systemic concentrations of MMP
inhibitors.
Limitations:

While rTIMP-3 delivery from MMP degradable hydrogels

significantly attenuated post MI remodeling, interstitial MMP activity was not
significantly different with rTIMP-3 delivery compared to hydrogel delivery alone.
Therefore additional studies are warranted to investigate other biological effects
of rTIMP-3 as in Aim 3.

Further, as discussed in the limitations of Aim 3,

delivering an MMP inhibitor very early following MI may prevent ECM turnover
necessary for wound healing; therefore, additional studies are warranted to find
an optimum window following MI for this therapeutic strategy.

In addition,

delivery of this therapy immediately following MI may not be relevant to clinical
scenarios of chronic MI. Also, serial echocardiography measurements revealed
progressive decline in LV function in all groups over the two week study,
therefore longer term studies are warranted to see if therapeutic effects are
maintained at later time points. Finally, as demonstrated in Aim 3, injection of
hydrogels alone has beneficial effects on post MI remodeling by bulking and
mechanically supporting the myocardium. Little effect was observed in this Aim
with hydrogel injection alone; therefore, hydrogels that degrade to release
encapsulated molecules may not be as optimal as they lose their mechanical
properties over time.
9.6. Future Directions
Based on the limitations of the studies performed in this dissertation, there
are numerous avenues of future exploration related to HA hydrogels for the
delivery of therapeutic proteins.
For all Aims in which hydrogels were injected immediately following MI,
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application of the hydrogel systems in chronic models of MI (injections weeks to
months following MI induction) would lead to a better understanding of the
therapeutic window available to deliver hydrogels and encapsulated proteins post
MI.

In addition, percutaneous delivery of the hydrogels through catheter

technologies would allow therapeutic application of the hydrogels and proteins in
a larger population of patients where a thoracotomy is not part of the current
clinical treatment. Finally, different doses of encapsulated proteins (SDF-1! and
TIMP-3) would identify optimal conditions for stimulating cell homing and MMP
inhibition.
For SDF-1! delivery, animal models with labeled bone marrow would
allow a more mechanistic understanding of the contribution of homed cells
towards myocardial repair.

In addition, animal models with humanized bone

marrow would better assess the therapeutic potential of sustained SDF-1!
delivery in patients.
For TIMP-3 delivery, longer therapeutic studies would better elucidate
whether early MMP inhibition delays the progression of LV remodeling or
permanently interrupts remodeling events.

Further, injectable hydrogels with

peptide crosslinks that degrade at different rates could be explored to identify an
optimal rate of MMP-triggered TIMP-3 release. In addition, to maintain hydrogel
bulking while delivering TIMP-3 on demand, inter-penetrating networks of an
MMP degradable phase and a stable phase could be constructed.
Finally, the hydrogels developed in this dissertation could be explored for
the delivery of a wide range of therapeutic proteins and combinations thereof by
simply mixing the reconstituted proteins with the hydrogel precursor solution.
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